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Importantly, Toradol’s proven efficacy
and tolerability help make it cost-effective
for Canadian hospitals.'3 Earlier hospital
discharge and a lower incidence of
complications result in considerable cost
savings - in one well-controlled study,
Toradol IM and tablets saved an average
of approximately $75.00 per patient
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For a better alternative to narcotics in
pain management, consider Toradol IM
and tablets. The non-narcotic analgesic
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S u rgical Training in Canada
John H. Duff, MD, FRCSC
Richard Ivey Professor o f Surgery and chairman, Department o f Surgery, Faculty o f Medicine,
University Hospital, The University o f Western Ontario, London, Ont.

owadays, surgical training in
Canada tends to be rigidly
compartmentalized by discipline.
Residents receive broad training
only during the core year(s) and
even then are encouraged to attend
the teaching sessions of their own
discipline rather than those of the
discipline in which they are work
ing. Off-service rotations have been
further limited by resident cuts and
the resulting pressure to cover the
“home service.” Moreover, many
teaching services are now narrowly
specialized even within a given dis
cipline. Breadth of training is, in
practice, not encouraged. This ap
proach may not be ideal for delivery
of surgical care. Blanchard’s article
in this issue of the journal (pages
531 to 535) is perhaps the first
Canadian study to document a mis
match between the skills and opera
tions learned during training and
those practised in the “real world.”
Blanchard’s data will not come as a
surprise to community surgeons,
who have been telling the teaching
centres about such a mismatch for
several years. Many Canadian com
munities not large enough to sup
port subspecialties have the benefit

N
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of broad surgical coverage because
general and other surgeons perform
procedures outside the customary
boundaries of their discipline. Re
placing these surgeons is becoming
increasingly difficult. Furthermore,
in the 1990s even communities
large enough by population to sup
port some subspecialties are unable
to do so because “impact analyses”
project costs they can not afford.
Blanchard’s paper raises impor
tant questions about the delivery of
surgical care in Canada. The obvi
ous question is, How do we provide
surgical trainees with broader train
ing? Not so obvious is where the
leadership will come from to create
the necessary changes in surgical
training programs. Who is responsi
ble for surgical care delivery in
Canada? The Royal College of Phy
sicians and Surgeons of Canada and
university surgical departments set
the standards for science and skills
and, along with the national special
ty societies, have raised the scientif
ic development of surgery in Cana
da to a very high level. However,
there has been relative silence on
the matter of delivery of surgical
services. Blanchard’s findings are

pertinent to delivery of surgical
care. They show that training for
community surgery requires greater
breadth than depth. They also show
that surgeons, willing and trained
to provide a broad range of surgical
services, can play an important role
in Canada. Perhaps the time has
come in Canada to create and rec
ognize training programs for such
surgeons.
Demand is increasing to recog
nize new subspecialties and to
create the corresponding training
programs, which, by providing
greater depth of knowledge and
skills, are expected to improve pa
tient care. How about programs to
provide greater breadth of training?
Blanchard’s data suggest that these
programs would also improve pa
tient care. Given the current eco
nomic constraints in Canada, our
unique geography and the large
number of patients treated in com
munity hospitals, such an approach
is worthy of consideration. Delivery
of care is an important issue that
needs to have a place alongside
science and teaching on the agen
das of our major surgical organiza
tions. ■

QUILL ON SCALPEL

General Surgery Training in Canada: Are
We in Trouble?
Bryce R. Taylor, MD, FRCSC, FACS
Chairman, Division o f General Surgery, Department o f Surgery, University o f Toronto, Ont.

n this issue (pages 531 to 535)
Blanchard has offered some sta
tistics from Manitoba, showing that
teaching hospitals may be evolving
in ways that render them and their
professors less capable of training
general surgeons. This applies not
only to the academic general sur
geon but also to the true generalist,
who needs experience in the areas
of general surgery, obstetrics, urol
ogy, orthopedics and plastic sur
gery. The issue demands an exami
nation of a number of factors, in
cluding the need for the general
surgeon in our society, the develop
ment of regional health centres
rather than the multiple-outpost
system frequently in place and a
re-evaluation of current training.
With respect to current training we
must consider: (a) the residency
level at which technical training is
most useful; (b) the number of
operations necessary for compe
tence; and (c) above all, how we in
the teaching institutions must adapt
to meet the needs of surgical train
ing for the many residents whose
expectations and ultimate activities
are so diverse.
The problem of uneven skills
training is not new. No resident
surgeon at the completion of train
ing has sufficient experience and
maturity to feel and be competent
in each and every area on which the
resident was examined during the
certification process. The develop
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ment of true technical competence
involves a learning process that is
life-long, not just the duration of a
postgraduate program.
It is ironic that although recent
training in many centres is aimed at
producing the surgeon-scientist, the
well-trained general surgeon proba
bly requires as much formal train
ing and, as an effective practitioner,
may be just as difficult to produce
as the academic surgeon.
When we look at training for the
future generalist as opposed to the
surgeon-scientist, we must keep in
mind the question of whether in 30
years this specialist will be required,
especially if the delivery of care
becomes increasingly centralized.
However, for the current discus
sion, we must assume that the need
for broad-based surgical experience
will continue to be important.

Technical Training
for the General Surgeon:
Which Level Is Most Fruitful?
General-surgery training was
lengthened to 5 years, beginning in
1989, for a number of reasons. One
of the major considerations was to
allow general-surgery residents to
be fully trained in the areas that
had been articulated by both the
Royal College of Physicians and
Surgeons of Canada (RCPSC) and
the American Board of Surgery —

surgery of the alimentary tract,
head and neck, breast, vascular and
endocrine systems, trauma and en
doscopy. The general-surgery resi
dent should also have the option
(and enough time) to gain experi
ence in other fields, such as ortho
pedic surgery, plastic surgery, ob
stetrics, critical care and trauma,
which would prove useful in a rural
setting. The temptation for pro
gram directors is to fulfil service
requirements of various specialties
at the junior level, thinking that
this type of experience for the fu
ture general surgeon will be valu
able training. However, we must
realize that most of the junior expe
rience in a surgical residency consti
tutes preparation toward the final
years in which all the components
of knowledge and skills are finally
integrated to produce a competent,
independent surgeon. In my opin
ion, broader training in the initial
years of surgery or additional rota
tions in the 2nd and 3rd years of
residency do not make a competent
general surgeon. The most valuable
experience in any discipline comes
at the most senior level possible.

The Number of Operations
Necessary for Competence
The RCPSC and the specialty
societies have generally considered
that further subspecialization is not
CJS, VOL. 35, NO. 5, OCTOBER 1992
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in the best interests of long-term
health care delivery. Despite this,
the gradual development of areas of
special interest and the consequent
erosion of the broad base in numer
ous teaching institutions is inevita
ble. This presents educational diffi
culties at many levels, including
undergraduate, prelicensure and the
surgical residency.
Also, the RCPSC and the special
ty societies have been reluctant to
attach numbers to the operations
required to gain competency in the
procedural specialties. Technical fa
cility comes with experience in the
operating room and may bear little
relation to the number of specific
operative types or in fact to the
number of operations performed.
The properly prepared resident may
learn more from assisting at 1 oper
ation than at 10 that are done
under the supervision of a surgeon
who is directing every move. Far
more important is the fundamental
understanding of the problems that
face the surgical resident and future
surgeon. The principles of surgery,
decision making and acquisition of
up-to-date knowledge used by the
competent well-trained clinician will
result in a good outcome no matter
how many particular operations
were performed by the resident.
Linking numbers of procedures
to competency may be dangerous
because of the inability of most
programs to provide specific num
bers and because of progress that
renders many operations obsolete.
In Dr. Blanchard’s Table IV, umbili
cal hernia repair, perianal opera
tions, pyloroplasty, splenectomy,
Billroth II gastrectomy and pseudo
cyst procedures were identified as
operations carried out in insuffi
cient numbers to adequately train
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residents. Because of the unusual
aspects of some of these proce
dures, there may be relatively few
training programs in North America
that can satisfy the criterion of
providing 10 of each of these par
ticular operations per trainee. In
fact, a number of these operations
have few indications as a result of
therapeutic advances, such as the
medical treatment of benign peptic
ulcer disease and the introduction
of laparoscopic surgery.

Suggestions
Blanchard has emphasized some
critical issues for current and future
surgical training in Canada. The
following points may amplify his
important observations:
• Teaching hospitals must en
courage and cultivate a secondary
care experience for a variety of
reasons, not the least of which is
the education of surgical residents
and all other members of the health
care team.
• “Peripheral” hospitals are
valuable to the teaching experience
as far as case-mix is concerned, but
they would be far more valuable if
they were positioned in small urban
or rural settings where the resi
dents are exposed not only to the
case-mix of secondary surgery, but
also to the life-style of the general
surgeon. Some programs have al
ready embarked on pilot projects to
encourage residents’ career choices.
For example, in the University of
Toronto general-surgery programs,
residents have an option of a rota
tion in a northern city for 3
months.
• Experience in an area of “ex
panded competence,” such as ob

stetrics, orthopedic surgery or plas
tic surgery, is far more productive
at a senior level, when the resident
is a competent, independent practi
tioner. Ideally, such training should
be individualized from the outset
and achievable within the frame
work of the 5-year program in
general surgery. A resident, for ex
ample, could have a senior generalsurgery residency in the 4th year,
and in the 5th year, when capable
of learning new techniques much
more quickly, could have “senior”
experiences in different disciplines
with the cooperation of other spe
cialties.
• During residency, the impor
tance of absolute numbers of opera
tions performed should be deemphasized. Concentration must be
on principles of surgery, the intel
lectual ability to assess the dynamic
process of surgical disease and the
confidence to act quickly and ap
propriately. An adequate level of
manual dexterity is fundamental,
but intellectual ability and flexibility
are far more important.
• Development of surgical-skills
courses in a number of specialties
provides a useful adjunct to the
conventional apprenticeship train
ing in technical surgery.
• The RCPSC accreditation
process should include more de
tailed reports of operations per
formed in each university institu
tion when programs are being re
viewed for accreditation.
• If provincial governments
wish to encourage general surgeons
to work in small urban areas, addi
tional steps must be taken to
achieve these ends. The Province of
Quebec has instituted a number of
changes, the long-term results of
which are undetermined at present.
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r. Blanchard, on pages 531 to
communities. The reason for this is
535 of this issue, has collected
that in the small community the
a list of the 20 most common general surgeon will have to deal
nontertiary operations performed in
with many of the common elective
Manitoba during 1985 and 1986
and emergency procedures ordinari
(his Table II). Comparing this list of
ly handled by the subspecialists in
operations with the most common
larger centres.
general surgery operations per
In Quebec, the situation seems to
formed in teaching hospitals for the
be somewhat different in that a very
same period (his Table IV), Blanch
small proportion of common proce
ard concludes that general surgery
dures in surgical subspecialties are
trainees who enter practice in small
performed by general surgeons (Ta
centres after training in the current
ble I). This is particularly applicable
programs will be inexperienced in a
to prostatectomy and tonsillectomy.
large proportion of common surgi
These observations from Manito
cal procedures required in those
ba and Quebec raise a very impor
T a b le 1.

Operations Performed by General Surgeons in Quebec in 1990*

O p eration

Prostatectomy
Tonsillectomy
Hysterectomy
Cesarean section
Source: Quebec Health Insurance Board

G e n e ra l s u rg e o n s , no. (% )

T o ta l no.

2 (0.02)
220(1.7)
702 (4.6)
1 139(6.3)

8 654
13 290
15 278
17 988

tant issue: What should the training
be for general surgeons who will
practise surgery in small centres?
Should we train general surgeons
to perform elective surgery (hyster
ectomy or prostatectomy) and emer
gency procedures (fractures, cesare
an section) in the subspecialties or
should we train general surgeons to
perform elective surgery in the do
main of general surgery (gastroin
testinal, vascular, trauma) and
therefore perform only emergency
operations in the subspecialties, re
ferring major elective surgery to a
larger regional centre?
A consensus has developed in
Quebec to regionalize basic surgical
services (nontertiary) that will prob
ably favour the latter evolution.
However, each province will have to
decide what training is needed for
general surgeons who will practise
in their community hospitals.*
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tumours are among
N eurogenic
the commonest primary neo

plasms of the mediastinum. They
arise from nerve cells, nerve sheaths
or ganglia of the sympathetic chain
and are usually located in the para
vertebral sulcus. The majority of
neurogenic tumours are benign, but
in 8% to 10% of cases, there is
extension of the intrathoracic com
ponent through the intervertebral
foramen, resulting in the so-called
“dumbbell tumour.” The report by
Shamji and colleagues in this issue
(pages 497 to 501) is important
because it addresses controversial
issues associated with diagnosis,
local staging and treatment of pos
terior mediastinal neurogenic tu
mours.
In modern thoracic surgery, fail
ure to fully investigate the local
extension of any posterior mediasti
nal mass before thoracotomy
should be considered negligent.
This investigation is important not
only because 40% to 50% of dumb
bell tumours are asymptomatic but
also because the unexpected finding
of spinal extension during removal
may contribute to permanent spinalcord damage.
Most neurogenic tumours are de
tected on routine chest radiographs,
where the tumour is seen as a
smoothly rounded mass located in
the posterior mediastinum. All pa
tients with these findings must un
470
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dergo computed tomography (CT),
because this technique is more sen
sitive than plain radiography in de
tecting enlargement of the foramen
and possible extension of the tu
mour into the spinal canal. If CT
clearly shows that the tumour is
extradural and extraspinal, no fur
ther investigation is required. If CT
is inconclusive, magnetic resonance
imaging (MRI) should be done, be
cause it accurately defines the exis
tence and extension of the intraspinal component of the tumour.1
With the use of MRI, myelography
is seldom necessary. The role of
thoracic aortography to document
the site of origin of the artery of
Adamkiewicz, which supplies the
anterior spinal artery, is controver
sial. Some surgeons, particularly
those in Europe, always perform
thoracic aortography before sur
gery, and if the artery of Adamkiew
icz is found to arise in the area of
the tumour, excision is not recom
mended unless absolutely neces
sary. If the artery is found to arise
at a distance from the tumour,
surgery can proceed without con
cern for possible damage to the
blood supply of the spinal cord.
Although observation alone is a
reasonable course of action for tu
mours that have been stable for
years, the majority of neurogenic
tumours should be resected, be
cause of uncertain diagnosis, loca

tion near or into the spinal canal or
possible malignancy of the lesion.
Neurogenic tumours that are ex
traspinal and extradural can be re
sected through a standard post
erolateral thoracotomy, and, more
recently, some tumours have been
successfully removed by videoassisted techniques. As Shamji and
colleagues state, a neurosurgical
opinion is mandatory when an intraspinal extension to the tumour is
suspected preoperatively. In such
cases, a combined approach, includ
ing thoracotomy and laminectomy,2
allows excision of both components
of the tumour in a single operation.
Resection of posterior mediastinal
neurogenic tumours should be con
sidered complex thoracic surgery
because erroneous operative tech
niques, often related to improper
preoperative staging, can lead to
serious and irreversible neurologic
complications.
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Surgical Treatment of Well-Differentiated
Thyroid Cancer
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he treatment of well-differen
tiated thyroid cancer (WDTC)
remains controversial. Although
most authorities agree that com
plete resection of the tumour is
necessary, their opinions vary as to
how much of the remaining thyroid
gland must be resected. Inability to
accurately predict the natural histo
ry of thyroid cancer because of the
slow growth of the majority of
these tumours has made it difficult
to address this problem prospective
ly. Previously, investigators tried to
identify those patients at risk for
recurrence or death with the use of
age-based risk groups. The AGES
classification from the Mayo Clinic,1
the AMES classification of Cady
and Rossi2 and, more recently, the
DAMES classification3 have retro
spectively identified prognostic fac
tors such as the age of the patient,
the extent and size of the tumour,
the presence of distal metastases
and the nuclear DNA content. Each
classification has identified a group
of patients who are at a high risk of
dying of their disease1-3 or having
recurrence,1-3 without addressing
the nature of the surgical interven
tion.
In this issue (pages 517 to 520),
Groot, Colquhoun and Murphy,
using the AMES classification, have
once again tried to resolve the
controversy as to whether the de
gree of surgical resection in thyroid

T

cancer influences the overall surviv
al in both high- and low-risk pa
tients. In this retrospective review
of 161 patients with WDTC they
were able to confirm the validity of
the AMES classification for death
rate, showing a significant differ
ence in the death rate from WDTC
between the low- and high-risk pa
tients (4% versus 47%). Follow-up
of the 161 patients ranged from 25
to 55 years. With this long follow
up, Groot, Colquhoun and Murphy
attempted to address the question
of whether the extent of thyroid
resection affects the long-term sur
vival. Unfortunately, their conclu
sion that long-term survival in lowrisk patients is not influenced by
the extent of surgical resection and
appears to not be clinically signifi
cant in high-risk patients cannot be
drawn from the data they present.
It is difficult to study the survival
advantage of surgical intervention
in WDTC because of the overall
good prognosis of this disease. Agebased groups have clearly demon
strated that high-risk patients have
a higher death rate than low-risk
patients. However, the majority of
patients with WDTC are low-risk
patients in whom the associated
death rate is 2% to 4%. Clearly, it
would take a very large number of
patients to be able to demonstrate
any survival benefit from the surgi
cal treatment in this low-risk group.

To overcome this problem, several
authors have looked at the local
and regional recurrence rates to
compare treatment regimens. Al
though there is no firm evidence to
support the opinion that local or
regional recurrence is equated to a
poorer survival, 40% to 50% of
patients who die of WDTC, die with
local or regional disease.4 It has
also been shown4 that 50% of pa
tients who suffer recurrence, die of
their disease. Groot, Colquhoun and
Murphy have given us no informa
tion on recurrence rates, which in
this small series may have been of
more value than overall survival.
The second problem with draw
ing conclusions as to the best surgi
cal intervention in this study relates
to the fact that there was no stan
dardization of the treatment arms,
making it impossible to compare
unilateral versus bilateral resection.
Many patients with unilateral resec
tions had external irradiation, ren
dering them athyroid. These pa
tients should therefore be included
in the bilateral resection group.
Furthermore, there is no informa
tion as to whether the patients who
died received adjuvant radiotherapy
or whether they had residual or
recurrent disease before they died.
Without standardization of treat
ment, it is difficult to assess wheth
er surgical intervention influences
survival.
CJS, VOL. 35, NO. 5, OCTOBER 1992
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Other retrospective series have
tried to address this problem, with
conflicting results. Some investiga
tors have demonstrated no improve
ment in survival with total thyroid
ectomy in both high- and low-risk
Farrar, Cooperman and James5 also
demonstrated a high complication
rate in patients subjected to total
thyroidectomy, with permanent hy
poparathyroidism approaching 21%,
strengthening the rational for uni
lateral procedures. Not everyone
would agree that total thyroidecto
my carries such a high morbidity.
Other series6-8 have clearly demon
strated that total thyroidectomy can
be done safely. It has also been
demonstrated that there is a lower
recurrence and improved survival
with bilateral or near-total thyroid
ectomy, especially when followed by
ablative iodine-131 therapy and thy
roid-stimulating-hormone suppres
sion.149-12 Even Cady and Rossi,
strong advocates of lobectomy
alone for low-risk patients, stated
that serious consideration should be
given to the use of bilateral opera
tions in the high-risk group.2 The
advantages of total thyroidectomy
versus unilateral lobectomy are out
lined in Table I. The advantages of
this procedure, however, are of no
benefit to the patient if the morbidi
ty is high.
What is obviously needed to de
termine the best surgical procedure
for WDTC is a randomized, con
trolled trial comparing unilateral re
section against total thyroidectomy
Table I. Advantages of Total
Thyroidectomy for Well-Differentiated
Thyroid Cancer
Allows for postoperative scanning and
ablation of metastatic disease
Removes all thyroid cancer (33% of
papillary thyroid cancers are bilateral)
Allows for serum thyroglobin assay as a
means of follow-up
Decreases recurrence
Eliminates anaplastic transformation
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and 131I ablation. Hay and associ
ates,1 demonstrated a trend toward
improved survival in high-risk pa
tients with bilateral procedures.
Therefore, I question whether it is
ethical to subject high-risk patients
*o such a study, knowing that it
will be years before any appreciable
difference may be seen. Low-risk
patients, however, have a low mor
tality, thus making it ethical to
randomize such patients to various
treatment groups. Presently, such a
study is under way in Sweden for
papillary thyroid cancer (PTC).13
Since 1987 all patients with PTC
confirmed by fine-needle aspiration
(FNA), no extension of tumour be
yond one lobe, diploid nuclear DNA
content on FNA and no metastasis
have been randomized to either lo
bectomy alone or total thyroidecto
my plus 131I ablation. It is hoped
that through this study the ques
tion as to the best type of surgical
resection for low-risk PTC can be
resolved. However, the question as
to what is the best surgical proce
dure for the high-risk patients and
those with follicular cancer, espe
cially minimally invasive carcinomas
still remains.
Although Groot, Colquhoun and
Murphy have made a valiant at
tempt to look at the long-term
survival of WDTC, this study dem
onstrates the difficulties we as sur
geons face. The extent of thyroid
surgery for both high- and low-risk
patients remains controversial. Re
ports as to the best surgical ap
proach to the low-risk patient are
conflicting. There does, however,
appear to be a trend toward im
proved survival and a decreased
recurrence rate when bilateral or
near-total thyroidectomy is done in
high-risk patients. Because of the
natural history of WDTC, it will be
a long time before the question as
to the best surgical procedure can
be resolved. Until then, total or
near-total thyroidectomy does offer
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some advantage over lobectomy;
however, thyroidectomy should not
be performed if it will result in a
significantly higher complication
rate.
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n 1987, the Ad Hoc Working
Group on Critical Appraisal of
the Medical Literature,1 proposed
that the structuring of abstracts for
articles on original clinical research
would provide more useful informa
tion to readers. Subsequently, Mulrow, Thacker and Pugh2 proposed a
similar structure for abstracts of
review articles. Then, in 1990,
Haynes and associates3 revised the
instructions for preparing struc
tured abstracts for both original
research and reviews.
Many journals have adopted the
structured abstract. They include
the Annals o f Internal Medicine, the
British Medical Journal, the Journal
o f Pediatrics and the Canadian Med
ical Association Journal.
The primary purpose of the
structured format of the abstract is
to allow readers “to judge quickly
the applicability and validity of the
findings of an article for clinical
practice.”3 This is particularly im
portant for users of electronic bibli
ographic databases, because, with
the structured abstract, they can
gain access to sufficient information
to select intelligently and efficiently
which articles they wish to read in
full. As well, the structured format
is believed to form a useful guide
for authors in summarizing the es
sential features of their articles.
Experience with the structured
abstract in the Canadian Medical
Association Journal over the past 2
years has convinced the editors of
that journal that the structured
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abstract is an important advance in
medical communication. Therefore,
effective Jan. 1, 1993, the editors of
the CJS will require that all origi
nal, clinical, research or review
manuscripts submitted to the jour
nal be accompanied by a structured
abstract. The following guidelines
are reprinted with permission from
the article by Haynes and associ
ates.3

Detailed Instructions for
Preparing Structured Abstracts
for Articles Reporting Original
Data From Clinical
Investigations With Human
Subjects
Authors submitting manuscripts
reporting the results of clinical in
vestigations should prepare an ab
stract of no more than 250 words
under the following headings: Ob
jective, Design, Setting, Patients (or
Participants), Interventions (if any),
Main Outcome Measure(s), Main
Results, Conclusions. The content
following each heading should be as
follows:
1. Objective. The abstract should
begin with a clear statement of the
precise objective or question ad
dressed in the report. If more than
one objective is addressed, the main
objective should be indicated and
only key secondary objectives stat
ed. If an a priori hypothesis was
tested, it should be stated.
2. Design. The basic design of

the study should be described. The
duration of the follow-up, if any,
should be stated. As many of the
following terms as apply should be
used.
a. Intervention studies: random
ized control trial . . . ; nonrandomized control trial; double-blind;
placebo control; crossover trial;
before-after trial.
b. For studies of screening and
diagnostic tests: criterion standard
(that is, a widely accepted standard
with which a new or alternative test
is being compared; this term is
preferred to “ gold standard”);
blinded or masked comparison.
c. For studies of prognosis: in
ception cohort (subjects assembled
at a similar and early time in the
course of the disorder and followed
thereafter); cohort (subjects fol
lowed forward in time, but not
necessarily from a common starting
point); validation cohort or valida
tion sample if the study involves the
modelling of clinical predictions.
d. For studies of causation: ran
domized control trial; cohort; casecontrol; survey (preferred to “ crosssectional study”).
e. For descriptions of the clinical
features of medical [surgical] disor
ders: survey; case series.
f. For studies that include a for
mal economic evaluation: cost-effec
tiveness analysis; cost-utility analy
sis; cost-benefit analysis. For new
analyses of existing data sets, the
data set should be named and the
basic study design disclosed.
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3. Setting. To assist readers to
determine the applicability of the
report to their own clinical circum
stances, the study setting(s) should
be described. Of particular impor
tance is whether the setting is the
general community, a primary care
or referral centre, private or institu
tional practice, ambulatory or hos
pitalized care.
4. Patients or Other Participants.
The clinical disorders, important eli
gibility criteria, and key sociodemo
graphic features of patients should
be stated. The numbers of partici
pants and how they were selected
should be provided (see below), in
cluding the number of otherwise
eligible subjects who were ap
proached but refused. If matching
is used for comparison groups, cha
racteristics that are matched should
be specified. In follow-up studies,
the proportion of participants who
completed the study must be indi
cated. In intervention studies the
number of patients withdrawn for
adverse effects should be given.
For selection procedures, these
terms should be used, if appropri
ate: random sample (where “ran
dom" refers to a formal, random
ized selection in which all eligible
subjects have a fixed and usually
equal chance of selection); popula
tion-based sample; referred sample;
consecutive sample; volunteer sam
ple; convenience sample. These
terms assist the reader to determine
an important element of the
generalizability of the study. They
also supplement (rather than dupli
cate) the terms used by professional
indexers when articles are entered
into computerized databases.
5. Intervention(s). The essential
features of any interventions should
be described, including their meth
od and duration of administration.
The intervention should be named
by its commonest clinical name (for
example, the generic term “chlor
thalidone”) [e.g., Whipple proce
474
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dure for pancreatoduodenectomy].
Common synonyms should be given
as well to facilitate electronic textword searching. This would include
the brand name of a drug if a
specific product was studied.
6. Main Outcome Measure(s).
The primary study outcome mea
surements) should be indicated as
planned before data collection be
gan. If the paper does not empha
size the main planned outcomes of
a study, this fact should be stated
and the reason indicated. If the
hypothesis being reported was for
mulated during or after data collec
tion, this information should be
clearly stated.
7. Results. The main results of
the study should be given. Measure
ments that require explanation for
the expected audience of the article
should be defined. Important mea
surements not included in the pre
sentation of results should be de
clared. [If] relevant, it should be
indicated whether observers were
blinded to patient groupings, partic
ularly for subjective measurements.
Due to the current limitations of
retrieval from electronic databases,
results must be given in narrative or
point form rather than tabular form
if the abstract is to appear in com
puterized literature services such as
MEDLINE. If possible, the results
should be accompanied by confi
dence intervals (for example, 95%)
and the exact level of statistical
significance. For comparative
studies confidence intervals should
relate to the differences between
groups. For nonsignificant differ
ences for the major study outcome
measure(s), the clinically important
difference sought should be stated
and the confidence interval for the
difference between the groups
should be given. When risk changes
or effect sizes are given, absolute
values should be indicated so that
the reader can determine the abso
lute as well as relative impact of the

finding. Approaches such as “num
ber needed to treat” to achieve a
unit of benefit are encouraged when
appropriate; reporting of relative
differences alone is usually inappro
priate. If appropriate, studies of
screening and diagnostic tests
should use the terms sensitivity,
specificity, and likelihood ratio. If
predictive values or accuracy are
given, prevalence or pretest likeli
hood should be given as well. No
data should be reported in the ab
stract that do not appear in the rest
of the article.
8.
Conclusion(s). Only those con
clusions of the study that are direct
ly supported by the evidence report
ed should be given, along with their
clinical application (avoiding specu
lation and over-generalization), and
indicating whether additional study
is required before the information
should be used in usual clinical
settings. Equal emphasis must be
given to positive and negative find
ings of equal scientific merit.
To permit quick and selective
scanning, the headings outlined
above should be included in the
abstract. For brevity, parts of the
abstract can be written in phrases
rather than complete sentences.
(For example: 2. Design. Double
blind randomized trial, rather than
2. Design. The study was conduct
ed as a double-blind randomized
trial.) This technique may make
reading less smooth but facilitates
selection scanning and allows more
information to be conveyed per unit
of space.

Detailed Instructions for
Preparing Structured Abstracts
for Review Articles
Authors submitting manuscripts
of review articles and articles re
porting the results of meta-analyses
should prepare an abstract of no
more than 250 words under the

STRUCTURED ABSTRACTS

following headings: Objective, Data
Sources, Study Selection, Data Ex
traction, Data Synthesis, Conclu
sions. The content following each
heading should be as follows:
1. Objective. The abstract should
begin with a precise statement of
the primary objective of the review.
The focus of this statement should
be guided by whether the review
emphasizes factors such as cause,
diagnosis, prognosis, therapy, or
prevention. It should include infor
mation about the specific popula
tion, intervention or exposure, and
test or outcome that is being re
viewed.
2. Data Sources. A succinct sum
mary of data sources should be
given including any time restric
tions. Potential sources include ex
perts or research institutions active
in the field, computerized databases
and published indexes, registries,
abstract booklets, conference pro
ceedings, references identified from
bibliographies of pertinent articles
and books, and companies or manu
facturers of tests or agents being
reviewed. If a bibliographic data
base is used, the exact indexing
terms used for article retrieval
should be stated, including any con
straints (for example, English lan
guage or human).
3. Study Selection. The abstract
should describe the criteria used to
select studies for detailed review
from among studies identified as
relevant to the topic. Details of
selection should include particular
populations, interventions, out
comes, or methodologic designs.
The method used to apply these
criteria should be specified; for ex
ample, blind review, consensus,
multiple reviewers. The proportion
of initially identified studies that
met selection criteria should be stat
ed.
4. Data Extraction. Guidelines
used for abstracting data and as
sessing data quality and validity

(such as criteria for causal infer
ence) should be described. The
method by which the guidelines
were applied should be stated; for
example, independent extraction by
multiple observers.
5. Data Synthesis. The main re
sults of the review, whether qualita
tive or quantitative, should be stat
ed. Methods used to obtain these
results should be outlined. Meta
analyses should state the major
outcomes that were pooled and in
clude odds, ratios or effect sizes,
and, if possible, sensitivity analyses.
Numerical results should be accom
panied by confidence intervals, if
applicable, and exact levels of sta
tistical significance. Evaluations of
screening and diagnostic tests
should address issues of sensitivity,
specificity, likelihood ratios, receiv
er operating characteristic curves,
and predictive values. Assessments
of prognosis could include summarizations of survival characteristics
and related variables. Major identi
fied sources of variation between
studies should be stated, including,
for example, differences in treat
ment protocols, co-interventions,
confounders, outcome measures,
length of follow-up, and drop-out
rates.
6. Conclusions. The conclusions
and their applications should be
clearly stated, limiting generaliza
tion to the domain of the review.
The need for new studies may be
suggested.
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QUILL ON SCALPEL

Survival of Breast-Cancer Patients
With Previous or Subsequent Neoplasms
Richard G. Margolese, MD, FRCSC
Director, Department o f Oncology, The S ir M ortim er B. Davis-Jewish General Hospital,
Montreal, Que.

ethodology in clinical science
is an increasingly important
tool. The controlled prospective
clinical trial is the mainstay of mod
ern clinical science; but not every
question lends itself to this tech
nique in a practical or timely way,
and it is sometimes necessary to
rely on other approaches. This does
not mean that we should accept
lower standards or be less critical in
evaluating our conclusions and our
methodology.
There are many examples of
seemingly good ideas in recent sur
gical science that were widely and
enthusiastically embraced only to be
discarded when good scientific
methodology eventually exposed
the truth. The Halsted mastectomy
is a prime example, and, even more
recently, gastric freezing and hyper
baric oxygenation were innovations
that did not live up to their promise
after being widely embraced with
out adequate testing. It may be an
exaggeration to represent these as
the 20th-century counterparts of
purgatives, leeching and poultices,
but improper clinical applications of
unproven ideas can best be con
trolled by careful scientific testing
— good methodology.
In the first half of the 20th
century, modern medicine made
enormous progress by conquering
many diseases that usually had a

M
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single cause that was the point of
successful intervention. Examples
of these are deficiency diseases,
corrected by supplying the neces
sary nutrient, and infectious diseas
es, corrected by immunization or
use of antibiotics. Our present-day
problems concern more complex
diseases without single causes.
Many display a heterogeneic face,
and different natural histories occur
even in the same disease category.
Cancer, heart disease, arthritis and
other degenerative diseases are ex
amples, and advances against these
complex diseases are incremental,
not immediately curative. More than
ever we need good methodology to
continue to advance our under
standing. We need more rigour, not
less, to be confident that the con
clusions we draw are valid.
The retrospective study of Peloquin and colleagues in this issue
(pages 481 to 484) illustrates the
point. In a review of 1510 cases
over 20 years, 157 patients had a
previous or subsequent second pri
mary cancer. The group with two
cancers had a better survival rate at
10 years from breast cancer or
overall cancer than the 1353 re
maining patients with a single tu
mour. In speculating about possible
mechanisms for this finding the
authors discuss possible differences
in growth rates and in host re

sponses, and they develop unsupportable ideas that positive nodes
are the cause and not the conse
quence of the disease.
Retrospective reviews are some
times done to gather information
for the generation of new hypothe
ses. There is the danger, however,
of going down the wrong track,
especially if the initial premise is
faulty. As scientists we are taught
to seek the simplest and best expla
nation. In this case the methodolo
gy and analysis are seriously
flawed. Although insufficient details
are given in the methods section of
the paper, the authors appear to
have treated the occurrence of sec
ond cancers as fixed rather than as
a time-varying covariate in the anal
ysis. This assumption could intro
duce substantial bias that would
suggest better survival in the group
with multiple cancers. To put it
simply, the sooner a patient suc
cumbs to the initial cancer the less
time there is available, and there
fore the less likelihood, for a second
cancer to develop. In other words,
patients who have a second cancer
represent a subset of the overall
group who happen to live longer
and therefore have more opportuni
ty for the second cancer to occur.
Therefore, it is not surprising that
patients in this subset live longer.
A better approach would have

BREAST-CANCER SURVIVAL

been to perform a multivariate anal
ysis in which the development of a
subsequent cancer is handled as a
time-varying covariate. The analy
ses should include adjustment by
fixed covariates for host and disease
factors that may be related to sur
vival, such as age at diagnosis for
the first cancer, tumour size of the
first cancer and type of treatment
for the first cancer. The time to
subsequent cancer occurrence and
the time to death should be calcu
lated from the date of diagnosis of
the first cancer.

Other criticisms, such as exclu
sion of those lost to follow-up and
failure to conduct a multivariate
analysis, adjusting for stage and
other baseline factors, are also rele
vant. Although these steps may or
may not change the outcome or
conclusions, the essential point is
that clinical scientists should not
hamper their understanding of dis
ease by using methods that could
introduce bias and result in mislead
ing conclusions. Although we can
not tell from the description of
methods given in the paper by Pelo-

quin and colleagues to what degree
the above criticisms apply, it would
have been much better had a dis
cussion of methodologic features
taken precedence over speculations
about host defence or the role of
involved lymph nodes, which are
not sustained by present-day biolog
ic evidence.
Our best defence against being
misled is good methodology.
The advice of Dr. Joseph P. Costantino,
Department of Biostatistics, University
of Pittsburgh, on statistical methodolo
gy is gratefully acknowledged.

BOOK REVIEWS
CRITIQUES DE LIVRES

The following books are also re
viewed in this issue: Phonosurgery:
Assessment and Surgical Manage
ment of Voice Disorders (page
492); Operative Surgery (page
501)
ATLAS OF CUTANEOUS LASER
SURGERY. Edited by David B. Apfelberg. 495 pp. Illust. Raven Press, New
York. 1991. $195. (US). ISBN 0 88167-764-7

This outstanding publication presents a
wealth of information in an organized,
precise and factual manner. It is a true
atlas, having enough text to make the
colour photographic illustrations mean
ingful. The illustrations, with a few
exceptions, are of very high quality.
David B. Apfelburg, the editor, is an
internationally recognized expert in
laser therapy. There are 75 contributors
from eight countries, who skilfully used
217 case presentations to illustrate the
indications, techniques, benefits and li
mitations of each laser type.
The first chapter on the physical
principles of lasers presents briefly, but
thoroughly, information that should be
common knowledge to all those who

use laser therapy. Physical properties,
rate of delivery, laser tissue interaction,
dosimetry and the differences between
the various types of lasers are dis
cussed.
There are eight pages on laser safety
in the second chapter. This is mandato
ry reading because of the significant
risk to both patient and personnel when
lasers are in use. Adherence to these
safety guidelines is essential to avoid
eye injury and environmental hazards.
The third chapter contains two pages
on eye safety, relating specifically to the
patient and illustrating nicely new eyesafety products.
The next four chapters are devoted
specifically to the four most commonly
used lasers: carbon dioxide, argon, yt
trium-aluminum-garnet (YAG) and tun
able dye laser. The largest chapter is
devoted to the use of the carbon-dioxide
laser. There are 85 case presentations
on the following topics: vascular and
related lesions, malignant and premalignant lesions, inflammatory and infec
tious lesions, tattoos, miscellaneous
surgery and surgical procedures.
The largest group of cases discussed
falls into the miscellaneous-surgery cat
egory, and it is apparent that little has
escaped the “surgeon with a laser”.

Lesions such as chondrodermatitis no
dularis chronica helicis, digital myxoid
cysts, keloid scars and neurofibromato
sis are a few of the ones presented. The
text addresses the rationale for using a
particular laser, gives details of the
technique and presents additional infor
mation or alternative methods of treat
ment and when they are indicated. The
high-quality and appropriate photo
graphic illustrations depict in an honest
manner not only the excellent results
that can be achieved but also the disap
pointing ones.
The chapter on the argon laser is
shorter, with a greater emphasis on
vascular and related lesions, but its
versatility in treating other lesions is
well documented.
The usefulness of the YAG laser is
illustrated, with emphasis on vascular
and related lesions and surgical proce
dures.
The indications for choosing the tun
able dye laser are defined clearly for
each lesion illustrated. The photo
graphs illustrate its benefits in treating
port-wine stains in children. In the first
chapter, the complex structure of this

continued on page 492
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Survival of Breast-Cancer Patients
With Previous or Subsequent Neoplasms
A. Peloquin, MD, FRCSC; M. Poljicak, MD, FRCSC; M. Falardeau, MD, FRCSC;
D. Gravel, MD, FRCSC; R. Ratelle, MD, FRCSC; R. Moisescu, MD;
L. Peloquin, MD
The authors reviewed retrospectively 1510 patients with breast cancer operated on
between 1960 and 1980. They compared 1353 patients who had an isolated breast
cancer (group 1) with 157 patients who also had breast cancer but had other cancers
either previously or subsequently (group 2). The mean age of patients in group 2
was 2 years more than that of patients in group 1. Group 2 patients had fewer T3
tumours, more T1 tumours (TNM classification), a lower incidence of lymph-node
involvement and clinically less advanced tumours than group 1 patients. Hormonal
status, histologic type of tumour and surgical and adjuvant treatment were identical
in both groups.
The 19-year survival rate (considering death from breast cancer) was 54.6% in
group 1 versus 78.1% in group 2. The overall survival rate (considering death from
breast cancer or from the other cancer) was 54.1% in group 1 versus 64.5% in group
2. Survival was also better in group 2 for each clinical stage.
The authors conclude that patients who have another cancer before or after the
development of their breast cancer have a better survival rate than those who have
isolated breast cancer with no previous or subsequent neoplasms.

uch has been written about
multiple cancers,1-6 but to our
knowledge nothing has been writ
ten about the survival o f patients
with breast cancer who have previ
ously had malignant tumours other
than breast cancer or who have
other cancers after the development
o f their breast cancer. Is the surviv
al rate in these patients higher or
lower than in those who have an
isolated cancer o f the breast? In
other words, is the behaviour o f
breast cancer in such circumstances
more or less virulent?

Les auteurs ont fait une etude retrospective des 1510 patientes souffrant du cancer
du sein qui ont ete operees entre 1960 et 1980. Ils ont compare 1353 patientes
porteuses d’un cancer du sein isole (le groupe 1) a 157 patientes qui, en plus de leur
cancer du sein, ont eu d’autres cancers, soit avant, soit subsequemment (le groupe
2). L’age moyen des patientes du groupe 2 etait de 2 ans plus eleve que celui des
patientes du groupe 1. Les patientes du groupe 2 ont presente moins de tumeur de
stade T3, plus de tumeurs de stade T1 (classification TNM), une plus faible
incidence d’atteintes ganglionnaires et des tumeurs moins evoluees que les patientes
du groupe 1. L’etat hormonal, le type histologique des tumeurs et les traitements
chirurgicaux et adjuvants etaient identiques pour les deux groupes. La survie a 10
ans (considerant les deces dus au cancer du sein) fut de 54,6 % pour le groupe 1 et
de 78,1 % pour le groupe 2. La survie globale (considerant les deces dus au cancer
du sein ou a d’autres formes de cancer) fut de 54,1 % pour le groupe 1 et de 64,5 %
pour le groupe 2. La survie du groupe 2 fut egalement meilleure pour chacun des
stades diniques.
Les auteurs conduent que les patientes souffrant d’un cancer du sein qui ont deja
eu ou qui developpent subsequemment une autre forme de cancer, ont un meilleur
taux de survie que celles qui presentent seulement un cancer du sein isole.

Patients and Methods

From the Department o f Surgery, Hopital Notre-Dame, Universite de Montreal, Montreal, Que.
Presented at the 14th meeting o f the Canadian A ssociation o f General Surgeons held in
conjunction with the 60th annual meeting o f the R o y a l College o f Physicians and Surgeons o f
Canada, Quebec, Que., Sept. 20, 1991
Accepted fo r publication Jan. 7, 1992
Reprint requests to: Dr. Andre Peloquin, H op ital Notre-Dame, 1560 Sherbrooke St. E, M ontreal,
P Q H 2 L 4M1
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Patients were excluded from this
study if their breast cancers were
first treated elsewhere or if the
tumours were bilateral, inflammato
ry or associated with pregnancy.
Men with breast cancer were also
excluded.
Our study included 1510 con 
secutive patients in whom breast
cancer was diagnosed and who were
operated on and followed up at
Notre-Dame Hospital in Montreal
between 1960 and 1980. Two
groups were studied: group 1 com 
prised 1353 patients with a single
episode o f breast cancer; group 2
comprised 157 women who had
breast cancer and who also had a
previous or a subsequent other can
cer, or both. Included in group 2
were eight patients who had had a
total o f three cancers, one before
and one after their breast cancer;
58 had a previous cancer only and
CJS, VOL. 35, NO. 5, OCTOBER 1992
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All information from records was
computerized. Survival analysis was
done with the Lee-Dezu nonparametric test. The x2 test was used to
validate the significance of the re
sults.

99 had a subsequent cancer only.
The various types of other cancers
are shown in Table I. The TNM
classification was used to to de
scribe the size of the tumours and
their clinical staging.7
The follow-up ranged from 5 to
25 years.

The Tumour

Results
Table 1. Location and Number of Second or
Third Cancer in 157 Patients With Breast
Cancer
Location

Age and Hormonal Status
Group 2 patients (mean age 57.5
years) were significantly older (p =
0.029) than group 1 patients (mean
age 55.3 years).
Menopausal status was based on
the date of last menstruation. In
group 1, 509 patients (37.6%) were
premenopausal and 841 (62.2%)
were postmenopausal. Data were

No. of cancers

Cervix
Breast
Skin
Endometrium
Colon
Nose, throat and
larynx
Ovary
Other

missing for three patients. In group
2, 50 (31.8%) were premenopausal
and 107 (68.2%) were post
menopausal. These differences were
not significant.

28
24
22
20
11
8
7
45

There were significant differences
(p = 0.0288) between the two
groups with respect to tumour size
(Table II). Patients in group 2 had
more T1 and fewer T3 tumours
than those in group 1. Nonpalpable
tumours and tumours with cutane
ous signs were found in the same
proportion. In both groups, 50% of
the tumours were T2. Data on
tumour size were missing in two
patients in group 1.
Axillary Lymph-Node Involvement

Table II. Tumour Size in Patients With Breast Cancer Alone (Group 1) and Patients With Breast
Cancer and Previous or Subsequent Malignant Lesion (Group 2)
Group 1
Tumour size, cm
< 2
2 -5
> 5
Nonpalpable
Data missing

Tumour class

No.

%

No.

»/o

233
725
285
64
44
2

17.2
53.6
21.1
4.7
3.3
0.1

42
81
22
8
4
0

26.8
51.6
14.0
5.1
2.5
0

1353

100.0

157

100.0

T1
T2
T3
T4
TO

Total

Group 2

Table III. Lymph-Node Involvement in Patients With Breast Cancer Alone (Group 1) and Patients
With Breast Cancer and Previous or Subsequent Malignant Lesion (Group 2)

involved

No.

%

No.

%

None
1 -3
4 -1 0
> 11

452
314
160
38

46.9
32.6
16.6
3.9

64
27
10
2

62.1
26.2
9.7
1.9

964

100.0

103

99.9

Total

Table IV. Clinical Stage of Tumour in Patients With Breast Cancer Alone (Group 1) and Patients
With Breast Cancer and Previous or Subsequent Malignant Lesion (Group 2)
Group 1
No.

°/o

No.

%

I
II
III
IV
Unknown

259
718
340
34
2

19.2
53.1
25.1
2.5
0.1

46
81
30
0
0

29.3
51.6
19.1
0
0

1353

100.0

157

100.0
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Clinical Stage
In group 2, more patients had
stage I tumours, fewer had stage III
tumours and the same number had
stage II tumours as patients in
group 1 (Table IV). These differ
ences were significant (p = 0.0041).
In only two patients (in group 1)
was the cancer not classified, be
cause information on tumour size
was missing.
Histologic Findings

Group 2

Tumour stage

Total

In patients who had an axillary
dissection, group 2 patients had
significantly (p = 0.0242) less
lymph-node involvement than group
1 patients (Table III). By this criteri
on, the multiple-cancer group
should have a better prognosis.89

The histologic types of the tu
mours are shown in Table V. Can
cers classified as “other” are rare
forms, such as hydrosadenoid, malpighian, carcinoid and papillary tu
mours. In only one case was the
tumour, although proven to be can-

BREAST CANCER AND OTHER NEOPLASMS

axillary dissection, plus radiothera
py. Differences between the two
groups were not significant.

cer on biopsy, not clearly classified.
Differences between the two groups
were not significant.

Adjuvant Treatment

Treatment
Adjuvant radiotherapy was given
to 819 (60.5%) patients in group 1
and 86 (54.8%) patients in group 2.
Radiation was given to the skin and
regional lymph nodes and to the
breast when present. When radical
surgical procedures were per
formed, radiotherapy was generally
added to the surgical treatment if
more than three axillary lymph
nodes were involved. Radiotherapy
was also used for all patients who
underwent simple mastectomy or
conservative procedures. Adjuvant
hormonal therapy (estrogen, andro
gen, castration or antiestrogen) was

Surgical Treatment
Approximately 60% of the pa
tients in each group had a Halsted
radical or a modified radical mastec
tomy (Table VI). Nearly 15% of the
patients in both groups had simple
total mastectomy without axillary
dissection, followed in all cases by
radiotherapy. Conservative surgical
treatment, which came into use at
Notre-Dame Hospital in the early
1970s, was carried out on 20% of
patients who had tumorectomy or
partial mastectomy with or without

Table V. Histologic Type of Tumour in Patients With Breast Cancer Alone (Group 1) and Patients
With Breast Cancer and Previous or Subsequent Malignant Lesion (Group 2)
Group 1

Survival
The survival study is based on
1482 patients. Twenty-eight of the
1510 patients were excluded from
the study: 14 because they were
lost to follow-up; 2 because the
stage of the cancer was unknown;
and 12 because the exact date of
their operation or of them last visit
was missing.
Overall Survival

Group 2

Histologic type of tumour

No.

%

No.

%

Infiltrating ductal
Infiltrating lobular
Medullary
Mucinous
Paget's disease
Intraductal in situ
Lobular in situ
Other
Incomplete data

1025
146
62
40
24
6
5
44
1

75.8
10.8
4.6
3.0
1.8
0.4
0.4
3.2
0.1

122
20
5
7
2
1
0
0
0

77.7
12.7
3.2
4.5
1.3
0.6
0
0
0

Total

1353

100.1

157

100.0

Table VI. Surgical Treatment of Tumour in Patients With Breast Cancer Alone (Group 1) and
Patients With Breast Cancer and Previous or Subsequent Malignant Lesion (Group 2)
Group 1

Group 2

Surgical treatment

No.

•A

No.

%

Halsted or modified radical
mastectomy
Simple mastectomy + radiotherapy
Conservative surgery

878
196
279

64.9
14.5
20.6

99
23
35

63.1
14.6
22.3

1353

100.0

157

100.0

Total

seldom used: only 96 patients
(7.1%) in group 1 and 7 patients
(4.5%) in group 2 had some form of
hormone therapy. Differences were
not significant. Adjuvant chemo
therapy was not widely used before
1980; only 93 patients (6.9%) from
group 1 and 7 (4.5%) from group 2
received chemotherapy. These dif
ferences were also not significant.

Table VII. Survival Rates in Patients With Breast Cancer Alone (Group 1) and Patients With Breast
Cancer and Previous or Subsequent Malignant Lesion (Group 2): Death Due to Breast Cancer
Survival rate, yr; % of patients
Group

No. of patients

5

10

15

1
2

1327
155

67.9
86.7

54.6
78.1

47.3
69.5

With respect to death due to
breast cancer alone, there was an
important significant difference
(p = 0.0000) between the two
groups (Table VII). At 10 years,
54.6% of patients in group 1 were
alive compared with 78.1% in group
2. It is possible that the deaths of
the group 2 patients were due to a
malignant lesion other than breast
cancer.
Table VIII shows death rates due
either to breast cancer or to previ
ous or subsequent neoplasms other
than breast cancer. Again, at 10
years, there was a significant (p =
0.0008) difference in survival rates;
only 54.6% of group 1 patients
were alive compared with 64.5% of
group 2 patients.
Stage and Survival
The survival rate for each tumour
stage (Table IX) was analysed. The
differences between the two groups
for stage I, II and III tumours were
CJS, VOL. 35, NO. 5, OCTOBER 1992
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significant at p = 0.0332, p =
0.0015 and p = 0.0118 respective
ly.

ed breast-cancer group (group 1),
and the previous or subsequent can
cer did not appear to be a cause of
death in these patients.
The fact that group 2 patients
had less advanced cancer does not
explain their improved survival.
Even when each stage was consid
ered separately, survival was always
higher for group 2 patients. The
explanation for this is unknown.
Possibly, the breast cancer behaved
less aggressively in the multiplecancer group, as suggested by the
earlier clinical stage and, more im
portantly, the lesser degree of
lymph-node involvement (if we con
sider lymph-node invasion more as
a cause than a consequence of the
disease6). It would have been of
great interest to compare the histo
logic and nuclear grades of the
tumours; however, these data were
infrequently recorded. The presence
or absence of estrogen or progester
one receptors would have been an
other interesting criterion. Howev
er, these tests were done for very
few patients and only in the late
1970s. Adequate validation of these
tests was not available at that time.

Discussion
Both our study groups were com
parable with respect to hormonal
status, histologic type of tumour
and modality of treatment, but dif
fered in tumour size, lymph-node
involvement and clinical staging.
Patients in group 2 appeared to
have had a less advanced breast
cancer.
A survey of the literature failed
to reveal reports of survival in
breast-cancer patients who had also
had a previous or a subsequent
other cancer. In our study, the
overall survival of these patients
(group 2) was higher than in pa
tients with breast cancer only. This
was true when we analysed death
from breast cancer only, death from
breast cancer and the other cancer,
and death from breast cancer for
each clinical stage. The death rate
of the multiple-cancer group (group
2) was lower than that of the isolat

Table VIII. Survival Rates in Patients With Breast Cancer Alone (Group 1) and Patients With
Breast Cancer and Previous or Subsequent Malignant Lesion (Group 2): Death Due to Breast or
Other Cancer
Survival rate, yr; % ot patients

Some patients may have less de
fence against cancerous cells. In
such patients less virulent cancer
cells grow easily. In other patients,
these cells would be destroyed.

Conclusions
We would expect that women
who had had another type of cancer
previous or subsequent to breast
cancer would have a lower survival
rate than women who had only one
breast cancer. However, our study
showed that multicancer patients
actually had a better survival rate
than patients with an isolated breast
cancer. More studies are neeeded to
explain these results.
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T otal Mastectomy Is Not Always
Mandatory for the Treatment of Recurrent
Breast Cancer After Lumpectomy Alone
David R. McCready, MD, FRCSC; Edward B. Fish, MD, FRCSC; George Y. Hiraki, MD, FRCSC;
Theodore M. Ross, MD, FRCSC; Jacqueline L. Wall, BSc; H. Lavina A. Lickley, MD, PhD, FRCSC
To determine the treatment that offered the best local control for isolated local
recurrences of breast cancer after lumpectomy without radiotherapy, the authors
reviewed 355 patients initially treated by lumpectomy (with or without axillary
dissection) without radiotherapy. Local breast cancer recurred in 79 patients. They
underwent either repeat partial mastectomy (PM) or completion total mastectomy
(TM). Twenty-four patients (5 TM, 19 PM) received radiotherapy. Local control was
defined as the absence of further recurrence of breast or chest-wall cancer. The 19
patients treated with repeat PM and radiotherapy had an actuarial local control rate
of 82% at 5 years. Those treated with TM (18 patients) or TM plus radiation (5
patients) had rates of local control of 60% and 52% respectively. Although there
were no significant differences between the TM and PM plus radiotherapy groups,
the 27 patients who had a repeat PM without radiotherapy had a significantly lower
rate of local control (32%, p < 0.005).
Treatment of recurrent breast cancer with PM and radiotherapy is a viable
alternative to TM for enhancing local control. Repeat PM alone gave much poorer
results. The authors conclude that local cancer recurrences after lumpectomy alone
do not necessarily require TM and can often be treated with repeat excision and
radiotherapy.

Afin de trouver quel traitement offre le meilleur controle local des recidives locales
isolees apres tumorectomie sans radiotherapie, les auteurs ont etudie les cas de 355
patientes qui avaient ete traitees initialement par tumorectomie (avec ou sans
dissection axillaire). Des recidives locales du cancer du sein sont apparues chez 79
patientes. Elies subirent, soit une seconde mastectomie partielle (MP), soit une
mastectomie totale completee (MT). Vingt-quatre (5 MT et 19 MP) eurent en outre
une radiotherapie. Le controle local a ete defini par l’absence d’autres recidives
cancereuses au sein ou a la paroi thoracique. Les 19 patientes qui furent traitees par
une seconde MP et radiotherapie ont presente un taux actuariel de controle local de
82 %, a 5 ans. Celles qui furent traitees par MT (18 patientes) ou par MT et
radiotherapie (5 patientes) ont eu des taux de controle local de 60 % et 52 %
respectivement. Bien que Ton n’ait pas observe de difference significative entre les
groupes MT et MP et radiotherapie, les 27 patientes qui eurent une deuxieme MP
sans radiotherapie, ont eu un taux de controle local significativement plus faible
(32 %, p < 0,005).
Le traitement des recidives du cancer du sein par MP et radiotherapie represente
une alternative acceptable a la MT. Une deuxieme MP seule a donne des resultats
significativement plus mauvais. Les auteurs concluent que les recidives cancereuses
locales apres tumorectomie seule ne necessitent pas necessairement une MT et
qu’elles peuvent souvent etre traitees par une nouvelle excision accompagnee de
radiotherapie.

T

his study was prompted by a
clinical problem. The authors
had been following up a number of
breast-cancer patients who were ini
tially managed with surgical exci
sion (lumpectomy) without radio
therapy. Most of the patients were
treated between 1977 and 1986,
and a number of breast cancers had
recurred locally. The treatment of
the isolated breast recurrences had
not been uniform. Some of these
patients underwent a completion
total mastectomy (TM), as was man
dated in National Surgical Adjuvant
Breast Project (NSABP) protocol
B -06,1 and others were managed
with repeat resection (partial mas
tectomy [PM]), alone or in combina
tion with postoperative radiothera
py as suggested by Clarke and
associates.2 A small number re
ceived both a TM and chest-wall
irradiation. Because these different
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treatments are unlikely to alter
overall survival of the cancer pa
tient, local control becomes more
important. Local recurrence is a
serious problem and affects the pa
tient’s quality of life directly.
The purpose of this study was to
review the results of the various
treatment strategies for isolated
breast recurrences following lum
pectomy alone and to assess their
value for local control. Although
postoperative radiotherapy is cur
rently recommended after lumpecto
my for primary breast cancer, many
patients, participants and nonpar
ticipants in study protocols13'4 did
not receive this adjuvant treatment.
Information is needed to optimize
treatment, if and when an isolated
breast recurrence develops. Because
there is little information in the
literature pertaining to this clinical
situation and no prospective or
case-control studies are forthcom
ing, we first carried out a retrospec
tive review.

Patients and Methods
Between 1977 and 1986, 1149
women with breast cancer were ad
mitted to the Women’s College
Hospital, Toronto, and PM (lumpec
tomy), with or without an axillary
dissection, was performed in 476
women with stage I or stage II
tumours. Of these, 355 patients
with partial mastectomy and a tu
mour-free margin did not receive
adjuvant radiotherapy as part of
their primary treatment. A breast
recurrence developed in 87 (24.5%)
during a median follow-up of 5.9
years from the time of diagnosis.
The breast recurrence rate was not
influenced by the performance of an
axillary dissection at the time of
primary treatment. Twenty-nine
(25%) breast recurrences occurred
in 115 patients who did not have an
axillary dissection, and 58 (24%)
486
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occurred in 240 patients who un
derwent primary lumpectomy and
axillary dissection. These results in
dicate a recurrence rate smaller
than that found in the NSABP
protocol B-06 study after extensive
follow-up.1 Eight women who had
local recurrences, in conjunction
with diffuse systemic disease or
extensive chest-wall metastases and
who received chemotherapy but no
definitive surgical treatment were
excluded from this study. The 79
women with isolated breast recur
rence in the absence of known
metastatic disease formed the index
population for the study.
Charts of the 79 women (median
age at time of initial treatment 56
years [range from 31 to 92 years])
with surgically treated local breast
recurrences were reviewed. The
pathologic features of the initial
tumour were checked. The histo
logic type, the presence of lymphat
ic invasion and of ductal carcinoma
in situ and the size of the tumour
were all documented. The estrogenreceptor status and progesteronereceptor status of the primary tu
mour, when available, were record
ed. The operative records of the
original surgery and of subsequent
surgery for recurrence were re
viewed, and the use of postoperative
radiotherapy for the recurrent dis
ease was noted. All surgical resec
tions for local recurrence were done
with tumour-free margins. Chemo
therapy or tamoxifen therapy after
operation for recurrent cancer was
also noted. The study’s endpoint
was the absence of any further local
(breast or chest-wall) recurrences
until last follow-up or patient death.
This constituted local control. To
compare the local treatments for
isolated local breast recurrence (i.e.,
completion TM versus repeat PM),
the common endpoint of local con
trol had to be employed even
though many believe that local re
currence after TM is a manifesta

tion of distant metastasis, implying
a worse overall prognosis than local
recurrence after PM.
The data were analysed using the
BMDP program (BMDP Statistical
Software, Inc., Los Angeles, Calif.).
The generalized Wilcoxon (Breslow)
test was considered significant at p
< 0.05.5

Results
Our results demonstrate that the
treatment strategy employed for the
first breast recurrence significantly
(.p < 0.005) affected the eventual
local control rate (Fig. 1). Re-exci
sion (PM) alone (27 patients) was
clearly inadequate as evidenced by
only a 32% rate of local control at 5
years and was significantly (p <
0.005) inferior to all other treat
ments. The group receiving a PM in
combination with radiotherapy (19
patients) had an actuarial local-con
trol rate of 82%. The rates of local
control of the TM (eight patients)

FIG. 1. Five-year local control rates for
each treatment modality of isolated
breast-cancer recurrence after primary
lumpectomy alone. Resection of recur
rence as lumpectomy in combination
with radiotherapy (PM + XRT) had
5-year local control rate of 82%, while
PM alone was associated with local
control rate of only 32%, which was
significantly (p — 0.005, Wilcoxon
text) worse than all other modalities.
Total mastectomy (TM) with or with
out radiotherapy showed intermediate
levels of local control but rates were
not significantly different from PM +
XRT group.

TREATMENT FOR BREAST CANCER RECURRENCE

breast tumour existed between the
treatment groups. The location of
the tumour recurrence and its rela
tionship to the original tumour site
could have influenced the surgical
treatment decision: 79% of the
group in whom the recurrence was
treated with PM had the recurrent
tumour situated in the same breast
quadrant as their initial tumour,
and 52% of those who underwent
TM for local recurrence had their
first tumour recurrence in a differ
ent quadrant from the primary tu
mour.

and the TM plus radiotherapy (five
patients) groups were 60% and 52%
respectively. The differences be
tween the TM groups and the PM
plus radiotherapy group were not
statistically significant.
The histologic features of the
primary tumour and the presence of
lymphatic invasion or ductal carci
noma in situ, tumour size and in
volvement of axillary lymph nodes
did not affect eventual local control,
nor did the estrogen and progester
one receptor in the primary tumour
(Table I). Similarly, the use of ta
moxifen or other chemotherapy, or
both, at the time of isolated breast
recurrence had no appreciable effect
on local control rates in this study
(Table II).
The mean size of recurrent breast
tumour for each treatment group is
shown in Table III. Larger recur
rent tumours tended to be treated
with a TM; however, no significant
differences in size of the recurrent

Discussion
This study has shown that select
ed breast-cancer patients who have
isolated breast recurrences at the
lumpectomy site alone do not nec
essarily require a TM. A repeat PM
combined with postoperative radio
therapy can provide effective local

Table 1. Effect of Estrogen-Receptor (ER) and Progesterone-Receptor (PR) Status of Primary
Tumour on Eventual Local Control
Receptor status't
ER+ PR+
ER+ P R ER- PR-

No. of patients

Local control,
no. (%)

32
20
16

21 (66)
12(60)
10(62)

’ + = positive, - = negative
tOne patient was E R - PR+ and was free of disease; the other 10 patients did not have ER and
PR measured.

Table II. Effect of Tamoxifen or Other Chemotherapy at Time of First Breast-Tumour Recurrence
Therapy
Tamoxifen
Other chemotherapy
Neither

No. of patients*

Local control,
(%)

16
9
55

69
67
62

*0ne patient received both tamoxifen and other chemotherapy and was free of local disease.

Table III. Treatment in Relation to Size (Mean ± SD) of First Breast-Tumour Recurrence After
Lumpectomy
Treatment of first tumour recurrence
Partial mastectomy + radiotherapy
Total mastectomy
Total mastectomy + radiotherapy
Partial mastectomy

Tumour size, cm
1.5
2.1
2.4
1.7

± 0 .9
± 1.3
± 1.5
± 1.6

control. However, re-excision alone
is associated with a significantly
higher recurrence rate.
As with all retrospective studies
the results must be interpreted cau
tiously. There were obviously pa
tient and tumour factors that influ
enced surgical decision making.
The patients who received a TM
tended to have larger tumours than
those who had a repeat PM, even
though the differences were not
significant. This is one factor that
may have decreased the local con
trol rate of the group treated with a
TM. Most patients whose recur
rences were treated with a PM had
those recurrences in the same
breast quadrant as the original tu
mour, whereas a larger proportion
of the TM patients had recurrences
in locations other than the original
tumour site. Recurrences in other
breast quadrants may represent
multicentric disease, and thus there
may have been a bias that selected
higher-risk patients for total mas
tectomies.
These biases may help to explain
the slightly lower local control rate
in the TM groups compared with
the rates in the groups treated with
repeat PM and radiotherapy. How
ever, it should be remembered that
no significant differences existed
between these groups, and each
treatment provides acceptable local
control. The finding that a repeat
PM alone provides significantly
worse local control is not affected
by the potential biases.
Traditional prognostic factors
that were measured at the time of
the initial surgery, such as histolog
ic type, tumour size, estrogenreceptor status or the presence of
lymph-node metastasis, had little, if
any, effect on eventual local control
after breast recurrence. The most
important factor in eventual local
control was the treatment used for
the first breast-tumour recurrence.
In previous studies of breast recurCJS, VOL. 35, NO. 5, OCTOBER 1992
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rence after primary lumpectomy and
radiotherapy6' 8 it was found that
variables such as the size of the
primary tumour and the presence of
multicentricity were associated with
the development of a first breasttumour recurrence and with overall
survival after recurrence. However,
such studies did not address eventu
al local control in those patients
who had already had recurrence
after lumpectomy alone. Thus,
when treating patients with this
type of breast-cancer recurrence
historical data should not be al
lowed to affect treatment decisions
unduly.
In summary, our results provide
evidence that, for an isolated breastcancer recurrence after lumpectomy
alone, repeat PM combined with
radiotherapy postoperatively pro
duces excellent local control if the
recurrence can be locally resected

with a tumour-free margin. A TM
may be mandated by special circum
stances, but it does not seem to
confer extra local control for small
recurrences near the original tu
mour site. A repeat PM or re-excision alone is inadequate. It is en
couraging that repeat breast-con
servation surgery in combination
with radiotherapy can offer accept
able rates of local control for breast
recurrences after lumpectomy alone
and thus diminish the need for TM
with its attendant physical and psy
chologic morbidity.
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SESAP VII Question / Question SESAP VII
Items 222 to 225

(A) Follicular carcinoma of thyroid gland
(B) Papillary carcinoma of thyroid gland
(C) Both
(D) Neither

222. Can be considered after a two-year disease-free interval
223. Occurs after irradiation to head and neck
224. Peak incidence in patients younger than 30

225. Systemic metastases appropriately treated with radioactive iodine
For each of the numbered items select the appropriate lettered heading.
For the critique of Items 222 to 225 see page 559.
(Reproduced by permission from SESAP ’9 2 -’93 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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0 *ln empiric therapy for a wide range of infections
0 * Of an enviable safety profile
“ After 10 years of clinical experience in hundreds of
thousands of patients, it is evident that cefotaxime remains
an excellent agent for a broad range of patients, from the
neonate to the octogenarian, with a variety of infections.”
r‘
Neu HC. Third Generation Cephalosporins:
Safety Profiles after 10 Years of Clinical Use.
J. Clin. Pharmacol. 1990; 30:396-403.

0 "O f cost-effectiveness1

oran

IV
IM

| PMAC |

A

ROUSSEL

Makes good $ense!

cefotaxim e
sodium

oran

IV
IM

A 10 year record!

P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s: pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterococci, e.g. S. faecalis), Staphylococcus
aureus (penicillinase and non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fe c tio n s : caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains
Bacteremia / Septicem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens
Skin infe c tio n s: caused by Staphylococcus aureus (penicillinase and non penicillinase producing), S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdominal in fe c tio n s: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological in fe c tio n s: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis: anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bactemides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus laecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (eg. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
antibiotics); therefore, it is im portant to consider its diagnosis in patients who develop diarrhea during
the adm inistration of Claforan. This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with caution in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coombs' test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
As with other beta-lactam antibiotics, granulocytopenia and, more rarely, agranulocytosis may develop during
treatment with Claforan, particularly if given over long periods. For courses of treatment lasting longer than 10
days, blood counts should therefore be monitored.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitivity (1.8%): Rash, pruritus, fever Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. Hem atologic System ( < 1%): Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and
agranulocytosis have been reported. Some individuals have developed positive direct Coombs' test during

treatment with Claforan and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGPT, serum
LDH and serum alkaline phosphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine and
BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
Dosage
Adults: The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the
infection and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)

Type of Infection

Daily Dose
(9)

Frequency and Route

Uncomplicated Gonorrhea

1

1 g IM (single dose)

Uncomplicated infections

2

1 g every 12 hours IM or IV

Moderately severe to severe infections

3-6

1-2 g every 8 hours IM or IV

Very severe infections (e.g. septicemia, CNS)

6-8

2g every 6-8 hours IV

Life-threatening infections

up to 12

2 g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows:
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1T/i2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period

♦ >

Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.

A

Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.

*

Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
Males:

Weight (kg) x (140 - age)

Females:

0.85 x above value

72 x serum creatinine
Administration
Intra m uscular: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
Stability
Claforan reconstituted in the original vial as described under RECONSTITUTION maintains satisfactory potency for
24 hours at room temperature (25°C) and for 48 hours under refrigeration (0-5°C).
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
S to ra g e : Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
•Reg'd TM of Abbott Laboratories.
Reference
1. Bivins B.A., et a l: Antibiotics for Penetrating Abdominal Trauma: A Prospective Comparative Trial of Single
Agent Cephalosporin Therapy Versus Combination Therapy. Diagn Microbiol Infect Dis. 1989; 12:113-118.
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Surgery for Critical Aortic Stenosis
in Newborns Is Still Good Therapy
After 25 Years
J. Suzanne Vobecky, MD, FRCSC; Claude Chartrand, MD, FRCSC; Herve Angate, MD;
Paul Stanley, MD
Because of the high operative mortality in newborn infants with critical aortic
stenosis, new therapeutic modalities have emerged. The authors reviewed their
results of surgery for this condition in newborn infants between January 1964 and
December 1990. Thirty-seven infants were operated on for critical aortic stenosis,
which was diagnosed at a mean patient age of 14.5 days. The surgical procedure was
done at a mean patient age of 37 days. Five infants died intraoperatively of
ventricular fibrillation at the time of incision. Transventricular valvotomy was
attempted in 4 infants, and the remaining 28 infants underwent transaortic
valvuloplasty. Overall survival improved markedly in the last 5 years of the study,
from 31% to 75%. All patients who had transventricular valvotomy died, as did the
only infant with previous percutaneous aortic valvuloplasty. Of the infants who died,
38% weighed less than 3000 g at the time of operation compared with 13% of the
survivors (p < 0.05). The duration of cardiopulmonary bypass was also identified as
a risk factor (p = 0.001). Of the surviving infants, 93% were followed up at a mean
of 66 months. All but one were in New York Heart functional class I or II.
The following risk factors were identified for operative mortality: year of surgery,
preoperative hemodynamic condition, associated anomalies of the left ventricle,
surgical weight less than 3000 g, transventricular valvotomy, year of surgery and
prolonged cardiopulmonary bypass. Because of the much improved survival recently,
surgery remains a good therapeutic choice for critical aortic stenosis in the newborn
infant.
A cause du fort taux de mortalite operatoire chez le nouveau-ne atteint de stenose
aortique critique, de nouvelles modalites therapeutiques sont apparues. Les auteurs
ont etudie leurs resultats chirugicaux chez des bebes nes avec cette affection entre
janvier 1964 et decembre 1990. Trente-sept nouveau-nes furent operes pour une
stenose aortique critique diagnostiquee a l’age moyen de 14,5 jours. L’intervention
chirurgicale fut pratiquee a l’age moyen de 37 jours. Cinq bebes moururent durant
l’operation, d’une fibrillation ventriculaire apparue au moment de Tincision. Une
valvotomie transventriculaire fut tentee chez 4 bebes et les 28 autres subirent une
valvuloplastie transaortique. La survie s’est amelioree sensiblement au cours des 5
dernieres annees de l’etude, passant de 31 % a 75 %. Tous les patients qui avaient
subi une valvotomie transventriculaire sont morts, de meme que le seul bebe qui
avait subi prealablement une valvuloplastie aortique percutanee. Des nouveau-nes
qui sont decedes, 38 % pesaient mois de 3000 g au moment de l’operation,
comparativement a 13 % chez les survivants (p < 0,05). La duree de circulation
extracorporelle fut aussi identifiee comme facteur de risque (p = 0,001). Des
survivants, 93 % furent suivis pendant une moyenne de 66 mois. A l’exception d’un,
tous appartenaient aux categories I et II de la classification New York Heart.
Cette etude a permis d’identifier les facteurs de risque suivants de mortalite
operatoire chez le nouveau-ne souffrant de stenose aortique critique : annee de la
chirurgie, etat hemodynamique preoperatoire, anomalies du ventricule gauche, poids
a la chirurgie inferieur a 3000 g, valvotomie transventriculaire et circulation
extracorporelle prolongee. A cause de l’importante amelioration de la survie
observee recemment, la chirurgie demeure un bon choix therapeutique chez le
nouveau-ne souffrant de stenose aortique critique.

he operative mortality in new
born infants with critical aortic
stenosis has ranged from 20% to
80%.1-5 In an effort to improve
these rates, percutaneous balloon
angioplasty has been considered as
a possible palliative alternative.6
Surgical and anesthetic techniques
in the newborn are being improved
upon continually, with better preor postoperative resuscitation. We
reviewed our surgical experience
over the last 25 years before modi
fying our therapeutic approach.

T

Patients and Methods
Critical aortic stenosis was de
fined as a valvular stenosis requir
ing pharmacologic support at the
time of diagnosis. Included in the
study were newborn infants whose
symptoms were present and the
diagnosis made before 3 months of
age and who were operated on at
Sainte-Justine Hospital, Montreal,
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between January 1964 and Decem
ber 1990.
Information was gathered from a
retrospective review of medical, sur
gical or autopsy records along with
those obtained at the last follow-up
visit. Statistical analysis was done
and differences in ratios and risk
factors were evaluated by the x2 or
Fisher’s exact test.
Included in the study were 37
newborn infants, with a male-tofemale ratio of 3:1 (28 males, 9
females). Over the 25-year span of
the study, the diagnosis was made
at an average of 14.5 ± 23.9 days
(range from 1 to 113 days). Howev
er, during the last 5 years, critical
aortic stenosis was diagnosed much
earlier, at 4.1 ± 2.9 days (range
from 1 to 9 days). For more than
two-thirds of the infants the diagno
sis of critical aortic stenosis was
made by the 2nd week, and for 98%
the diagnosis was made in the 1st
month of life (Fig. 1).
The diagnosis was made by
echocardiography alone in 13 (35%)
infants. Cardiac catheterization
with angiography was done in 20
(54%) infants; 10 catheterizations
were done in association with
echocardiography. The diagnosis in
the last four (11%) infants was
made, and treatment done, on a
clinical basis alone; three of these
infants were seen in the mid-1960s.

Results
Since 1964, 22 of 37 infants died
at operation or in the first few
postoperative days, for a total mor
tality of 59% (Table I). In the last 5
years, two of eight infants died, a
significant decrease in the death
rate, from 69% (from 1964 to 1984)
to 25% (from 1985 to 1990) (p =
0.034, Fisher’s exact test).
In the early years, four infants
had transventricular aortic valvotomy through a posterolateral left
490
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thoracotomy; all died. With the in
troduction of transaortic valvulo
plasty under cardiopulmonary by
pass and aortic cross-clamping
without cardioplegia, the operative
death rate has been decreased from
100% (transventricular valvuloplas
ty) to 46% (transaortic valvuloplas
ty) (Table I). In five infants, no
surgical correction was attempted
because they died of ventricular
fibrillation at the time of incision.
Analysis of the final outcome

according to the preoperative he
modynamic condition is shown in
Table II. Although 3 (27%) of the
11 infants who were hemodynamically stable died, there were 19
deaths in the 26 newborns who
remained hemodynamically unstable
despite intensive preoperative phar
macologic support. This was a sta
tistically significant difference (p =
0.04, Fisher’s exact test).
There was no significant differ
ence in survival according to associ
ated cardiac anomalies. However,
the morphologic characteristics of
the left ventricle, as described on
preoperative echocardiography or
angiography, had some prognostic
value (Table III). Newborn infants
with a hypoplastic or dilated left
ventricle or with associated en
domyocardial fibroelastosis were at
significantly higher risk of dying at
surgery (p = 0.012, Fisher’s exact
test; p = 0.02, x2 test). On the
other hand, infants with a normal
or hypertrophic left ventricle had a
much better survival with an odds
ratio of 7.8. Unfortunately, informa
tion on the mitral valve was too

FIG. 1. Age distribution of infants with
critical aortic stenosis at time of diag
nosis. For period 1964 to 1990, mean
age was 14.5 ± 23.9 days (range from
1 to 113 days); for period 1985 to
1990, mean age was 4.1 ± 2.9 days
(range from 1 to 9 days).

Table I. Number of Newborn Deaths by Calendar Year and Surgical Technique
Period

Procedure

1964 -1990

1964 -1984

1985 -1990

No. of
No. of
patients deaths (%)

No. of
No. of
patients deaths (%)

No. of
No. of
patients deaths (%)

Transaortic
valvuloplasty
Trans ventricular
valvotomy
Ventricular fibrillation
Total

28

13 (46)

20

11 (55)

8

2* (25)

4
5

4(100)
5(100)

4
5

4(100)
5(100)

0
0

0
0

37

22 (59)

29

20 (69)f

8

2 (25)t

0
0

*0ne premature death (weight < 2400 g) and one heart failure after percutaneous angioplasty
t p = 0.034 (Fisher's exact test)
Table II. Number of Newborn Deaths by Hemodynamic Condition
Period
1964-1990
Preoperative hemodynamic
condition
Stable or medical control
Severe failure shock

p = 0.042 (Fisher's exact test)

1985-1990

No. of
patients

No. of
deaths

No. of
patients

No. of
deaths

11
26

3
19

6
2

0
2

AORTIC STENOSIS IN NEWBORNS

incomplete to allow valuable statis
tical analysis.
The average age at surgery was
similar to the age at the time of
diagnosis. From 1964 through
1990, surgical correction was done
at a mean age of 37 ± 49 days
(range from 1 to 259 days), but
since 1985 the age at surgery aver
aged 31 ± 33 days (range from 2 to
99 days). There was no statistically
significant difference in the age at
surgery among the survivors (44 ±
64 days) compared with those who
died (32 ± 36 days).
The average weight at surgery
remained stable over the years at
3418 ± 942 g. However, results
demonstrate that an operative
weight under 3000 g was associat
ed with a significantly higher (p =
0.05) perioperative mortality. Of the
deceased newborns, 38% weighed
less than 3 kg compared with 13%
of the surviving newborns.
From a study of the duration of
the cardiopulmonary bypass in rela
tion to the final outcome, cardiopul
monary bypass appeared to be sig
nificantly longer (p = 0.001) among
the deceased infants (83 ± 30 min)
than among the survivors (44 ± 1 7
min).
All but 1 of the 15 survivors
(93%) were followed up for a mean
of 66 months (range from 40 days
to 18 years). All were assessed
according to the New York Heart
Association functional classifica
tion, and all but one were in class I
or II. Residual peak transaortic gra
dient, as estimated on the echo
T a b le III. N u m b e r o f N e w b o rn D e a ns by
L e ft-V e n tric u la r M o rp h o lo g y
M o rp h o lo g y of
le ft v en tricle
N o rm a l o r h y p e rtro p h ic
D ilated h y p o p la s tic
fib ro e la s to s is
U n kn o w n

No. of
patien ts

No. of
deaths

19

9*

14
4

12*
1

* p = 0 .0 1 2 (F is h e r’s e x a c t te s t) o r = 7 .8 , p
= 0 .0 2 ( x 2 te s t)

Doppler study at the last follow-up
visit, was 57.2 ± 18.6 mm Hg. In
every patient who is still alive, myo
cardial contractility was normal; in
two, mild aortic and mitral insuffi
ciencies were discovered. At the end
of the study, only one child re
quired aortic-valve replacement with
Konno-type enlargement of the aor
tic annulus 5 years after initial
valvuloplasty; that child is now
asymptomatic and well. A second
child, now in her 14th year after
initial valvuloplasty, is awaiting
valve replacement.

Discussion
The analysis of our surgical re
sults of critical aortic stenosis in
the newborn identified the following
as risk factors for surgery: calendar
year of surgery, surgical technique,
preoperative hemodynamic condi
tion, associated morphologic anom
alies of the left ventricle, surgical
weight under 3000 g and prolonged
cardiopulmonary bypass.
The operative death rate in criti
cal aortic stenosis in the newborn
as reported by others1-3 and by us
(59%), is still too high. However,
there has been a trend toward im
provement in recent years (75%
survival in our study). Like oth
ers,2’4'5 we believe the improvement
is in part due to early introduction
of prostaglandins, which stabilize
the hemodynamic condition, and to
continuous progress in surgical and
anesthetic techniques in the new
born. Hence, results with new ther
apeutic techniques (e.g., percutane
ous balloon valvuloplasty) should
not be compared with the results
from surgical techniques used in
previous decades. In our study, the
two deaths in the last 5 years were
not unexpected; one death was in a
premature infant weighing less than
2400 g and the second in an infant
with end-stage heart failure second

ary to major aortic insufficiency
after percutaneous balloon angio
plasty.
Many surgical techniques have
been reported in literature: trans
aortic valvuloplasty with venous oc
clusion,78 transventricular valvotomy 1>9’10 and transaortic valvuloplas
ty under cardiopulmonary by
pass.1'5’11-15 Even though the trans
ventricular approach was described
as successful by some, at our insti
tution it was a major risk factor
(100% mortality). Although this
technique was abandoned in favour
of transaortic valvuloplasty, we
would emphasize that the transven
tricular valvotomy was done in the
early years of our study and often
on infants in serious hemodynamic
condition while a more expeditious
technique was sought.
Like others,1'2 we were able to
confirm an unstable preoperative
hemodynamic condition as a predic
tor of unfavourable outcome. Al
though our results indicate that the
duration of cardiopulmonary bypass
could be a significant risk factor (p
= 0.001), we believe it is only an
indicator of an unstable preopera
tive hemodynamic condition. Lon
ger myocardial support was at
tempted in all infants arriving at
operation in unstable condition.
Mitral-valve and left-ventricular
anomalies are predictors of an un
favourable operative result.11-13-15 In
our study group, all newborns with
associated endomyocardial fibro
elastosis and a hypoplastic left ven
tricle died at surgery. Unfortunately
information on the mitral valve in
these cases was missing as well as
the actual size of the aortic annu
lus, which would be useful in treat
ing infants with critical aortic ste
nosis. A hypoplastic left ventricle
should probably be considered a
variant of hypoplastic left-heart syn
drome and be treated as such.11
Contrary to reports by others,214
we did not identify age at the time
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of surgery as a significant risk
factor. Regardless of age, operative
weight under 3000 g was a signifi
cant risk factor (p = 0.05). This
result is of particular interest be
cause there is a tendency to an
earlier diagnosis and a younger age
at surgery in these infants.

Conclusions
In view of our surgical experi
ence over the last 25 years, surgery
is still a good therapeutic choice for
critical aortic stenosis in the new
born. As our results indicate, transaortic valvuloplasty under cardio
pulmonary bypass should be per
formed in a newborn infant without
associated fibroelastosis and with a
normal-sized left ventricle. Maxi
mum preoperative support should
be given until an optimum hemody
namic condition is reached. Finally,
because the transplantation pro
gram is available and fully orga
nized in our institution, we would
consider a heart transplant for a
child with a left-ventricular mor
phology that is predictive of un
favourable prognosis.
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BOOK REVIEWS
continued from page 477

laser is discussed, and the need for
frequent and regular maintenance of the
instrument is emphasized.
A chapter is devoted to new technol
ogies such as copper-vapour laser, goldvapour laser, the hexoscan device, KTP
and photodynamic therapy. There are
32 case presentations that illustrate the
potential benefits of this developing
technology.
Finally, many of the book’s case
illustrations are accompanied by refer
ences, and a helpful glossary of terms is
included in the book. The bibliography
is organized by type of laser and by
classification of lesion.
All laser surgeons who treat cutane
ous lesions will want this book close at
hand. It has a wealth of reference
material that is readily accessible. It
should certainly be on the shelf of all
libraries used by trainees in dermatolo
gy and plastic surgery.
A.D. Courtemanche, MD, FRCSC
Plastic and reconstructive surgeon
306 Laurel Medical Centre
888 W 8th Ave.
Vancouver, BC
V5Z 3Y1

PHONOSURGERY: ASSESSMENT
AND SURGICAL MANAGEMENT OF
VOICE DISORDERS. Edited by
Charles N. Ford and Diane M. Bless.
255 pp. Illust. Raven Press, New
York. 1991. $98. (US). ISBN 0 88167-781-7

Phonosurgery is a relatively new and
exciting field in the specialty of otolar
yngology. In the past, surgery of the
larynx has been directed at curing the
disease without serious concern for
voice improvement. Phonosurgery is
aimed primarily at disease removal, with
voice improvement as a planned result.
This text is complete in its discussion
of all aspects of phonosurgery. It is
enjoyable to read, thorough and ex
tremely well referenced. The text in
cludes 13 concise and well-written
chapters, containing clear figures and
tables.
For those unfamiliar with phono
surgery, the introductory chapter con
cisely and clearly describes what phonocontinued on page 501
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Descending Thoracic Aortic Aneurysms:
Surgical Treatment With the Gott Shunt
Alain Verdant, MD, FRCSC
Over the past 16 years, 267 consecutive patients underwent surgery for a
descending thoracic aortic aneurysm. To provide optimal protection of surrounding
organs during aortic occlusion, a 9-mm Gott shunt was used for distal perfusion in
all cases. The shunt was placed preferentially between the ascending aorta and the
descending aorta; however, alternative sites of proximal and distal cannulation were
chosen according to the location and the extent of the aneurysmal disease and the
presence of a concomitant aneurysm along the aortic conduit. In one-third of the
patients, a flowmeter on the shunt recorded shunt flows, which varied from 1100
mL/min to 4900 mL/min (mean 2526 mL/min). Because the highest shunt flows
were obtained with proximal systolic pressures lower than 140 mm Hg,
nitroglycerin and nitroprussate were used routinely to improve distal perfusion
by arterial vasodilatation and release of proximal organs from a circulatory overload.
The mean aortic cross-clamp time was 33 minutes for the entire series but was
reduced to 25 minutes for the last 140 patients. The hospital death rate was 14.6%
overall (12.2% if ruptured aneurysms were excluded). Of the 267 patients, 260
survived the operation and underwent clinical neurologic assessment. No paraplegia
or other spinal-cord ischemic deficit occurred.

Au cours des 16 dernieres annees, 267 patients ont ete operes pour un anevrisme de
l’aorte thoracique descendante. Dans le but d’assurer une protection optimale des
organes adajacents pendant la periode d’occlusion aortique, une derivation de Gott
de 9 mm fut installee dans tous les cas pour procurer une perfusion distale. De
preference, la derivation etait placee entre l’aorte ascendante et l’aorte descendante;
toutefois, selon la localisation et l’etendue de l'anevrisme, ou la presence d’un autre
anevrisme le long de l’aorte, d’autres sieges de cannulation proximale et distale
durent etre choisis. Chez un tiers des patients, un debitmetre place sur la derivation
a permis de mesurer des debits variant de 1100 mL/min a 4900 mL/min (moyenne
de 2526 mL/min). Comme les plus forts debits ont ete obtenus avec des tensions
systoliques inferieures a 140 mm Hg, de la nitroglycerine et de l’acide
nitroprussique ont ete administres systematiquement pour ameliorer la perfusion
distale par vasodilatation arterielle et liberation des organes proximaux d’une
surcharge circulatoire. Pour toute la serie, le temps de clampage moyen a ete de 33
minutes, mais il fut reduit a 25 minutes pour les 140 derniers patients. La mortality
hospitaliere globale fut de 14,6 % (12,2 % si Ton exclut les ruptures d’anevrismes).
Des 267 patients, 260 survecurent a l’operation et subirent une evaluation
neurologique. Aucune paraplegie ou autre deficit ischemique de la moelle epiniere
n’est survenue.
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ne of the greatest challenges
and priorities in thoracic aortic
surgery is the avoidance of paraple
gia, which may occur after only 15
to 20 minutes of aortic cross-clamp
ing.1 Carrel,2 in 1910, and others3-6
40 years later showed experimental
ly and clinically that the time of
aortic occlusion could be safely pro
longed by using an external shunt
to provide uninterrupted perfusion
of the spinal cord during aortic
repair. Following this principle of
organ protection, we, in 1974,
adapted the 9-mm Gott shunt
(TDMAC-heparin shunt; Sherwood
Medical Industries, St. Louis, Mo.)
as a single method of distal perfu
sion during the interposition of Da
cron grafts for reconstruction of
the descend- ing thoracic aorta.7

O

The Shunt
The shunt is a transparent tube
made of polyvinyl chloride, de
signed with an unequal diameter
throughout its length. The central
portion has an inner diameter of
12.5 mm to reduce the overall re
sistance to blood flow. To facilitate
aortic cannulation, each end is ta
pered to reach an outer diameter of
9 mm. The greatest advantage of
the shunt is the throm boresistant
property of its heparin-coated inner
surface; this eliminates the need for
systemic heparinization.

Clinical Material
In the last 16 years, 267 con
secutive patients underwent resec
tion of an aneurysm of the descend
ing thoracic aorta (situated between
CJS, VOL. 35, NO. 5, OCTOBER 1992
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the left subclavian artery proximally
and the crux of the diaphragm
distally). There were four different
causes: traumatic aneurysms (67
patients), degenerative aneurysms
mostly classified as arteriosclerotic
in origin (122 patients), dissecting
aneurysms (57 patients) and con
genital aneurysms (21 patients).
Patients ranged in age from 18 to
82 years (mean 55 years) with a
male predominance (65%). Seventyeight aortic reconstructions were
undertaken as emergency proce
dures: 33 were acute traumatic aor
tic disruptions, 33 were acute dis
sections and 12 were ruptured arte
riosclerotic aneurysms.

Surgical Technique
Because I operated on 94% of the
cases, the technique became stan
dardized early in the series.7 Four
major principles were established
and have been followed rigorously:
• A 9-mm Gott shunt was used
in all patients.
• The aneurysmal disease was
controlled with the shortest resec
tion anatomically feasible: the prox
imal one-third of the aorta in 85%
of cases; two-thirds of the aortic
length in 14% and all the descend
ing aorta in 1%.
• Every technical detail was re
fined to reduce the aortic cross
clamp time below the 30-minute
critical level.
• The inclusion technique was
not used. A full-thickness anasto
mosis was accomplished so that a
circumferential incorporation of the
adventitia was achieved at all anas
tomotic sites.
The left chest was approached
through the bed of the fourth, fifth
or sixth resected rib in accordance
with the location and extension of
the aneurysmal disease. In 20 pa
tients (7.5%), a long aortic resection
necessitated a double intercostal ap
proach through a single skin inci
494

JCC, VOL. 35, N° 5, OCTOBRE 1992

sion. In two patients, because of the
presence of a right aortic arch and a
right-sided descending aorta, a
right-chest approach was selected.
A double-lumen endotracheal tube
for selective collapse of the left lung
was used to achieve optimal expo
sure without causing undue com
pression of the heart during lung
retraction.
The ascending aorta for proximal
cannulation (189 cases) and the
descending aorta for distal cannula
tion (170 cases) were the preferen
tial sites for insertion of the Gott
shunt (Fig. 1). In 26 cases, because
either an associated aneurysm or a
previous surgical procedure in
volved the ascending aorta, the aor
tic arch was used for proximal
cannulation. In 52 cases, with ei
ther a midthoracic or a lower tho
racic position of the aneurysm, the
first centimetres of the descending
aorta were suitable for proximal
cannulation. In 97 cases, the close
proximity of the diaphragm or the
presence of a dissecting process
involving the thoracoabdominal
aorta necessitated the use of the

FIG. 1. Preferential sites for proximal
and distal insertion of Gott shunt are
ascending and descending aorta.

femoral artery because it was the
only distal arterial access available.
The distal end of the shunt was
introduced through a 10-mm woven
Dacron prosthesis, previously anas
tomosed as a side branch to the
femoral artery. There are two ad
vantages to this technique. First, a
9-mm shunt can always be used
whatever the size of the femoral
artery. Second, distal perfusion of
the leg is preserved, avoiding clot
formation and metabolic acidosis.
Cannulation of the ascending
aorta deeply situated from a leftchest approach is the most difficult
part of this shunting procedure.
Cannulation can be facilitated by
surrounding the aorta with an um
bilical tape. Any tear of the main
pulmonary artery, the right pulmo
nary artery, the superior vena cava
or the right auricle should be avoid
ed during this manoeuvre. The as
cending aorta pulled out of the
pericardium is then cannulated in
the middle of a double pursestring
suture. A rubber ring added at each
extremity of the shunt avoids exces
sive penetration into the aortic
lumen and facilitates proper posi
tioning. In an acute situation, the
shunt is first inserted proximally
and distally before any anatomical
dissection is initiated so that distal
perfusion is available immediately if
emergency aortic cross-clamping is
needed. This is recommended par
ticularly in repair of acute rupture
of the descending thoracic aorta.
The reliability of this method of
perfusion depends on constant and
optimal performance of the shunt.
Performance can be assessed by
three methods.
• The simplest is the visualiza
tion of the blood velocity through
the transparent wall of the shunt as
soon as the aorta is cross-clamped.
• Distal aortic pressure is also
easy to monitor and shows a slight
increase as soon as the shunt is
opened. Measured in 37 patients, it

DESCENDING THORACIC AORTIC ANEURYSMS

varied from 15 to 100 mm Hg
(mean 62 mm Hg), correlating with
a mean proximal systolic pressure
of 140 mm Hg. A mean shunt gra
dient of 68 mm Hg is generated due
to the resistance of the wall.
• The most precise method is
measurement of blood flow. This
was realized in 91 patients by
adapting a flowmeter on the shunt.
Shunt flows ranged from 1100
ml/min to 4900 ml/min (mean
2526 ml/min). In 93% of the pa
tients, the flow was greater than
1500 ml/min, in 85% it was greater
than 2000 ml/min, in 67% greater
than 2500 ml/min and in 34% it
was greater than 3000 ml/min.
The average amount of blood
flow delivered through the shunt
varied in relation to the site of
proximal cannulation (ascending
aorta 2685 ml/min, aortic arch
2235 ml/min, descending aorta
2330 ml/min) and of distal can
nulation (descending aorta 2690
ml/min, femoral artery 2276
ml/min). In nine patients, it was
clearly demonstrated that shunt
flow was directly related to the level
of the proximal systolic pressure, a
35% increase of the latter resulting
in a 33% increase in shunt flow.
However, in two patients shunt
flows of 4000 ml/min and 4900
ml/min were recorded with normal
systolic pressures of 110 mm Hg
and 140 mm Hg respectively.
The use of an autotransfusion
unit allows rapid reinfusion if blood
loss is extensive and a better he
modynamic stabilization. In 218
cases, the proximal aortic clamp
was applied between the left com
mon carotid artery and the left
subclavian artery, and in 5 it was
temporarily applied between the in
nominate and the left carotid arter
ies. The aortic cross-clamp time
varied from 8 to 105 minutes (mean
33 minutes). For the last 140 pa
tients, this was reduced to 25 min
utes.

Results
The overall hospital death rate
was 14.6% (39 of 267 patients).
Eight of 12 patients with ruptured
arteriosclerotic aneurysms died. If
this group of patients is excluded,
the overall hospital death rate was
12.2% (31 of 255 patients). Respira
tory failure (in 16 patients) and
perioperative hemorrhage (in 11 pa
tients), encountered in ruptured an
eurysms, repeat procedures and ex
tensive chronic dissecting aneu
rysms, were the most common
causes of death. Of the 267 pa
tients, 260 survived the operation,
and precise clinical neurologic eval
uation was possible. None of them
suffered paraplegia or spinal-cord
ischemic deficit. Only one patient
(0.4%) had renal failure and needed
hemodialysis. This patient had a
ruptured arteriosclerotic aneurysm
and was in profound shock.

Discussion
The spinal cord is highly vulnera
ble to ischemia, so any method of
perfusion that is not associated with
a single case of paraplegia must be
considered very reliable. The size of
the shunt is of upmost importance,
and in my group we have never
used one smaller than 9 mm. Con
tinuous monitoring of shunt perfor
mance is as important as monitor
ing the extracorporeal circuit dur
ing open-heart surgery, and we
have found measurements of shunt
flows the most reliable method.
Since the highest shunt flows
have been obtained with normal
proximal systolic pressures, we use
nitroglycerin or nitroprussate, or
both, to reduce the peripheral re
sistance so as to optimize distal
perfusion and keep the proximal
aortic pressure lower than 150
mm Hg. This relieves the circula
tory strain imposed on the heart
and brain during aortic clamping.

Experience from open-heart sur
gery has shown that the pump flow
is much more important for organ
preservation than the distal aortic
pressure generated by the circuit.
This is in agreement with Craw
ford’s observation that larger flows
with low distal pressures were asso
ciated with less neurologic injury
than high pressures with lower
flows.8
/
In addition to strict adherence to
the use of a single method of dis/tal
perfusion for all elective and enliergency cases, two important princi
ples were respected. First, This
method of perfusion like any 9 ther
available method cannot reproduce
perfectly the normal physiology of
an unclamped aorta. Therefore the
aortic cross-clamp time should be
kept to a minimum, and emphasis
should be placed on rapid restora
tion of pulsatile flow. Second, to
save critical intercostal arteries, the
aortic disease should be controlled
with the shortest resection anatomi
cally feasible. This principle applies
mostly to dissecting aneurysms in
volving the thoracoabdominal seg
ment; only the site of perforat'on if
clearly visualized and the adjacent
dilated aortic segment are resected.
Paraplegia is such a devastating
complication and its related death
rate so high (23% to 70%)9 that
compromises on the length of aortic
resection have to be accepted, tak
ing for granted that total aortic
replacement is accompanied by pro
hibitive operative mortality and
morbidity.
The rare occurrence of renal fail
ure in one patient showed also the
efficiency of this shunting proce
dure in protecting distal organs.
Remarkable hemodynamic and met
abolic stability was also observed
during aortic cross-clamping.

Conclusions
Replacement of descending thoCJS, VOL. 35, NO. 5. OCTOBER 1992
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racic aorta remains a significant
physiologic enterprise that should
allow the patient to survive the
removal of a life-threatening lesion
without damage to surrounding or
gans. Throughout this experience
the 9-mm Gott shunt was found to
be a versatile and reliable method of
\ distal perfusion. Precise monitoring
x of shunt performance, short aortic
(seclusion time and limited aortic
rejection are three important fac
tors in optimal protection of the
spifiial cord.
\

Addendum

Since this manuscript was accept
ed for [publication, 52 new cases of
descending thoracic aortic aneu
rysms have been diagnosed and

resected using the Gott shunt. The
entire series comprises 319 cases.
The hospital death rate is 13.4%
overall (11.2% if ruptured aneu
rysms are excluded). None of the
312 patients who survived the oper
ation have suffered from paraplegia
or any other spinal-cord ischemic
deficit.
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CANADIAN SOCIETY OF CARDIOVASCULAR AND THORACIC SURGEONS

Central Neurogenic Tumours
of the Thoracic Region
Farid M. Shamji, MD, FRCSC;* Thomas R. Todd, MD, FRCSC;* Eric Vallieres, MD, FRCSC;*
Harold J. Sachs, MD, FRCSC;* Brien G. Benoit, MD, FRCSCt

Of special concern in the management of neurogenic tumours arising in the thorax
is spinal-cord compression resulting from either intraspinal lesions or
vertebral-body destruction and collapse. A review of 16 cases disclosed three
dumbbell tumours, six intrathoracic tumours, one case of neurofibromatosis with
multiple intraspinal neurogenic tumours, two malignant neurogenic tumours with
vertebral-body destruction causing spinal-cord compression and four foraminal
lesions with central intraspinal (extradural) extension. There were 3 men and 13
women, ranging in age at the time of operation from 37 to 79 years. Three patients,
of the six with intrathoracic tumours, were asymptomatic; the remaining 13 had
preoperative symptoms ranging in duration from 3 weeks to 12 months (average, 9
months). Back pain with intercostal neuralgia was present in eight patients and
neurologic signs were present in six patients. A routine chest radiograph was
abnormal in 10 patients, and x-rays of the thoracic spine were abnormal in 4 of the
other 6 patients. The tumour was excised surgically in all patients. Complications
developed postoperatively in two patients: one had Horner’s syndrome, transient
paraparesis and bleeding; the other had a small subarachnoid-cutaneous fistula. The
authors conclude that dumbbell neurogenic tumours and those causing
vertebral-body destruction and collapse demand a multidisciplinary one-stage
surgical approach. If the lesion is malignant and resection is not complete,
radiotherapy or chemotherapy is necessary.
Dans le traitement des tumeurs neurogenes apparaissant dans le thorax, la
compression de la moelle epiniere causee soit par des lesions intraspinales, soit par
la destruction et l’ecrasement du corps vertebral, represente un probleme
particulier. L’etude de 16 cas a revele trois tumeurs du mediastin superieur
penetrant dans l’espace sous-dural, six tumeurs intrathoraciques, un cas de
neurofibromatose associee a de multiples tumeurs neurogenes intraspinales, deux
tumeurs neurogenes malignes avec destruction du corps vertebral causant une
compression de la moelle et quatre lesions du trou de conjugaison avec extension
intraspinale centrale (extradurale). On comptait 3 hommes et 13 femmes dont I’age
au moment de l’operation variait de 37 a 79 ans. Trois des 6 patients porteurs de
tumeurs intrathoraciques etaient asymptomatiques; les 13 autres patients
souffraient de symptomes ayant apparu de 3 semaines a 12 mois (moyenne, 9 mois)
avant le diagnostic et l’operation. Une douleur dorsale avec nevralgie intercostale
etait presente chez huit patients et des signes neurologiques, chez six patients. La
radiographie pulmonaire reguliere etait anormale chez 10 patients. La radiographie
de la colonne dorsale etait anormale chez quatre des six autres patients. La tumeur
fut excisee chirurgicalement chez tous les malades. Des complications
postoperatoires sont apparues chez deux patients ; un presenta un syndrome de
Horner, une paraparesie transitoire et des saignements; l’autre eut une petite fistule
sous-arachnoi'do-cutanee. Les auteurs concluent que les tumeurs du mediastin
superieur penetrant dans l’espace sous-dural et celles qui causent la destruction et
l’ecrasement du corps vertebral exigent un abord chirurgical pluridisciplinaire en un
temps. Si la lesion est maligne et la resection incomplete, la radiotherapie ou la
chimioterapie sont necessaires.

horacic neurogenic tumours
differentiate from the neuroepi
thelium that originates in the neu
ral crest during the development of
the peripheral nervous system .1
Most of the peripheral nervous tis
sue in the thorax is situated in the
posterior mediastinum in the para
vertebral gutters. Consequently,
this is the commonest location for
the majority of intrathoracic neuro
genic tumours — at the site o f the
sympathetic chain and in the path
of the spinal and intercostal
nerves.2
The histologic type of neurogenic
tumour is less important to the
thoracic surgeon than the anatomi
cal relationship of the tumour to
other posterior mediastinal struc
tures and, in particular, to the inter
vertebral foramen. The possibility of
intraspinal extension through the
foramina is the single most impor
tant factor affecting surgical inter
vention.
We present our experience, albeit
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small, because it outlines the impor
tance of thorough anatomic assess
ment of these tumours. It stresses
the involvement of the neurosur
geon in the assessment, decision
making and surgical intervention.

Clinical Data
We reviewed our experience with
16 posterior mediastinal neurogenic
tumours between 1977 and 1990.
Data were obtained from hospital
statistics and patient charts re
viewed retrospectively.
Although neurogenic tumours
present at all ages, they occur pre

dominantly in young adults. The
average age of the 16 patients (13
women, 3 men) in our series was 40
years (range from 37 to 79 years).
The female predominance is in
agreement with that in other re
ports.3' 5 Neurogenic tumours can
occur in any site, but the posterior
mediastinum is the favoured loca
tion. In our experience all the neu
rogenic tumours were located in the
region of the thoracic spine and the
sulcus costovertebralis. The clinical
presentation was related to the loca
tion of the tumour in the thorax
(Fig. 1).
Three of our patients had true
dumbbell neurogenic tumours (Fig.

2), as defined by Love and Dodge6
when the tumour was found to be
involving the spinal canal. Six pa
tients had intrathoracic tumours. Of
these, two patients had radiologic
evidence of intraforaminal extension
(Fig. 3); one of them had bilateral
tumours at the same level. Four
patients had neurogenic tumours
arising within the intervertebral fo
ramina with central intraspinal ex
tension. Two patients had malig
nant neurogenic tumours in the
paravertebral gutter, showing evi
dence of vertebral-body invasion.
The last patient had neurofi
bromatosis with multiple intraspinal
tumours.

FIG. 1. (Top left) Intrathoracic neurogenic tumour (T) that is extraspinal and extrapleural (four patients). Tumour is
asymptomatic or causes vague chest pain. (Top right) Intrathoracic neurogenic tumour (T) with foraminal extension (two
patients). Tumour causes radicular chest pain. (Bottom left) Intraspinal neurogenic tumour (T) that is extradural (five patients).
Tumour is associated with spinal-cord compression. (Bottom right) Dumbbell neurogenic tumour (T) that is intraspinal and
intrathoracic (three patients). Tumour is associated with spinal-cord compression.
498
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Symptoms

All but three patients presented
with symptoms. The three asymp
tomatic patients all had intrathorac
ic tumours. Ten patients (3 with
dumbbell tumours, 2 with malig

ration of symptoms up to the time
of diagnosis ranged from 3 weeks
to 12 months (mean 9 months).

nant tumours, 4 with foraminal
neurogenic tumours and the 1 pa
tient with neurofibromatosis) pre
sented with symptoms of spinalcord compression. Three of the six
patients with intrathoracic tumours
presented with chest pain. The du7

Radiologic Examination

All of the patients underwent
radiography of the chest and tho
racic spine and computed tomogra
phy; myelography was performed in
patients with symptoms of spinalcord compression. Magnetic reso
nance imaging, which supersedes
computed tomography and oblique
polytomography of the thoracic
spine in the assessment of these
tumours, has been available only
recently at our institution. Spinalartery angiography was not per
formed because all the tumours
were above the T8 level, and there
is less concern about the major
radicular arterial blood supply to
the spinal cord in the upper thorax.
The chest radiograph was abnormal
in 10 of the 16 patients and x-ray
films of the thoracic spine were
abnormal in 4 of the other 6.

OTTAWA CIVIC HSP
INTL 1200S)

FIG. 2. Computed tomography scan showing enlarged intervertebral foramen
(arrow), destruction of pedicle and intraspinal extension of tumour mass.

Surgical Management
All tum ours were resected. The
surgical approach was based on the
location of the tumour (Table I).
Multilevel laminectomy alone was
performed by the neurosurgeon in
five patients who had intraspinal
tumours, four patients with foraminal lesions and central extension
and one patient with neurofi
bromatosis. Posterolateral thoracot
omy was th e approach used by the
thoracic surgeon in four patients
when the tum our was intrathoracic
and benign - The two patients who
had malign a n t neurogenic tumour
in the paravertebral gutters and
evidence ° f local invasion were ap
proached th rough a posterolateral
thoracotomy with the assistance of
an 01-thoPe<dic surgeon; spinal fu
sion of th e T1 to T3 vertebrae was

FIG. 3. Computed tomography scan demonstrates bilateral neurogenic tumours
(arrows) with foraminal extension. Intervertebral foramen is widened and pedicle is
still intact.
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necessary in one patient. Both pa
tients received radiotherapy postoperatively. In the two patients who
had intrathoracic tumours with ex
tension into the intervertebral fo
ramina, posterolateral thoracotomy
with foraminectomy was the proce
dure favoured by thoracic and neu
rosurgeons to remove the tumour
safely. Of the three patients with
dumbbell tumours, two underwent
staged procedures — laminectomy
performed by the neurosurgeon to
remove the intraspinal component
followed in 2 to 3 weeks by a
posterolateral thoracotomy to re
sect the intrathoracic component.
The third patient had the dumbbell
tumour removed completely in one
stage — a laminectomy followed
immediately by posterolateral thora
cotomy.

Results and Complications
In this series, 14 (88%) of the 16
patients had benign nerve-sheath
tumours: neurilemmoma (schwan
noma) in 10 and neurofibroma in 4.
There were two malignant tumours
(12%); both patients had malignant
schwannoma. A review of the litera
ture indicates that the incidence of
malignancy in mediastinal neuro
genic tumours ranges from 3% to
19%.4
Complications of the operation
occurred in two patients. One pa
tient who had a malignant schwan
noma resected with spinal fusion

Table 1. S u
Location of tumour
In tra s p in a l
In tra th o ra c ic
In tra th o ra c ic w ith v e rte b ra l-b o d y
in v a s io n
In tra th o ra c ic w ith fo ra m in a l
e xte n s io n
D u m b b e ll

500

suffered from Horner’s syndrome,
transient paraperesis and bleeding
requiring re-exploration. The other
patient, who underwent posterolat
eral thoracotomy and foraminecto
my to resect the tumour had a small
subarachnoid-cutaneous fistula,
which closed spontaneously.
Of the 14 patients with benign
neurogenic tumours, none is known
to have died as a result of recurrent
tumour. The two patients with ma
lignant schwannoma had recurrent
tumour and died at 16 months and
24 months after the initial opera
tion respectively.

Discussion
Patients with neurogenic tu
mours arising in the thorax should
undergo early surgical exploration
and complete resection of the tu
mour if possible. Arising within the
confines of the narrow thoracic spi
nal canal or the intervertebral fora
men, these lesions may become
symptomatic quite early on, with
spinal-cord compression or segmen
tal radicular pain caused by early
spinal-nerve involvement. Neurosur
gical consultation is a prerequisite
for safe removal of these tumours
when the intervertebral foramina
are traversed. Fortunately, most in
trathoracic neurogenic tumours are
small, benign, unilateral, extrapleu
ral and extraspinal. The diagnosis
can often be established readily with
current diagnostic imaging tech

niques, and the tumour can be
removed safely with adequate expo
sure through a posterolateral thora
cotomy. When the thoracic surgeon
suspects preoperatively that the tu
mour has an intraspinal extension,
the neurosurgeon should be con
sulted before exploration is consid
ered. Indeed, in all patients who
have a lesion adjacent to the inter
vertebral foramen, a neurosurgical
consultation should be obtained. In
these circumstances, the patient’s
spinal cord is at considerable risk of
permanent damage from ill-advised
surgical manoeuvres. The proce
dures that should not be attempted
without intraoperative assistance of
a neurosurgeon include enlarging
the intervertebral foramen (forami
nectomy), application of undue trac
tion on the tumour during dissec
tion, tamponading the bleeding ves
sels in the foramen when hemorrh
age is difficult to control and partial
removal of the tumour. Conse
quently, it is of utmost importance
that all neurogenic tumours arising
in the posterior location be studied
very carefully with special reference
to the intervertebral foramen and
possible intraspinal extension. The
value of computed tomography and
magnetic resonance imaging has
been well established.7 Prior knowl
edge of a dumbbell tumour or of a
predominantly intrathoracic tumour
with foraminal extension dictates a
combined thoracic-neurosurgical
procedure.89 The approach consists
of a standard posterolateral thora-
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No. of
patients
5

4
2
2
3
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Surgical
approach
L a m in e c to m y
P o s te ro la te ra l th o ra c o to m y
P o s te ro la te ra l th o ra c o to m y +
s p in a l fusion
P o s te ro la te ra l th o ra c o to m y +
fo ra m in e c to m y
L a m in e c to m y + p o s te ro la te ra l
th o ra c o to m y

Surgeon’s
specialty
N e u ro s u rg e ry
T h o ra c ic s u rg e ry
T h o ra c ic s u rg e ry
O rth o p e d ic s u rg e ry
T h o ra c ic s u rg e ry
N e u ro s u rg e ry
N e u ro s u rg e ry
T h o ra c ic s u rg e ry

Complications
N one
None
H o rn e r’ s s y n d ro m e , p a ra p a re s is a n d
b le e d in g (1 p t)
T ra n s ie n t s u b a ra c h n o id - c u ta n e o u s
fis tu la (1 p t)
N one

THORACIC CENTRAL NEUROGENIC TUMOURS

cotomy and laminectomy. Dural de
fects should be closed meticulously
to prevent the development of a
subarachnoid-pleural fistula and
possible meningitis.
Controversy exists over the ur
gency of excising neurogenic tu
mours in the posterior mediasti
num. Those that are lateral to the
costovertebral gutter may be ma
naged conservatively with surgery
reserved for when enlargement oc
curs. For the more centrally located
tumours such as those presented
here, we advise surgical interven
tion for the following reasons:
• An increase in the size of the
tumour mass, which may increase
the risk or difficulty of surgery
from osseous erosion or intraspinal
extension.4
• The possibility of malignancy
must be taken in to account, realiz
ing that most neurogenic tumours
are benign (overall rate of malig
nancy ranging from 3% to 19%).34
Furthermore, the possibility of ma
lignant degeneration should be
borne in mind, and it is difficult to
find exact data on this point in the
literature.4
• The risk of permanent damage
to the spinal cord from compression
due to intraspinal tumour or intra
spinal extension from an intrathoracic lesion. Nearly 10% of neurogen
ic tumours of the posterior medias
tinum extend into the spinal canal
through the intervertebral fora
men;8 neurologic symptoms indicat
ing intraspinal extension occur in
about 60% of dumbbell tumours,8
therefore the dual location should
always be considered and defined
preoperatively.

Conclusions
Careful evaluation and surgical
resection of benign neurogenic tu
mours of the thorax result in a low
morbidity and excellent long-term

results. Collaboration between tho
racic surgeons and neurosurgeons
is recommended. For malignant le
sions, if resection is incomplete,
further treatment in the form of
radiotherapy or chemotherapy
should be instituted.

5.

6.

7.
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BOOK REVIEWS
continued from page 492

surgery includes. The chapters on the
laryngeal anatomy and physiology are
detailed yet comprehensible. The bibli
ography in the chapter on neurology of
the laryngeal system is extensive, with
172 references. For otolaryngologists
interested in phonosurgical techniques,
including injectable substances, the
chapters on this topic are complete. The
brief discussions of the results and
follow-up of each procedure are invalu
able additions for the surgeon. The role
of voice and supportive therapies con
clude the text.
This is an ideal textbook for speech
therapists and otolaryngologists inter
ested in voice disorders. It should be in
every training program library and
should be a mandatory text for all
trainees in otolaryngology and speech
therapy.
I enjoyed reading this textbook.

Melvin D. Schloss, MD

Professor and chairman
Department of Otolaryngology
McGill University
The Montreal Children’s Hospital
2300 Tupper St.
Montreal, PQ
H3H 1P3

OPERATIVE SURGERY. Sir Roy
Caine and Stephen G. Pollard. 480 pp.
Illust. Gower Medical Publishing, New
York. 1991. $149.50. (US). ISBN 0 3 9 7 -4 4 6 2 8 -4

This coffee-table-sized textbook on op
erative surgery is a uniquely British
offering from Sir Roy Caine and Ste
phen G. Pollard of the Addenbrooke’s
Hospital in Cambridge. Over 120 surgi
cal procedures covering general, thorac
ic, vascular, pediatric and gynecologic
specialties are presented. The layout is
clear, consistent and concise. The sub
headings are well chosen, and operative
technique is described sensibly in point
form. Each operative procedure is ac
companied by well-chosen and clear
colour illustrations. One-quarter of the
chapters have been authored or coau
thored by Stephen Pollard, the rest by
trainees within the department of sur
gery of Addenbrooke’s Hospital. No
single chapter appears to have been
written by Professor Caine.
As stated in the preface, the authors
intend the book for surgery residents as
a practical guide as well as a preparacontinued on page 545

CJS, VOL. 35, NO. 5, OCTOBER 1992

501

In Four Hours, Dr. LeMaitre
And His Valvulotome
Could Forever Change The Way
You Look At Bypass Grafting.
In Situ Grafting Conies Of Age
In the time it takes to perform a single bypass
procedure, you’ll see why Dr. LeMaitre’s Valvulotome
has become the “Instrument of Choice” for vascular
surgeons performing In Situ grafting.
You’ll also understand why a growing number of
surgeons are shifting from reverse grafting to semiclosed In Situ, opting to minimize trauma to the vein
graft, minimize endothelial shearing and maximize
cumulative patency rates.
In about four hours, you’ll see how the LeMaitre
Valvulotome has simplified the performance of bypass
grafting and shortened the In Situ learning curve.
That’s why it’s currently being used in over 1200 hos
pitals including 500 teaching hospitals.
“An Elegant Instrument For An Elegant Technique”
Drawing on the pioneering work of other leaders in
the field, and his 11 years experience performing
In Situ bypass grafting, Dr. LeMaitre has modified and
simplified both the valvulotomy technology and the
procedure. The LeMaitre Valvulotome employs a
unique circular
blade that cuts saphenous valves
instantaneously, //.< safely and without blade manip
ulation as in
other systems. There is no need
to open the leg,
no guesswork concerning valve

location or lysis, no tearing or disruption of venous
walls. The stainless steel cylinders were designed to
minimize endothelial contact as they travel the length
of the saphenous vein.

THE LEMAITRE VALVULOTOME’S streamlined design, with smoothly
tapered head and follower, and recessed circular blade, minimizes
endothelial trauma while ensuring valvulotomy.
Y ou G et T h e In str u m e n t A n d T h e S u p p o rt

The entire Vascutech team, including Dr. LeMaitre
himself, is committed to providing the information, support
and tools you’ll need to determine for yourself the signifi
cant advantages of this very elegant technique. For more
infonnation about Dr. LeMaitre’s work and his
Valvulotome, just call us at 800-628-9470, or mail in the
coupon below.

Now available in two new sizes
2.5 and 3.5 mm

----------------------------------------- 1

FREE BOOK OFFER
To receive your complimentary
copy of Dr. LeMaitre’s highly
acclaimed book, In Situ, please fill
out and mail this coupon to:
Free Book Offer,
Vascutech, Inc. 790 Turnpike St.
North Andover, MA 01845

Offer good in the U.S.A.
and Canada only.

|
|
|
|
I
I
I

C JS 10/92

Name________________________________ .____________________
Address_______________________.______ ;____________________
City, State, Zip _____________________________________________
Principal Hospital
Affiliation___________________________________________________

J

L

VASCUTECH

Maker of the LeMaitre Valvulotome

790 Turnpike Street / North Andover, MA 01845
(800) 628-9470 ■ (508) 685-6677 ■ FAX (508) 685-3844

There is no evidence in a nim al o r human studies th a t ketorolac tromethamine induces o r inhibits the h epatic enzymes
capable o f m etabolizing itself or other drugs. Hence, it would not be expected to a lter th e pharmacokin etics o f other
d rugs d ue to e nzym e induction or inhibition mechanisms.

lOmg TABLETS & 30mg IM INJECTIONS

(keto rolac tromethamine)

NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS

PRESCRIBING INFORMATION
TO RADOL (ke toro la c trom etham ine) 10 mg table ts
TO RAD O L IM (ke toro la c tromethamine) 15 m g/m L and 30 m g/m L intram uscular injections

THERAPEUTIC CLASSIFICATION
Analgesic A g e n t

ACTION
Toradol (ketoro la c trom etham ine) is a non-steroid al anti-infla m m atory d rug tha t exhibits analgesic activity. Its mode
of action is to inhib it th e cyclo-oxygenase enzym e system , thereby inhibiting th e synthesis o f prostaglandins, and is con
sidered to be a peripherally acting analgesic. At analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tro m e tha m in e is rapidly and com ple tely a bsorbed when adm inistered by both the oral and intramuscular
routes, a nd pharm acokin etic s a re linear followin g sin gle a nd multiple dosing.
Steady sta te p lasm a levels are attained after o ne d ay o f Q .I.D. dosing. Based only on pharm acokinetic principles, a
faster a tta inm e n t o f the steady state plasma le vel m ig ht b e a chieved w ith a loadin g dose of about tw ice the m ain
tenance d ose. This occurs when the d osin g interval is a pp roxim ately e q ua l to th e d ru g 's half-life.
Following o ra l adm inistratio n, peak plasma c oncentrations o f 0.52 to 1.31 m cg/m l occurred 35 m in utes a fter a single
10 mg dose. The te rm in a l plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly
subjects (m ean age: 72 years) it ranged between 3.0 and 6.1 hours. A high fa t d ie t decreased the rate but not the
extent o f a bso rptio n o f oral ketorola c trom etham ine, w hile a ntacid had no effect.
Follo wing in tra m usc u la r adm inistratio n, peak plasm a concentrations o f 2.2 to 3.0 m cg/m l occurred dn avera ge of
50 m inutes a fte r a sin g le 30 mg dose. The term in al pla sm a half-life ranged between 3.8 and 6.3 h ours in young adults
and between 4.4 a nd 8.6 hours in eld erly subjects (m ean a ge: 72).
The p rim ary rou te o f excretion of ketorolac trom etha m ine and its m etabolites (conjugates and the p-hydroxy m eta b o
lite) is in th e u rin e (91.4% ) and th e rem ain der is e xcreted in th e feces.
More tha n 9 9 % o f th e ketorolac in plasma is p rotein b ound o ver a wide c oncentration range.

Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhibition of renal
lithium clearance leading to an increase in plasma lithium concentration and p otential lithium toxic ity has been
reported with som e non-steroidal anti-inflammatory drugs. The effect of ketorolac trom etham ine on lithium plasma levels
has n ot been studied.
Concom itant adm inistration o f methotrexate and some non-steroidal anti-inflam m atory d rugs have been reported to
reduce the c learance o f methotrexate, enhancing the toxicity o f methotrexate. The effect o f ketorolac tromethamine
on m ethotrexate c learance h as n ot been studied.
There is limited experience on concurrent administration w ith morphine. Available inform ation show s n o evidence o f
adverse interactions. The extent of a possible narcotic-sparing effect of ketorolac trom etham ine is currently under
investigation.

ADVERSE EFFECTS
Toradol tablets: The incidence of adverse reactions in approximately 6 00 patients and subjects receiving short-term
oral therapy (less than 2 weeks) with Toradol (ketorolac tromethamine) a re listed below. The m ost c om m on a dverse
effects include: G astrointestinal: dyspepsia (2%). g astrointestinal pain (2%), nausea (2%). Central nervous system:
headache (2%), d izziness (2%).
The following a dverse events a re ra re but have been reported (less than 1%): Gastrointestinal: flatulence, gastritis.
Respira tory: dyspnea. Derm atologic: urticaria, rash, pruritus. Metabolism/nutritional: edema. Body a s a whole: asthe
nia. Hem ic a nd lymphatic: purp ura. Musculoskeletal: myalgia.

Toradol IM: The a dverse re actions listed below were reported to be probably related to Toradol IM in clinicol trials in
which p atients received up to 20 doses o f 30 mg o f intramuscularly administered Toradol over a period o f up to five
days.
Incidence betw een 3 and 9%: Gastrointestinal: nausea, dyspepsia, g astrointestinal pain. Central nervous system:
drowsiness.
incidence b etween 1 and 3%: Gastrointestinal: diarrhea. Centra l nervous system: d izziness, h eadache, sweating. Body
as a whole: edem a. Injection site pain w as reported by 2% o f patients in m ulti-dose stud ies (vs. 5% for morphine control
group).
Incidence 1% or less: Gastrointestinal: constipation, flatulence, gastrointestinal fullness, liver function abnormalities, meiena,
peptic u lcer, rectal b leeding, stomatitis, vomiting. Body a s a whole: asthenia, myalgia. Cardiovascular: vasodilatation,
pallor. Hemic and lymphatic: purpura. Nervous system: dry mouth, nervousness, paresthesia, abnorm al thinking, depres
sion, euphoria, excessive thirst, inability to concentrate, insomnia, stimulation, vertigo. Respira tory: dyspnea, asthma.
Urogenital: increased urinary frequency, oliguria. Derm atologic: pruritus, urticaria. Special senses: abnormal taste,
abnormal vision.

INDICATIONS

OVERDOSAGE

O rally a dm iniste re d Toradol (ketorolac trom etham in e) is indicated fo r th e short-te rm management o f m ild to m oder
ately severe p ain , including post-surgical pain (such as general, orthopedic and d ental surgery), a cute m usculoskeletal
traum a p ain a nd p ost-partum uterin e c ram pin g pain.

The a bsence o f experience w ith a cute overdosage precludes characterization o f sequelae a nd assessm ent of anti
dotal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses o f 360 mg given over an 8-hour interval
for each o f five consecutive days (3 tim es the highest recommended dose) caused a bdom inal pain and p eptic ulcers
which recovered after d iscontinuation o f dosing.

Intram uscular in je c tio n of Toradol is indicated fo r the short-term m anagem ent o f m oderate to severe pain, including
pain fo llo w in g m a jo r abdominal, o rthopedic a nd gynecologic al operative procedures.

CONTRAINDICATIONS
Toradol (ketorola c trom etham ine) should not be used w here there is a known o r suspected hypersensitivity to the drug.
Because o f th e possib ility of cross-sensitivity, ketorola c trom etham in e should n ot b e used in patients in whom acetylsalicylic a cid (ASA) o r other non-steroid al anti-infla m m atory agents in duce a cute asthm atic attacks, urticaria, rhinitis
or o ther a llerg ic manifestations. Fatal a naphylactoid re actio ns m ay o c c ur in such individuals.
Toradol (ketoro la c trom etham ine) also should n ot be u sed in p atients with p eptic u lc e r or active infla m m atory disease
of the g astroin te stin a l system.

WARNINGS
Long-term a dm inistratio n of ketorolac trom etham in e oral form ulation h as show n tha t this drug shares the risks that other
non-steroidal anti-in fla m m atory d rugs pose to patients when taken chronic ally. Peptic ulceration, perforation and g a s
trointestinal b le e din g , sometim es severe a nd occasionally fatal have b een reported d uring therapy w ith non-steroidal
anti-infla m m atory d ru gs and m ay occur w ith ketorola c trom etham ine, both in th e presence o r a bsence of previous
symptoms. Elderly and debilitated individuals are most susceptible to these complications, the incidence o f which increases
with dose a n d d uratio n o f treatm ent. Close m edical supervisio n is recom m ended in patie nts prone to gastrointestinal
tra ct irrita tion, p artic ula rly those w ith a history o f peptic u lc er, d ivertic ulosis or othe r inflammatory d isease o f the g as
trointestinal tra c t. In th ese cases the p hysicia n m ust w eigh the benefits o f tre a tm e nt a gainst the p ossible hazards.
Patients taking a ny non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to contact
a physic ia n im m ed ia tely if they experie nce sym ptom s or sig ns suggestive of p eptic ulcera tion or gastrointestinal b leed
ing. These re a ctio n s can occur a t a ny tim e d uring th e treatm ent. If p eptic ulc era tio n is suspected o r confirm ed, or if
g astroin testinal ble edin g occurs, ketorolac trom etham ine should be discontin ued and appropriate treatm ent instituted
dnd th e p a tie n t c lo se ly monitored.
Keto rolac tro m e tha m in e is not recom m ended fo r routine use with other non-steroid al anti-inflammatory d rugs because
of th e p oten tia l fo r additive sid e effects.

Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy o r lactatio n.
Ketorolac tro m e tha m in e is not recom m ended for use as an obstetric al p reoperative m edication or fo r obstetrical a nal
gesia b ecause o f th e known effects o f non-steroidal anti-inflam matory drugs on uterine contraction and fetal circulation.

Use in children: Safe ty and efficacy in children h ave n o t been established. The re fore . Toradol is not recom m ended for
use in c h ildren u n d e r age 16.
Use in the elderly: Because ketorolac is cle ared som ew hat m ore slow ly by the e ld e rly (See PHARMACOKIN ETICS) w ho
are also m ore se n sitive to the renal effects o f non-steroidal anti-infla m m atory d rugs, extra caution and th e lowest effec
tive d ose sh ou ld b e used.

PRECAUTIONS
Renal effects: As w ith other drugs that inhibit p rostagla ndin b iosynthesis, e le va tio ns o f b lood urea nitrogen (BUN) and
creatinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and ils metabo
lites a re e xc re te d primarily by the kidney, patie nts with sig nific ant im p airm ent o f renal function (serum creatinine
values g re a te r th a n 5 mg/dL) should not receive ketorolac trom etham in e unless th e expected b enefits outweigh the
risks. In p a tien ts w ith moderately im paired renal functio n serum creatinin e va lue s ranging from 1.9 to 5.0 mg/dL, the
rate of ketorolac clearance was reduced to approximately half o f normal. The total daily dose of ketorolac tromethamine
should b e re d uc e d by half in such patients. The d isposition o f ketorola c in d ialysis p atients has not been studied.
Pa tients w h o a re vo lum e d eple ted b eca use o f b lood lo ss o r se ve re d eh yd ra tio n may be d e pe n d en t on renal
p rostagla ndin p rod uctio n to m aintain renal perfusio n a nd therefore g lom erula r filtra tio n rate. In such situations the use
of drugs w hic h in hib it prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised
if ketorolac tro m e tha m in e is used in such c ircum stances. Close m onitorin g o f u rine output, serum urea a nd serum c re
atin ine is rec om m e n d e d until the patie nt is norm ovolemic.

Hepatic effects: Meaningful elevations (greater than 3 tim es normal) o f serum transam in ases (glutamate pyruvate (SGPT
or ALT) a nd g luta m ic oxalacetic (SGOT o r AST)) occurred in controlled c lin ic al trials in le ss than 1% o f patients. If clini
cal signs a nd sym p tom s consistent with liver d isease develo p, or if system ic m anifestations occur (e.g., eosinophilic,
ra sh, etc.), keto rola c tromethamine should be d iscontinued. Patie nts w ith im paired hepatic function from cirrhosis do
not have a n y c lin ic a lly important changes in ketorola c trom etham in e cle arance. Studie s in patients with a ctive hepati
tis o r c h olesta sis h ave not been perform ed.
Fluid and electrolyte balance: Fluid retention and ed e m a have been ob served in patients treated with Toradol.
Therefore, a s w ith m a ny other non-steroid al anti-infla m m atory drugs, th e p ossib ility o f precipitating congestive heart
fa ilure in e ld e rly p a tie n ts or those with com prom ised c ardia c functio n should b e b orne in mind. Toradol should be used
with caution in p a tie n ts with cardia c decom pensatio n, hypertension o r othe r c ond itions predisposing to fluid retention.
Hematologic effects: Ketorolac trom etham in e inhibits p latelet function and m a y prolong bleeding tim e. It d oes n ot
affect p latele t c o u n t, prothrombin tim e (PT) o r partia l throm bopla stin tim e (PTT). Patients who have coagulation dis
orders o r a re re c e iv in g drug therapy that in terferes with hem ostasis should be carefully observed when ketorolac
trom etham ine is adm inistered. Unlike the prolo nged e ffe c ts from aspirin , the inhibitio n of platelet function by ketoro
lac tro m etha m in e is normalized w ithin 24 to 48 hours a fte r the d rug is discontinued.
Blood d ysc ra sia s associa ted with th e use of non-steroidal anti-infla m m atory d ru gs a re rare, but could oc c ur with severe
consequences.

Infection: In c om m o n with other anti-inflammatory drugs, ketorolac tromethamine m ay mask the usual sig ns of infection.
Drug Interactions: Toradol (ketorolac tromethamine) is hig hly bound to hum an p lasm a protein (mean 99.2%) and binding
is ind epend ent o f concentration.
Prothrombin tim e should be carefully monitored in all p atients receiving ora l anticoagula nt therapy concomitantly with
ketorola c tro m e tha m in e .

DOSAGE AND ADMINISTRATION
Adults: Dosage should be adjusted according to the severity o f the p oin and the response o f the patient.
Oral: The usual o ra l d ose o f Toradol (ketorolac tromethamine) is 10 m g every 4 to 6 hours for pain a s required. Doses
exceeding 40 m g p er d ay a re not recommended.
Toradol is recom m ended fo r short-term use only i.e. for a maximum of a few weeks.

Parenteral: The recom m ended usual initial dose is 30 mg. Subsequent d osing m ay b e 10 m g to 30 m g every 4-6 hours
as needed to control pain. A tower initial dose may be suitable for patients under 50 kg in b ody weight, over age 65years
and/or w ith less severe pain a t baseline. In the initial post-operative period, more freq uent dosing (e.g., every 2 hours)
may be em ployed, b ut the total d aily d ose should n ot e xceed 120 mg. Dose a bove 120 mg could cause drug toxic
ity (see W arnings 8c Precautions). If supplemental analgesia is required, a concomitant tow dose of opiate can be used.
The adm inistration o f c ontinuous m ultiple daily doses of Toradol IM should not exceed 5 days fo r Injection dosing. There
has been lim ited experience with dosing for more than 5 days since the vast m ajority o f p atients have tra nsferred to
oral m edication o r no longer required analgesic therapy a fter this time.

Directions for use: Insert the plunger into the syringe barrel and thread it onto the screw. W ITHOUT REMOVING THE NEEDLE
G UARD, app ly quick, firm pressure to the plunger to break the inner seal (you w ill feel it let go). Pull back on the plunger
slightly to relieve pressure. Rem ove the needle guard by tw isting as you pull. Use the unit a s you would a norm al syringe.
Dispose o f properly. Single use only. Discard unused portions.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets m ay be used e ither as monotherapy o r a s follow-on therapy to p arenteral ketorolac. In the latter case,
the total com bined d aily d ose o f ketorolac should not exceed 120 m g on the d ay th e c hange o f fo rm ula tion is made,
this includes a m axim um o f 4 o f the 10 mg tablets.
Toradol (ketorolac trom etham ine) is a Schedule F drug,

COMPOSITION
Toradol Tablets: Each Toradol ta blet contains ketorolac tromethamine, the active ingredient, with m icrocrystalline cel
lulose, lactose and m agnesium stearate. The coating suspension contains hydroxy-propyl-methylcellulose, titanium dioxide
and p olyethylene glycol.

Toradol IM: Toradol IM is availoble fo r intramuscular administration as: 15 mg in 1 m L (1.5%), or 30 mg in 1 m L (3%) of
ketorolac trom etham ine in sterile solution. The 15 m g/mL solution contains 10% (w/v) alcohol, USP. and 6.68 mg sodium
chloride in sterile w ater. The 30 m g/m L solution c ontains 10% (w/v) a lcohol. USP and 4.35 m g sodium c hloride in sterile
water. The pH is a djusted with sod ium hydroxide o r hydrochloric acid. The sterile solutions a re clear and slig htly yellow
in colour.

STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store a t room temperature. The blister package tablets should be p rotected from light.
Toradol IM: Store a t room tem perature w ith protection from light.
AVAILABILITY OF DOSAGE FORMS
Toradol (ketorolac trom etham ine) is available as 10 mg white round film coated ta blets with one side printed in red
with TO RADOL inside a bold T and the other side with Syntex. Toradol (ketorolac trom etham ine) 10 m g tablets are avail
a ble in b ottles o f 100 and 5 00 tablets.
Toradol IM is a va ilab le in 1 m L syringes containing 15 o r 30 m g/mL of ketorolac tromethamine.
Product M onograph a va ilab le on request.
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Colorectal Leiomyosarcomas:
a Pathobiologic Study With Long-Term
Follow-up
Randall Friesen, MD, FRCSC;* Terence N. Moyana, MB, ChB, FRCPC;t Robert B. Murray, MD,
FRCPC;f Fergus Murphy, MD, FRCPC;t Frederick G. Inglis, MD, MSc, FACS, FRCSC*
Colorectal leiomyosarcoma (CLM) is an uncommon tumour. Reports of its
occurrence have been published mostly as single cases or small series. This study
documents 12 cases of CLM that were seen over a 28-year period in Saskatchewan.
The annual incidence of CLM was 0.45 per million people and constituted 0.12% of
all colorectal malignant tumours seen during the study period. CLMs had a
predilection for the rectum and sigmoid and commonly were associated with rectal
bleeding or abdominal pain. More than half the tumours were detected by
sigmoidoscopy. A correct preoperative or intraoperative histologic diagnosis of
leiomyosarcoma was made in only two out of six cases. A potentially curative
surgical procedure was done in 10 of the 12 patients. The mean follow-up was 6.9
years. Eight patients had tumour recurrence or metastasis, or both. From the
findings of this study the authors recommend wide excision of colorectal
smooth-muscle tumours whenever there is a suggestion of malignancy.

Le leiomyosarcome colorectal (LMC) est une tumeur rare. Les publications ou ils
sont signales rapportent des cas uniques ou de courtes series. La presente etude
decrit 12 cas de leiomyosarcomes observes en Saskatchewan au cours d’une periode
de 28 ans. Ceci represente une incidence annuelle de LMC de 0,45 par million
d’habitants et 0,12 % de toutes les tumeurs colorectales malignes observees pendant
la periode de l’etude. Les LMC ont une predilection pour le rectum et le sigmoi'de, et
sont souvent associes a des saignements rectaux ou a une douleur abdominale. Plus
de la moitie des tumeurs furent detectees a la sigmoidoscopie. En preoperatoire ou a
l'examen histologique peroperatoire, un diagnostic exact de leiomyosarcome fut
pose dans seulement deux cas sur six. Une intervention a visee curative fut
pratiquee chez 10 patients sur 12. La surveillance moyenne des suites
therapeutiques a ete de 6,9 annees. Huit patients eurent des recidives ou des
metastases ou les deux. Des observations relevees dans cette etude, les auteurs
recommandent une excision large du muscle lisse colorectal, chaque fois que Ton
soupfonne une tumeur maligne.

C

olorectal leiomyosarcomas
(CLMs) are uncommon tu
mours. In the literature, most
studies on CLMs are case reports or
reports of small series.1-8 Because
these tumours respond poorly to
both chemotherapy and radiothera

py, surgery is the mainstay of treat
ment.2'7’9-12 Therefore it is impor
tant for the surgeon to be thor
oughly familiar with the pathobiology of CLMs. This study documents
our experience in managing these
tumours and includes long-term fol

From the *Department o f Surgery and the fDepartment o f Pathology, University o f
Saskatchewan and Royal University Hospital, Saskatoon, Sask.
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low-up. It represents the largest
series of CLMs to date in which the
leiomyogenic nature of the tumours
was verified by special pathological
techniques.1314

Patients and Methods
For the last 45 years, all patients
living in Saskatchewan who had
malignant tumours were required to
be registered with the Saskatche
wan Cancer Clinic. Initially, we
wanted to review all patients who
had had CLMs during those 45
years but upon tracing back the
cases to the hospitals in which the
patients had been managed, we
found that in some cases the tissue
blocks and slides had already been
discarded. However, by considering
the 28-year period 1961 to 1989,
we were able to obtain the patho
logical materials required to review
all the diagnoses and to apply addi
tional, relatively recent pathological
techniques.1314 Twelve patients (11
men and 1 woman) with CLM were
reported during the 28-year study
period. We performed immunohistochemical tests on the slides; in all
12 cases we obtained positive re
sults when the sections were tested
for muscle-specific actin and nega
tive results when they were tested
for S-100 protein, confirming that
all the tumours originated from
smooth muscle. The standard
pathological feature of malignancy
for smooth-muscle tumours is mi
totic activity, and 10 of the 12
tumours were found to have at least
CJS, VOL. 35, NO. 5, OCTOBER 1992
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one mitotic figure per 10 high-pow
er fields.1516 Two cases had fewer
mitotic figures and had originally
been reported as leiomyomas. How
ever, in both these cases the tu
mours recurred, and both recur
rences showed at least one mitotic
figure per 10 high-power fields; the
tumours were therefore reclassified
as leiomyosarcomas. It is not clear
whether the original tumours had
been inadequately sampled or
whether the tumours had dedif
ferentiated and recurred as leio
myosarcomas. Nevertheless, the 10
original leiomyosarcomas and the

two reclassified tumours are the
subject of this report. The clinical
features of the 12 patients are
shown in Table I.

Findings (Table II)
The 12 patients ranged in age
from 35 to 83 years (mean 65
years). More than half the tumours
were located in the rectum and
sigmoid. Rectal bleeding and ab
dominal pain were the commonest
presenting symptoms, occurring in
seven and four patients respectively.

yi

Diagnostic Procedures
A correct preoperative diagnosis
was made in 9 of the 12 patients;
this was established primarily by
sigmoidoscopy in 6 patients and by
barium enema in 3 (Fig. 1). In two
other patients the preoperative di
agnosis was diverticular disease.
Both these patients actually had
diverticular disease, with peridiverticular abscess formation in one
(patient 6 in Table I). However,
both patients also had a leiomyosar
coma which was missed in both
instances by sigmoidoscopy as well

V
•A

i
Table I. Clinical Features of the 12 Patients Who Had Colorectal Leiomyosarcomas
Patient
no.

Colorectal
site

Sex

Age, yr

1

F

83

Descending

Rectal bleeding

2

M

48

Rectum

Rectal bleeding

3

M

70

Rectum

Rectal bleeding

4

M

62

Cecum

ABD pain; weight
loss

5

M

55

Cecum

6

M

82

Sigmoid

7

M

66

Sigmoid

8

M

57

Sigmoid

9

M

81

Rectum

Presentation

Incidental at
cholecystectomy
ABD pain; partial
bowel
obstruction
Rectal bleeding;
weight loss
Rectal bleeding;
partial bowel
obstruction
Confusion;
dyspnea; rectal
bleeding

10

M

70

Ascending

ABD pain

11

M

71

Ascending

ABD pain; weight
loss; anemia

12

M

35

Rectum

Rectal bleeding

________________________________

Preoperative
diagnosis
Sigmoidoscopy: tumour
Frozen section: leiomyoma
Sigmoidoscopy: tumour
Frozen section: malignant
disease — spindle-cell tumour
Sigmoidoscopy: tumour
Pathology: — *
Barium enema: tumour
Frozen section: sarcoma —
spindle-cell tumour
None
Sigmoidoscopy: diverticular
disease
Barium enema: diverticular
disease
Pathology: — *
Sigmoidoscopy: tumour
Pathology: — *
Sigmoidoscopy: diverticular
disease
Barium enema: diverticular
disease
Pathology: — *
Sigmoidoscopy: tumour
Endoscopic biopsy:
leiomyosarcoma
Diagnostic imaging:
metastases in lungs
and brain
Barium enema: tumour
Pathology: — *
Barium enema: tumour
Colonoscopy: tumour
Endoscopic biopsy:
leiomyosarcoma
Sigmoidoscopy: tumour
Endoscopic biopsy:
leiomyoma

Operative
procedure

Survival
outcome

Local excision

204 mo, DOC

Abdominoperineal
resection

80 mo, DOD
Recurrence at 6 mo

Local excision

172 mo, DOD
Recurrence at 162 mo
8 mo, DOD
Liver metastases

A
Inoperable, liver
metastases
present
Local excision

178 mo, NED

Sigmoid colectomy

25 mo, DOD
Liver metastases at
12 mo

Sigmoid colectomy

129 mo, DOC

Sigmoid colectomy

39 mo, DOD
Lung metastases

Inoperable

Right
hemicolectomy
Right
hemicolectomy

3 days, DOD
Lung and brain
metastases
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r
1

21 mo, DOD
Lung metastases at
16 mo
82 mo, DOC
A
4

Local excision

60 mo, AWD
Recurrence at 18 mo

‘ Biopsy specimen not obtained
ABD = abdominal, DOC = died of other causes, DOD = died of disease, NED = no evidence of disease, AWD = alive with disease
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as by barium enema. In the last
case, the leiomyosarcoma was
found incidentally at cholecystecto
my.
A preoperative incisional biopsy
or an intraoperative frozen-section
biopsy was carried out in six cases.
The correct diagnosis of lei
omyosarcoma was rendered by the
pathologist in two instances. Two
other cases were diagnosed as lei
omyomas, whereas in the remaining
two cases the tumours were called
malignant spindle-cell neoplasms
not otherwise specified.
Operative Findings and Procedures

At operation, four of the tumours
were locally excised because they
appeared small and well demarcated

Table II. Profile of Patients Who Had
Colorectal Leiomyosarcomas
Total no. of patients
Males: females
Mean age, yr (range)
Location of tumours, no.
Rectum
Sigmoid
Ascending colon
Cecum
Descending colon
Common presenting
features, no.
Rectal bleeding
Abdominal pain
Loss of weight
Preoperative diagnosis, no.
Tumour
Diverticular disease
Incidental
Pre- or intraoperative
pathological diagnosis, no.
Leiomyosarcoma
Leiomyoma
Malignant spindle-cell
tumour
Operations performed, no.
Local excision
Sigmoid colectomy
Right hemicolectomy
Abdominoperineal
resection
Inoperable
Outcome
Mean follow-up, yr
Recurrence or metastases,
or both, no. of patients
No disease, no. of patients

12
11:1
65 (35-83)
4
3
2
2
1

(Fig. 2). Three patients underwent a
sigmoid colectomy, two had a right
hemicolectomy and one had an ab
dominoperineal resection. In the re
maining two patients the disease
was inoperable: in one liver metastases were found on exploratory
laparotomy in addition to the CLM,
and in the other brain and lung
metastases were disclosed by diag
nostic imaging after an endoscopic
biopsy that was positive for CLM.
Outcome

The mean follow-up was 6.9
years; 10 patients were followed up
until death. The two patients who
are still alive have been followed up
for a mean of 10.0 years. Eight
patients had tumour recurrence or
metastases, or both, and seven of
these died. Once the tumour re
curred or metastasized, the disease
could not be eradicated despite sev
eral subsequent operations on some
patients. Four patients were cured
of their disease, one of them is still
alive; the other three died of unre
lated causes.

7
4
3
9
2
1

Discussion
Colorectal leiomyosarcomas be
long to a broad group of gastroin
testinal tumours called mesenchy
mal or stromal tumours.1314 This
group includes other tumour sub
sets such as neurogenic tumours,
fibrogenic neoplasms and fi
bromatoses17' 23 that may be part of
a variety of clinical syndromes or
formes frustes, and this may alter
the overall clinical approach to the
patient.20-23 Recently, it has been
shown that some gut tumours that
appear to be leiomyomas on routine
microscopy are actually derived
from neural or fibrous tissue.1314
Thus, to ensure that we were deal
ing with a specific subset of tu
mours, we used an immunohistochemical technique to verify that all
the tumours were leiomyogenic.
Colorectal leiomyosarcomas are
uncommon tumours to the extent
that, generally, only large referral
centres have reported substantial
series of these tumours. However, it
is often difficult to determine the
incidence of these tumours from
data derived from these referral cen
tres.1 The present study was based
on a well-defined, constant popula
tion base of about one million peo
ple24 (range from 925 200 to
1 O il 200) and a comprehensive,
centralized provincial cancer regis
try. Our methods gave an incidence
of CLMs of 0.45 cases per million

2
2
2
4
3
2
1
2
6.9
8
4

FIG. 1. Large polypoidal cecal lei
omyosarcoma (patient 4 in Table I)
showing as filling defect on barium
enema (arrow).

FIG. 2. Low-power photomicrograph
of well-demarcated rectal tumour that
was locally excised (patient 3 in Table
I) but subsequently recurred (hematox
ylin and eosin, original magnification
X 4 ).
CJS, VOL. 35, NO. 5, OCTOBER 1992
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people annually; they constituted
0.12% of all colorectal malignant
tumours seen during that period.
In accordance with the findings
of previous studies, our results
show that CLMs are typically tu
mours of adulthood that show a
male predominance.1-7 Rectal bleed
ing and abdominal pain are common
presenting symptoms, which mimic
the symptomatology of the most
prevalent colorectal malignant con
dition, namely, carcinoma. Similar
ly, most CLMs were located in the
rectum and sigmoid. Given the dom
inant complaint of rectal bleeding
and the predilection of CLMs for
the rectosigmoid region, sigmoidos
copy would appear to be the investi
gation of choice rather than colo
noscopy or barium enema examina
tion. Furthermore, because some of
these tumours may show a predom
inantly mural or extramural growth
pattern rather than a pedunculated
luminal growth pattern, they are
liable to be missed by barium enema
studies.
Another problem with respect to
evaluating these tumours relates to
the pathologic features: the malig
nant potential of these tumours is
generally determined by the degree
of mitotic activity, and assessment
of such activity in smooth-muscle
tumours requires adequate tissue
sampling.23 51516 It may not be pos
sible to inform the surgeon whether
a smooth-muscle tumour is benign
or malignant based on the limited
tissue material obtained from an
endoscopic or frozen-section biop
sy. Therefore the nature and extent
of the definitive procedure to be
done by the surgeon may depend
more on the findings at operation
and on the surgeon’s knowledge of
the pathobiology of smooth-muscle
tumours. The present study and
others show that one of the major
problems with CLMs is tumour re
currence.1'2'6101116 In fact, in this
study, no patient who had tumour
508
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recurrence or metastases was ever
cured of the disease. Therefore, we
recommend wide excision of any
colorectal smooth-muscle tumour
even though it may appear to be
well demarcated. This aggressive
approach is further vindicated by
the poor response of these tumours
to chemotherapy and radiothera
py.10'11

Conclusions
CLMs are uncommon tumours
that generally present in adulthood
with rectal bleeding or abdominal
pain. They have a predilection for
the left side of the large bowel.
Because a histologic diagnosis of
leiomyosarcoma generally requires
extensive tissue sampling, the sur
geon often does not have a defini
tive diagnosis of malignancy at the
time of operation. Wide excision of
the tumour is recommended if there
is a suspicion that it is a lei
omyosarcoma, because these tu
mours often manifest their biologic
aggressiveness by local recurrence
in the first instance.
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Thoracoscopic Transthoracic Dorsal
Sympathectomy
Ronald F. Pace, MD, FRCSC, FACS; Peter M. Brown, MD, FRCSC; John R. Gutelius, MD, CM, FRCSC, FACS
The authors report on three patients who underwent thoracoscopic transthoracic
dorsal sympathectomies by the techniques of minimal-access surgery learned from
laparoscopic cholecystectomy. All three had histologic confirmation of removal of
the sympathetic chain and have had an encouraging early postoperative result. The
authors believe that thoracoscopic transthoracic dorsal sympathectomy can be
accurately and safely performed and will become the method of choice for dorsal
sympathectomy.

Les auteurs donnent un compte rendu sur trois patients chez lesquels on a pratique
une sympathectomie dorsale transthoracique par thoracoscopie a l’aide des
techniques d’intrusion chirurgicale minimale mises au point dans la
cholecystectomie par laparoscopie. Chez les trois patients, il y a eu confirmation
histologique de Penlevement de la chaine sympathique et les premiers resultats
postoperatoires ont ete encourageants. Les auteurs croient qu’il est possible que ce
type de sympathectomie puisse etre effectue avec precision et securite et deviendra a
l’avenir la methode de predilection pour la sympathectomie dorsale.

sympathectomy is the
D orsal
standard surgical treatment for
reflex sympathetic dystrophy of the
upper limb, certain vasospastic dis
orders affecting the hands and dig
its, and severe upper-limb hyperhidrosis. The standard approach to
remove the upper portion of the
sympathetic chain includes either
supraclavicular dissection or transaxillary thoracotomy. Both these
surgical approaches have the disad
vantage of causing significant pa
tient discomfort postoperatively at
the incisions required to gain ac
cess, and this limits the use of these
techniques. We have employed the

surgical techniques learned from
laparoscopic cholecystectomy to
perform four thoracoscopic trans
thoracic dorsal sympathectomies in
three patients.

Methods
Under single-lung anesthesia, the
patient is placed in the lateral decu
bitus position with the arm hyperabducted and fastened to the ether
screen. A Veress needle is inserted
in the fourth intercostal space in
the midaxillary line, and the pleural
space is insufflated with 1 L of

From the Department o f Surgery, Queen's University, Kingston General Hospital. Kingston,
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carbon dioxide. A 10-mm trochar is
then placed into the pleural space
through the same site as the Veress
needle, and the pleural cavity is
inspected with the 10-mm thoraco
scope. Pleural insufflation with car
bon dioxide to a pressure of 5
cm H20 is used to maintain the
lung in a collapsed state. A second
10-mm trochar is placed in the
posterior axillary line in the fourth
intercostal space, and a 5-mm tro
char is placed in anterior axillary
line in the fourth intercostal space.
The orientation of these two trochars can be reversed, depending on
the side of the chest being operated
on and whether the surgeon is right
or left handed. If required, a fourth
trochar (5 mm) is placed in the fifth
or sixth intercostal space below the
thoracoscope port, and a blunttipped probe is used to retract the
lung during the procedure (Fig. 1).
The video screen is placed above
the patient’s head.
On the left side, the arch of the
aorta and the left subclavian artery
are visualized to aid in orientation
(Fig. 2), and on the right side the
mediastinal pleura and the azygos
vein are used as landmarks (Fig. 3).
The inferior border of the first rib
can easily be palpated and marks
the superior limit of the dissection,
with the sympathetic chain running
vertically along the head of the ribs.
A transverse incision is made in the
pleura over the head of the fourth
rib, and the sympathetic chain is
identified over the bony substance
CJS, VOL. 35, NO. 5, O CTOBER 1992
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of the rib. A vertical incision is then
made in the pleura to expose the
sympathetic chain and is extended
to the border of the first rib. The
sympathetic chain is mobilized by
blunt dissection, doubly clipped and
divided below the level of the fourth
ganglion. With the use of elec
trocautery to divide the nerve fibres
tethering the ganglia to the posteri
or thorax, the sympathetic chain is
dissected superiorly to the inferior
margin of the first rib, where it is
again clipped and divided. The spec
imen is removed and sent to the
pathology laboratory to confirm the
presence of ganglion cells. After
irrigation of the operative site, all
free fluid is aspirated from the
chest, the lung is re-expanded
under direct vision and the trochars
are removed. A 24- French catheter
may be left in the pleural space
until re-expansion of the lung has
been confirmed radiographically,
but in our last three cases we

FIG. 1. Diagram showing trochar ori
entation during left thoracoscopic
transthoracic dorsal sympathectomy.
Thoracoscope with attached camera is
inserted through 10-mm trochar; sec
ond 10-mm trochar is placed posterior
ly to allow access for dissecting instru
ments and 10-mm clip applier. Anteri
orly, 5-mm trochar is used for dissect
ing instruments, and fourth 5-mm tro
char may be placed interiorly to permit
retraction of lung with blunt-tipped
probe.
510
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omitted the chest drain and simply
closed the skin using absorbable
subcuticular sutures. No attempt
was made to close the deep muscle
layers. The patient can be dis
charged home the next day.
We have performed this opera
tion with two surgeons in atten
dance. One is the primary operator
who has the manual dexterity re
quired for the technical manoeuvres
acquired from laparoscopic chole
cystectomy procedures; the second
is the assistant for the thoracoscop
ic procedure but has extensive ex
perience with the standard “open”
technique of transthoracic dorsal
sympathectomy. This collaboration
ensures that if there are technical
problems with the thoracoscopic
procedure, we can rapidly and safe
ly convert to an “open” procedure.
With experience in both aspects of
this procedure, one operator and
one assistant could easily perform
the operation. As our experience
with this operation has increased,
the operating time has decreased

A total of four dorsal sympathec
tomies were performed on three
patients (Table I). Patient 1, who
suffered from intractable upper-limb
hyperhidrosis, underwent right and
left dorsal sympathectomies per
formed 1 week apart. He had an
excellent early result with no sweat
ing from either limb and no disabili
ty related to the trochar incisions.
Patients 2 and 3 had a left dorsal
sympathectomy for reflex sympa
thetic dystrophy. Both reported a
significant improvement in their
pain syndromes. Patient 2 reported
some minor scapular discomfort 2
weeks postoperatively but was oth
erwise well. No patient had Horn-

FIG. 2. Thoracoscopic view during left
dorsal sympathectomy. Arch of aorta
and left subclavian artery are readily
apparent, and sympathetic chain is
faintly visible as it courses over head
of ribs. Inferior border of first rib is
identified by palpation, whereas other
ribs are visualized directly. Sympathet
ic chain is resected from level of fourth
rib to inferior border of first rib.

FIG. 3. Thoracoscopic view during
right dorsal sympathectomy. Superior
vena cava and azygos vein are readily
apparent, and sympathetic chain is
faintly visible as it courses over head
of ribs. Sympathetic chain is resected
from level of fourth rib (hidden behind
lung in this diagram) to inferior border
of first rib, which is identified by
palpation.

from 2.5 hours to 45 minutes, with
a large portion of the time being
taken up by processing the speci
men for quick-section confirmation
of the removal of the sympathetic
ganglia.

Results

TRANSTHORACIC DORSAL SYMPATHECTOMY

er’s syndrome. Histologic demon
stration of ganglion cells in the
resected specimens confirmed the
removal of sympathetic ganglia in
all four operations, and no patient
had any residual pulmonary compli
cations. Discomfort following the
procedure was minimal. Patient 3,
who had had a right-sided “open”
transaxillary dorsal sympathectomy
2 years earlier, described a marked
improvement in the level of postop
erative pain after his thoracoscopic
procedure.

Discussion
Surgical techniques learned from
laparoscopic cholecystectomy are
being applied to many surgical pro
cedures. The improved optics and
high-resolution video cameras pro
vide a bright and magnified image,
which frequently gives better visual
ization of structures than had previ
ously been available at the time of
“open” surgery. Although there is
a considerable learning curve in
developing the dexterity required to
perform the surgical dissection ac
curately, once mastered, even very
complex procedures can be per
formed “laparoscopically.”
The thoracoscopic approach to
the sympathetic chain has been re
ported from European centres to
have been used in the treatment of
reflex sympathetic dystrophy, Ray
naud’s phenomenon and upper-limb

hyperhidrosis. Some of these cen
tres have had a large experience.1-4
The reports indicate that these au
thors have tended to employ elec
trocautery to ablate the sympathetic
chain rather than to perform an
accurate surgical dissection with
excision of the chain and the associ
ated ganglia. We believe that resec
tion is preferable because it allows
histologic confirmation of the suc
cess of the operative procedure and
is superior with respect to prevent
ing regrowth of the nerve fibres.
Further extension of minimally
invasive surgical techniques will
permit therapy for a wide range of
thoracic diseases. Pleuroscopy with
biopsy, although not a new proce
dure, will be enhanced by the im
proved visibility and manoeuvrabili
ty of the “laparoscopic” instru
ments, and as a result of the devel
opment of extracorporeal knot
tying and the linear stapler, pericar
dial windows, lung resections, api
cal bullectomies and even esopha
geal resections will fall within the
realm of minimally invasive thoracic
surgery. It is possible that, given
the time for further developments in
instrumentation and for the acquisi
tion of the necessary manual skills,
thoracic surgeons may be able to
perform the bulk of their surgical
procedures “endoscopically.” We
believe that a thoracoscopic trans
thoracic dorsal sympathectomy can
be performed safely and rapidly and
will gain further acceptance as tho
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racic surgeons become more famil
iar with the new minimal-access
surgical techniques.
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Androcur (cyproterone acetate) is a steroid
which clinically demonstrates two distinct
properties:
a) Antiandrogenic: Cyproterone acetate
blocks the binding of dihydrotestosterone the active metabolite of testosterone to the specific receptors in the prostatic carci
noma cell.
b) Progestogenic/antigonadotrophic:
Cyproterone acetate exerts a negative feed
back on the hypothalamo-pituitary axis, by
inhibiting the secretion of LH leading to dimin
ished production of testicular testosterone.
The absorption o f Androcur following oral ad
ministration is complete. Peak plasma levels
are reached 3-4 hours after administration.
Plasma levels fall rapidly during the first 24
hours as a result of tissue distribution and ex
cretion, and plasma half-life was 38 ± 5 hours.
Most o f the cyproterone acetate is excreted
unchanged in the feces (60%) or urine (33%)
within 72 hours. Cyproterone acetate is
eliminated with the urine mainly in the form
of unconjugated metabolites and with the
bile (feces) in the form of glucuronidized
metabolites.
The principal metabolite identified was
156-hydroxy-cyproterone acetate.
Androcur Depot: Following intramuscular
Androcur Depot administration, mean maxi
mum blood levels were attained 3.4 days after
injection. The mean elimination half-life was
found to be 4 days.

Indications
Androcur (cyproterone acetate) is indicated
for the palliative treatment of patients with
advanced prostatic carcinoma.

Contraindications
Known hypersensitivity to the drug. Active liver
disease and hepatic dysfunction.
Renal insufficiency.

Warnings

■ V n.
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Liver Function: Cyproterone acetate has
been found at low doses o f 2-10 mg/kg to
cause liver abnormalities in dogs and rats in
the form of proliferative liver changes including
increased liver weight, liver cell hypertrophy
with an increase in the smooth endoplasmic
reticulum and a rise in the serum glutamic
pyruvic transaminase (SGPT). A t high doses
of 50-100 mg/kg, nodular hepatic hyperplasia
and hepatomas have also been observed.
Although cyproterone acetate has shown
good liver tolerance in man, liver function tests
including SGOT, SGPT and LDH should be
performed at least semi-annually during
Androcur therapy.
Inhibition of Spermatogenesis: The sperm
count and the volume of ejaculate are reduced
at oral doses of 50-300 mg per day. Infertility
is usual, and there may be azoospermia after
8 weeks of therapy, which is associated with
atrophy of seminiferous tubules. Follow-up
examinations on discontinuation of therapy
have shown these changes to be reversible.
Spermatogenesis usually reverts to its
previous level about 3-5 months after stopping
Androcur, or in some patients, after up to
20 months. Production of abnormal spermato
zoa during Androcur therapy has been
observed; their relationship to abnormal fertil

ization or malformed embryos is not known.
Gynecomastia: Benign nodules (hyperplasia)
of the breast have been reported; these gener
ally subside 1-3 months after discontinuation
of therapy and/or after a reduction of dosage.
The reduction of dosage should be weighed
against the risk of inadequate tumor control.
Depression: Androcur therapy has occasionally
been associated with an increased incidence
of depressive mood changes, especially during
the first 6-8 weeks of therapy. Similar mood
changes have also been seen following surgi
cal castration and are considered to be due to
androgen deprivation. Patients with tendencies
to depressive reaction should be carefully
observed.

Precautions
Thromboembolism: Clinical investigations
have shown that when cyproterone acetate is
used alone, it has a minor effect on blood
clotting factors. However, when cyproterone
acetate was combined with ethinyl estradiol,
changes were found in increased coagulation
capability.
There is an inherent risk for those patients
with a history of thrombophlebitis or throm
boembolism for recurrence of the disease.
Cyproterone acetate should be discontinued
at the first sign of thrombophlebitis or throm
boembolism.
The patient should be carefully re-evaluated
if manifestations of thrombotic disorders should
occur, e.g. thrombophlebitis, cerebro- vascular
complications, renal thrombosis or pulmonary
embolism.
Adrenocortical Function: Suppression of
adrenocortical function tests have occurred
in patients receiving high doses (100 mg/m2)
of Androcur. Reduced response to endoge
nous ACTH was noted by the metyrapone test;
furthermore, reduced ACTH and cortisol blood
levels determined by the Mattingly method
were also found. It is therefore recommended
that adrenocortical function tests should be
monitored periodically by serum cortisol assay.
Diabetes: Androcur may impair carbohydrate
metabolism. Parameters of carbohydrate
metabolism, fasting blood glucose and glucose
tolerance tests, should be examined carefully
in all patients and particularly in all diabetics
before and regularly during therapy with
Androcur.
Hematology: Hypochromic anemia has been
observed rarely during therapy with Androcur.
Regular hematological assessment is
recommended.
Nitrogen Balance: A negative nitrogen
balance is usual at the start of therapy, but
does generally correct itself within 3 months
of continued therapy.
Metabolic Effects: Fluid retention, hypercal
cemia and changes in plasma lipid profile may
occur. Accordingly, Androcur should be used
with caution in patients with cardiac disease.
Skin: Androcur therapy may cause a reduction
of sebum production leading to dryness of the
skin, and transient patchy loss o f body hair.
Concomitant Alcohol: Alcohol may reduce
the antiandrogenic effect of Androcur in hyper
sexuality. The relevance of this in prostatic
carcinoma is not known. However,
it would be prudent to inform the patients
that the use of alcohol during Androcur therapy
is not advisable.
Physical Performance: Patients should be in
formed that fatigue and lassitude are common
in the first few weeks of therapy,
but usually become much less pronounced
from the third month onwards. Marked lassi

tude and asthenia necessitate special care
when driving or operating machinery.
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Adverse Effects
The most frequently recorded adverse effects
with Androcur (cyproterone acetate) are those
related to the hormonal effects o f the drug.
These reactions usually disappear upon dis
continuation of therapy or reduction of dose.
Hormonal: inhibition of spermatogenesis;
abnormal spermatozoa; impotence; breast ten
derness; breast enlargement; gynecomastia;
benign nodular hyperplasia; galactorrhea.
Central Nervous System: fatigue; lassitude;
weakness; depression; headache.
Gastrointestinal: diarrhea; nausea; vomiting;
constipation; indigestion.
Cardiovascular: edema; shortness of breath on
effort; thrombophlebitis.
Laboratory Function Tests: Abnormal values
have been found in the following tests:
Liver Function Test: SGPT and SGOT increase.
Adrenocortical Function test: decreased re
sponse to ACTH and lowered cortisol.
Hematology: hypochromic anemia. Negative
nitrogen balance initially and hypercalcemia.
Adverse reactions are rarely of sufficient
severity to require dosage reduction or discon
tinuation of treatment. If reactions are severe,
it may be beneficial to reduce the dosage.

Symptoms and Treatment
of Overdosage
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A

There have been no reports of fatal over
dosage in man with Androcur (cyproterone ac
etate). There are no specific antidotes, and
treatment should be symptomatic.
If oral overdosage is discovered within two
to three hours, gastric lavage can safely
be used if indicated.

Dosage and Administration
Oral Tablets: The usual daily initial and
maintenance dose o f Androcur is 4-6 tablets
(200-300 mg) divided into 2-3 doses and taken
after meals. After orchiectomy, a lower daily
dose o f 2-4 tablets (100-200 mg) is
recommended.
Injectable: The usual initial and maintenance
dose of Androcur Depot is one weekly intra
muscular injection o f 3 mL (300 mg). For
orchiectomized patients, the recommended
dose is one intramuscular injection of 3 mL
(300 mg) every two weeks. Androcur or
Androcur Depot (cyproterone acetate) therapy
should not be discontinued when remission
or improvement occurs.
Because of their pharmacokinetic properties,
Androcur (oral) and Androcur Depot (i.m.)
can be interchanged in the course of long-term
treatment. The dosage may be reduced if
side effects are intolerable but should be kept
within the oral range o f 2-6 tablets tablets daily
(100-300 mg) or intramuscular injections of
300 mg at weekly intervals, or every two
weeks.

Availability
Androcur (cyproterone acetate) 50 mg tablets bottles of 60. Each white, round, flat-sided
scored tablet with bevelled edges, imprinted
one side HBV" in a regular hexagon, other side
scored, contains 50 mg of cyproterone acetate.
Androcur Depot (cyproterone acetate) 3 mL
(300 mg) ampoules. Each 3 mL ampoule
contains cyproterone acetate 100 mg/mL in
a castor oil solution.

Product monograph
available upon request.

4,

92012E

A

4
' f

V

•-1

ORIGINAL ARTICLES

Prevention of Herpes Simplex
Virus Infection by Oral Acyclovir
After Cardiac Transplantation
Michel Carrier, MD, FRCSC; Guy B. Pelletier, MD, FRCPC; Raymond Cartier, MD;
Yves Leclerc, MD, FRCSC; L. Conrad Pelletier, MD, FACS, FRCSC
Infection with herpes simplex virus is common among immunosuppressed patients.
In an attempt to prevent such infection, 58 patients (group 1) who underwent
cardiac transplantation between 1987 and 1990 were given acyclovir (200 mg orally
three times a day) prophylactically throughout their postoperative hospital stay
(mean 22 days ± 1 day). The patients’ immunosuppressive protocol included
cyclosporine, azathioprine and prednisone. The course of these patients was
compared to that of 24 patients (group 2) who underwent cardiac transplantation
between 1983 and 1986 but were not given prophylactic antiviral treatment
postoperatively. The immunosuppressive protocol in these patients consisted of
cyclosporine and prednisone. Herpes infection developed during the 1st year in 5
patients (9%) in group 1 and in 11 patients (46%) in group 2 (p < 0.05). The
actuarial rates of freedom from herpes infection at 1, 6 and 12 months after
transplantation were 100%, 98% ± 2% and 95% ± 3%, respectively, in group 1 and
82% ± 7%, 58% ± 11%, 53% ± 11% in group 2. All viral infections were cutaneous
or mucosal, except for one, which developed in a patient with pneumonia. All
infections responded well to treatment, althr,"'*h
-------was left with a permanent visual deficit.
The authors conclude that prophylaxis of herpes simplex virus infection with
acyclovir administered orally in the early postoperative period is effective in
preventing viral infections during the 1st year after cardiac transplantation.

Les infections a herpes simplex sont frequentes chez les malades immunodeprimes.
Dans l’espoir de prevenir ces infections, 58 patients (groupe 1) qui ont subi une
greffe cardiaque entre 1987 et 1990 ont refu de l’acyclovir (200 mg trois fois par
jour par voie orale) a titre prophylactique pendant toute la duree de leur
hospitalisation postoperatoire (22 ± 1 jours). Pour ces patients, le regime
immunosuppresseur comprenait cyclosporine, azathioprine et prednisone.
L’evolution de ces patients a ete comparee a celle de 24 patients (groupe 2) qui
subirent une greffe cardiaque entre 1983 et 1986, mais qui ne re?urent aucun
traitement preventif antiviral postoperatoire. Le traitement immunosuppresseur de
ces patients comprenaient cyclosporine et prednisone. Des infections a herpes sont
apparues durant la premiere annee chez 5 patients (9 %) du groupe 1 et chez 11
patients (46 %) du groupe 2 (p < 0.05). Les taux actuariels de protection contre
l’infection herpetique 1, 6 et 12 mois apres la transplantation, ont ete de 100 %,
98 % ± 2 % et 95 % ± 3 %, respectivement dans le groupe 1, et de 82 % ± 7 %, 58 %
± l l % e t 5 3 % ± l l % dans le groupe 2. Toutes les infections virales ont ete
cutanees ou muqueuses, a l’exception d’une qui est survenue chez un patient
souffrant de pneumonie. Toutes les infections ont bien repondu au traitement, bien
qu’un patient qui souffrait d’une infection corneenne ait conserve un deficit visuel
permanent.
Les auteurs concluent que l’acyclovir administre par voie orale dans la periode
postoperatoire immediate est efficace comme traitement preventif de l’infection a
herpes simplex durant la premiere annee qui suit une transplantation cardiaque.
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eart transplantation is now a
widely accepted treatment for
end-stage heart disease. Survival
has improved and the overall results
are good, but infectious complica
tions remain a major postoperative
concern and are the main cause of
morbidity beside rejection.1"3
Herpesvirus infection is a com
mon problem among strongly im
munosuppressed patients during
the 1st year after transplantation.4 5
Although herpes infections are usu
ally benign and are rarely life
G.ivaienmg, most of them being
limited to cutaneous and mucosal
lesions, they can at times have
long-term sequelae, and all of them
cause some degree of suffering for
the patient.
Since 1987, to prevent herpes
virus infections, low doses of oral
acyclovir were administered prophy
lactically during the immediate
postoperative period to all patients
who underwent heart transplanta
tion.6 We carried out a retrospective
study to analyse the value of pro
phylactically administered acyclovir
in preventing herpesvirus infections
in heart-transplant patients.
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Patients and Methods
Eighty-two patients who received
a cardiac transplant between 1983
and 1990 were studied retrospec
tively. From 1987 to 1990, 58 of
these patients received cyclospo
rine, prednisone and azathioprine
for immunosuppression and were
given acyclovir (200 mg every 8
hours orally) from the 2nd postop
erative day to the day of discharge
from the hospital (average 22 days
± 1 day) (group 1). From 1983 to
1987, 24 patients who received a
cardiac transplant received a combi
nation of cyclosporine and predni
sone for immunosuppression, with
out antiviral prophylactic treatment
(group 2). All patients were evaluat
ed at the outpatient clinic for heart
transplantation and were followed
up according to the same protocol.
Acute rejection according to Billingham’s classification was treated
by an increase in the prednisone
dose and intravenous administration
of Solu-Medrol or rabbit anti
thymocyte globulin, as required by
the severity of rejection. Acyclovir
was given during the period of
treatment of acute rejection in
group 1 only. In both groups, cy
closporine serum levels were main
tained around 200 nmol/L in the
1st month after transplantation and
were lowered to 100 nmol/L there
after.
Clinical herpesvirus infection was
defined by the presence of symp
tomatic culture-positive lesions or
by characteristic vesicles and ulcer
ations of mucous membrane and
skin. Results of serologic testing
could not be obtained prospectively
in all patients, because some pa
tients received their transplant on
an emergency basis. Our prophylac
tic management, therefore, was not
based on positive serologic results.
Data are presented as means and
standard error of the means. The
frequency of infection and rejection
514
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are expressed as linear rates. Differ
ences between the two groups were
evaluated by Student’s f-test; infec
tion and survival rates were
analysed by the actuarial method
and the difference between the two
groups by the Mantel-Cox test.
Statistical significance was estab
lished at a p value of 0.05.

Findings
Patients in group 1 were signifi
cantly older than patients in group
2 and the hospital stay was shorter
(Table I). The rates of nonherpetic
infection and acute rejection were
similar in both groups.
During the postoperative follow
up, herpesvirus infection occurred
in 5 (9%) of the 58 patients with
prophylactic treatment, compared
with 11 (46%) of the 24 patients
without prophylactic treatment (p <
0.05). The actuarial rates of free
dom from any herpes infection 1, 6
and 12 months after transplantation
were 100%, 98% ± 2% and 95% ±
3% among patients in group 1, and
82% ± 7%, 58% ± 11% and 53% ±
11% in patients in group 2, differ
ences that were significant (Fig. 1).

Actuarial survival rates were similar
for the two groups (Fig. 2).
All viral infections were mucosal
or cutaneous, except for one epi
sode of pneumonia in a patient in
group 2. All responded well to
treatment, although in one case a
corneal infection left a permanent
visual deficit. No herpesvirus infec
tion occurred during prophylactic
treatment in group 1 patients. Acy
clovir was well tolerated, and no
adverse reaction was observed.7

Discussion
Herpesvirus infections are com
mon among immunosuppressed pa
tients. During our initial experience
(group 2), 46% of the patients suf
fered such infections within the 1st
year after transplantation. Despite
the relatively benign and non-lifethreatening course of herpesvirus
infection, it can be the source of
major morbidity and often necessi
tates hospitalization for intravenous
acyclovir treatment.89 Prophylactic
treatment with low-dose, orally ad
ministered acyclovir restricted to
the period of initial hospital stay
after transplantation decreased sig-
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VIRAL INFECTION AFTER CARDIAC TRANSPLANTATION

nificantly the incidence of herpes
virus infections during the 1st year
of follow-up of these patients.6
The majority of herpesvirus in
fections among patients who re

ceived a renal transplant is believed
to be the result of reactivation of
latent virus.10 Preventing reactiva
tion with acyclovir during the peri
od of most intense immunosuppres

FIG. 1. Actuarial rates of freedom from herpes simplex infection after cardiac
transplantation. Group 1 patients (acyclovir, open squares, n = 58) have
significantly lower rates of herpesvirus infection than group 2 patients (no
acyclovir, closed squares, n = 24) (p < 0.05, Cox-Mantel test). Numbers in figure
indicate number of patients at risk in interval depicted.

sion could explain the prolonged
protective effect of the short course
of low-dose oral acyclovir against
herpesvirus infection observed in
the present study. It has been sug
gested that the herpes simplex virus
is particularly sensitive to the initial
immunosuppressive therapy, and
that virus shedding peaked during
the first 2 weeks after transplanta
tion.11 It has also been shown that
cellular immunity against herpes
simplex infection is maximally de
pressed immediately after cardiac
transplantation and is normal 6
months later.12 Prophylactic acy
clovir was used successfully after
bone-marrow transplantation, and
these experiences support the re
sults of the present study.6
The prophylactic use of acyclovir
in all patients remains controversial,
because herpesvirus infection ap
pears to be uncommon among se
ronegative patients.10 However,
since heart transplantation is often
performed on an urgent basis, and
this prophylactic treatment has no
serious side effects,713 we support
the systematic use of low-dose,
orally administered acyclovir during
the period of intense immunosup
pression immediately after cardiac
transplantation. In our experience,
the use of acyclovir immediately
after cardiac transplantation signifi
cantly decreased m ucocutaneous
herpesvirus infection and patient
discomfort.
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Unilateral Versus Bilateral Thyroid
Resection in Differentiated Thyroid
Carcinoma
Gary Groot, MD, FRCSC;* Brian P.D. Colquhoun, MD, FRCS(Edin), FACS, FRCSC;*
Fergus A. Murphy, MD, FRCPCf
Risk-group definitions have been developed recently in an attempt to clarify which
operation to do for whom in differentiated thyroid carcinoma. The authors attempted
to confirm the validity of an age-based risk-group definition for identifying patients
at high risk of death from thyroid carcinoma and to test whether the degree of
surgical resection in either high- or low-risk groups affected patient survival.
An age-based risk-group definition was used in the retrospective analysis of 161
patients with differentiated thyroid carcinoma seen at the Saskatoon Cancer Centre,
University of Saskatchewan, between 1933 and 1964. A significant difference was
found in the death rate between low- and high-risk groups (4.3% versus 47%
respectively). This confirms the validity of such an age-based risk-group definition.
Although a long-term survival benefit was suggested with the use of bilateral
thyroid resection in high-risk patients, the difference was not significant. In low-risk
patients, there was no difference in the survival rate between patients who
underwent unilateral or bilateral thyroid resection, followed up for as long as 55
years.

Des definitions de groupes a risque ont ete elaborees depuis peu, dans un effort
pour determiner quel type d’operation doit etre pratique et chez qui, dans les cas de
cancer thyroidien differencie. Les auteurs ont tente de confirmer la validite d’une
definition basee sur l’age d’un groupe a risque, pour identifier les patients porteurs
de cancers de la thyroi'de a risque de mortalite eleve et pour verifier si l’etendue de
la resection chirurgicale, chez les patients a faible comme a haut risque, influencait
la survie.
Une definition du risque selon l’age a ete utilisee dans une etude retrospective de
161 patients souffrant de cancer thyroidien differencie vus au Centre pour le cancer
de Saskatoon, de l’ Universite de Saskatchewan, entre 1933 et 1964. Une difference
statistique a ete observee entre les taux de mortalite des groupes a risque faible ou
eleve (4,3 % contre 47 %). Ceci confirme done la validite de cette definition du risque
selon l’age. Meme si la resection thyroidienne bilaterale semble prolonger la survie
chez les patients a risque eleve, la difference n’atteint pas le seuil de signification.
Chez les patients a faible risque, on n’a pas constate de difference dans le taux de
survie entre les patients qui ont subi une resection thyroidienne unilateral et ceux
qui ont eu une resection bilaterale et qui ont fait l’objet d’une surveillance allant
jusqu’a 55 ans.

From the *Department o f Surgery and fDepartment o f Pathology, Royal University Hospital,
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everal studies have demonstrat
ed the usefulness o f an agebased risk-group definition in differ
entiated
thyroid
carcin om a,1-4
whereas others question its validi
ty.5 The intent o f these studies has
been to define a group o f patients
who have a low risk o f recurrence
or death from their disease and who
may be treated more conservatively.
Recently, Cady and Ross3 from the
Lahey Clinic reported on a riskgroup classification they have devel
oped, which is practical to use
clinically and in which 89% o f pa
tients had a 1.8% death rate com 
pared with a 45% deat! rate in the
remaining 11%. We thought it
would be beneficial to attempt to
confirm the ability o f the age-based
risk-group definition to predict
which patients had more lethal thy
roid cancer and to test whether the
degree o f surgical resection in ei
ther high- or low-risk groups affect
ed patient survival.

S

Patients and Methods
The records o f all patients treated
for carcinoma o f the thyroid gland
and registered with the Saskatoon
Cancer Centre between 1933 and
1964 were reviewed. From this
group were drawn all patients treat
ed for differentiated thyroid carcino
ma (follicular or papillary). They
formed the study group. Data were
CJS, VOL. 35, NO. 5, O CTOBER 1992
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recorded on patient age and sex,
the histologic type of the tumour,
the extent of the primary tumour in
terms of involvement of the tumour
capsule in follicular carcinoma and
extrathyroid extension in papillary
carcinoma as well as on the pres
ence of distant metastasis at the
time of the original surgery. The
pathological classification was per
formed by a senior pathologist
(F.M.).
The risk-group definition as de
scribed by Cady and Rossi was used
because of its clinical applicability.3
The low-risk group was defined as
all men 40 years of age or younger
and all women 50 years of age or
younger. Also included in this
group were older patients with pri
mary papillary cancers less than 5
cm in diameter that were confined
to the thyroid gland or with primary
follicular cancers less than 5 cm in

diameter displaying only minor in
vasion of the tumour capsule. Pa
tients with distant metastasis at the
time of presentation were classed as
high risk.
Patients considered to have died
of their disease included those who
died intraoperatively or postoperatively, those with residual or recur
rent disease who died of other
causes, those who were lost to
follow-up and who had active dis
ease at that time, as well as patients
whose death was directly attributed
to their disease.
Follow-up was by examination at
the Saskatoon Cancer Centre clinic,
by autopsy or by doctor’s letter
until death or 1989. Follow-up was
complete in all but four cases that
were lost. A minimum follow-up of
25 years and a maximum follow-up
of 55 years were achieved.
The data were studied by stan

Table I. Application of the Risk-Group Definition to Patients in Three Series
Series

Patients, no. (%)

Mayo Clinic (Hay et al, 19874)
Low risk
High risk
Lahey Clinic (Cady and Rossi, 19883)
Low risk
High risk
Saskatoon Cancer Centre
Low risk
High risk

Died, no. (%)

737 (86)
121 (14)

15( 2)
56(46)

277 (89)
33 (11)

5 ( 2)
15 (45)

116(72)
45 (28)

5(4)
21 (47)

FIG. 1. Life-table analysis of survival rates for high-risk (45 patients) and low-risk
(116 patients) groups. Difference between groups was significant (p < 0.001).
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dard life-table methods. The Kaplan-Meier method was used. Sig
nificance was tested with the logrank test.

Results

■*

t

~r

Between 1933 and 1964, 205
patients were registered with the
Saskatoon Cancer Centre. Of these,
161 had differentiated thyroid car
cinomas, either papillary or follicu
lar. Of the remaining 44 patients,
32 had either anaplastic cancer or
lymphoma, 1 had a transitional cell
carcinoma metastatic to the thyroid,
6 had cancers found incidentally at
autopsy and in 5 patients the details
were lacking or the charts were
missing.
When we applied the age-based
risk-group definition to our 161
patients, 116 had low-risk tumours
and 45 had high-risk tumours. Of
the 116 low-risk patients, 5 (4%)
died of their disease, whereas 21
(47%) of the 45 high-risk patients
died of their disease. These rates
are comparable to those of Hay and
associates4 from the Mayo Clinic
and Cady and Rossi3 from the
Lahey Clinic (Table I). Fig. 1 shows
the survival rates for the two risk
groups. Using log-rank analysis,
the difference between the two
groups was significant (p < 0.001).
This confirms the ability of the
age-based risk-group definition to
differentiate patients at high risk of
death from carcinoma of the thyroid
gland. No statistical difference was
noted between patients with papilla
ry or follicular carcinoma when
those two groups were analysed
separately. Exclusion of patients
with metastasis at the time of pre
sentation from the high-risk group
(since these patients may represent
a subgroup with more lethal dis
ease) did not alter the death rate in
this group. Eleven patients in the
high-risk group presented with
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FIG. 2. Life-table analysis of survival rates in low-risk group for those who had
bilateral thyroid resection (45 patients) and those who had unilateral thyroid
resection (56 patients).

FIG. 3. Life-table analysis of survival rates in high-risk group for those who had
bilateral thyroid resection (18 patients) and those who had unilateral thyroid
resection (13 patients).

metastatic disease (Table II). Two
were children aged 9 years and 5
years. The possibility that younger
patients with extraglandular disease
at the time of presentation might
represent a higher-risk group was
also considered, but the death rate
in this subgroup was not signifi
cantly different from that of the
low-risk group as a whole.
The survival rates for 101 pa
tients in the low-risk group who
had either a bilateral thyroid resec
tion (45 patients) or a unilateral
resection (56 patients) were similar
(Fig. 2). Previous studies have dem
onstrated no difference in survival
between total thyroidectomy and
subtotal thyroidectomy, and there
fore, these two have been grouped
together.4 The remaining 15 pa
tients in the low-risk group under
went less than a thyroid lobectomy
(most of these patients were treated
in the earlier part of the study). Of
the 45 patients who had bilateral
resections, 16 received adjuvant ra
diotherapy, 2 received adjuvant ra
dioactive iodine and 1 received both
radioactive iodine and radiotherapy
postoperatively. Of the 56 patients
who had a unilateral resection, 13
received adjuvant radiotherapy and
none had radioactive iodine therapy.
Differences in survival rates for
31 high-risk patients who had bilat
eral (18 patients) or unilateral (13
patients) thyroid resection were not
significant (Fig. 3). The remaining
14 patients in the high-risk group
underwent less than a lobectomy
(biopsy only or enucleation). Of the
18 patients who underwent bilateral
resection, 6 had adjuvant radiother
apy alone postoperatively, 2 pa
tients received radioactive iodine
therapy, and 3 patients had both
radioactive iodine and radiotherapy.
Of the 13 patients who underwent
unilateral resection, 10 patients had
postoperative adjuvant radiothera
py. None of these patients received
radioactive iodine. Although there
CJS, VOL. 35. NO. 5, OCTOBER 1992

519

GROOT, COLQUHOUN, MURPHY

appears to be a survival advantage
beyond 25 years for patients who
undergo bilateral resection, this ad
vantage is not statistically signifi
cant.

Discussion
For patients with differentiated
thyroid carcinoma, the concept of
an age-based risk-group definition
has been proposed to guide thera
py. Although papers have demon
strated the usefulness of this riskgroup definition, at least in distin
guishing patients with more lethal
disease from those whose disease
follows a more benign course,1-4
others have not found the agebased risk-group definition valid.5
The question of whether to per
form a total thyroidectomy or a
lesser procedure in patients with
differentiated carcinoma of the thy
roid gland continues to be contro
versial. There are several aspects to
the problem as it applies to differen
tiated thyroid carcinoma. First is
the question of patient survival —
Is there any survival advantage to
bilateral versus unilateral thyroid
resection? In the low-risk group of
patients, we have demonstrated, as
have Hay and associates4 and Cady
and Rossi,3 that there is no survival
advantage with bilateral thyroid re
section. In patients at higher risk,
Hay and associates4 demonstrated
an improvement in survival that was
not statistically significant and be
came noticeable after 10 years. We
showed a similar benefit after 25
years, but again this was not sig
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nificant. Both these studies had
limited numbers of patients in the
high-risk groups. The possibility
that the differences could become
significant with a larger number of
patients is acknowledged.
Another reason for bilateral thy
roid resection is the ability to diag
nose and treat metastatic disease
without first having to ablate a
large thyroid remnant. Our study
did not address this issue, but we
noted that metastatic disease in the
low-risk group was almost nonexis
tent. Others have noted that youn
ger patients with advanced disease
appear to do well despite their ex
tensive disease.2-6-9 High-risk pa
tients may benefit from treatment of
their metastases with radioactive
iodine therapy, and this may be a
consideration for total or subtotal
thyroidectomy in this group.
Yet another reason for bilateral
resection is the incidence of recur
rence in the neck, which, although
not necessarily lethal, may lead to
significant morbidity for the patient.
Grant and associates9 at the Mayo
Clinic recently looked at this ques
tion with regard to the risk-group
definition as described by their
group. Their data demonstrated an
increase in local recurrence for pa
tients with papillary carcinoma who
underwent a unilateral thyroid re
section, although no difference be
tween total or subtotal thyroidecto
my was seen. Therefore, in patients
with papillary carcinoma, it may be
reasonable to perform a bilateral
thyroid resection in order to de
crease the chance of any local re
currence.

In summary, an age-based riskgroup definition is useful to identify
patients with aggressive disease.
Bilateral thyroid resection does not
offer a survival advantage over uni
lateral resection, and a decision to
perform a bilateral resection should
be based on other considerations.
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Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is achieved through inhibition of DNA
gyrase, an essential component of the bacterial DNA replication system. Inhibition of the alpha subunit of the DNA gyrase blocks
the resealing of the nicks on the DNA strands induced by this alpha.subunit, leading to the degradation of the DNA by
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Ciprofloxacin retained some of its bactericidal activity after inhibition of RNA and protein synthesis by rifampin and
chloramphenicol, respectively. These observations suggest ciprofloxacin may possess two bactericidal mechanisms, one
mechanism resulting from the inhibition of DNA gyrase and a second mechanism which may be independent of RNA and protein
synthesis.
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Respiratory Tract Infections: Acute bronchitis and acute pneumonia caused by: £ cloacae, E. coli, H. influenzae, K. pneumoniae,
P. mirabilis, P aeruginosa, S. aureus, S. pneumoniae
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agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
should be performed periodically during therapy to detect the emergence of bacterial resistance.
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hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded.
Pseudomembranous colitis has been reported with virtually all antibacterial agents, including ciprofloxacin, and may range in
severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients with diarrhoea subsequent
to the administration of antibacterial agents.
Subsequent to diagnosis of pseudomembranous colitis, therapeutic measures should be initiated. Mild cases will usually respond
to discontinuation of drug alone. In moderate to severe cases, consideration should be given to the management with fluids,
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in the serum.

Infectious Diarrhea: (When antibacterial therapy is indicated) caused by: £ coli (enterotoxigenic strains), C. jejuni, S. flexneri,
S. sonnei
B) Intravenous Administration
CIPRO® I.V. (Ciprofloxacin injection) may be indicated for the treatment of patients with the following infections caused by
susceptible strains of the indicated microorganisms:

Concomitant administration of a nonsteroidal anti-inflammatory drug (fenbufen) with a quinolone (enoxacm) has been reported to
increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the absorption of ciprofloxacin. Concurrent
administration with these agents should be avoided.

Respiratory Tract Infections: acute pneumonia caused by: £. coli, K. pneumoniae, E. cloacae, P. mirabilis, P aeruginosa,
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tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
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advised.

Urinary Tract Infections: Upper and lower complicated urinary tract infections including pyelonephritis caused by: C. diversus,
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ADVERSE REACTIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are generally well tolerated. During
worldwide clinical investigation, 16,580 courses of ciprofloxacin treatment were evaluated for drug safety.
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organisms causing the infection and to determine their susceptibilities to ciprofloxacin. Therapy with CIPRO® and CIPRO® I.V.
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CONTRAINDICATIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
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immature dogs revealed permanent lesions of the cartilage. Consequently, CIPRO® and CIPRO® I.V. should not be used in
prepubertal patients. Experience in pubertal patients below 18 years of age is limited.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in the treatment of infections in pregnant women has not yet been established
(see PRECAUTIONS).
PRECAUTIONS
General Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients receiving therapy with CIPRO®
and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). These reactions may occur within the first 30
minutes following the first dose and may require epinephrine and other emergency measures.
CIPRO® and CIPRO® I.V. may cause central nervous system (CNS) stimulation which may lead to tremor, restlessness, light
headedness, confusion, and very rarely to hallucinations or convulsive seizures. Therefore, CIPRO® and CIPRO® I.V. should be
used with caution in patients with CNS disorders, such as severe cerebral arteriosclerosis or epilepsy. Patients with known
convulsive seizure disorders should only be treated with CIPRO® and CIPRO® I.V. if anticonvulsant therapy has been initiated
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT ADMINISTRATION OF
CIPRO® I.V. AND THEOPHYLLINE. These reactions include cardiac arrest, seizure, status epilepticus and respiratory failure.
Similar serious adverse events have been noted with administration of theophylline alone, however, the possibility that
ciprofloxacin may potentiate these reactions cannot be eliminated If concomitant use cannot be avoided, the plasma levels of
theophylline should be monitored and appropriate dosage adjustments should be made.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia, jaundice, and hepatic necrosis with fatal outcome
have also been reported to occur very rarely in patients receiving ciprofloxacin in combination with other drugs. The possibility
that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be withdrawn at the first appearance
of a skin rash or other signs of hypersensitivity.
Crystalluna related to ciprofloxacin has been reported only rarely in man because human urine is usually acidic. Crystals have
been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well

In orally treated patients enroled in clinical trials, the most frequently reported events, possibly,probably drug-related were:
nausea (1.3%) and diarrhea (1.0%).

Events possibly, probably drug-related occurring at a frequency of less than 1% with ciprofloxacin oral and i.v. treatment during
clinical trials and subsequent post-marketing surveillance are as follows:
Gastro-lntestinal: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis,
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration,
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis. The following have been reported very rarely: hypertension, hot flashes,
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris,
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion,
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine, increase of intracranial
pressure. In some instances these reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has
to be discontinued and the doctor should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis,
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, corneal
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis; very rarely,
major liver disorders including hepatic necrosis, joint pain, Lyell Syndrome.

Sequential IV/PO Therapy

Blood and Blood constituents: eosinophilia, leukocytopenia, leukocytosis, anaemia. Very rarely: haemolytic anaemia,
thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase,
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubmemia, hyperuricemia, increased
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis,
crystalluria and haematuria.
Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in seventy .There have been 54 reports of
arthropathies with CIPRO®. Ten of these reports involved children. Arthralgia was usually the first symptom which led to rapid
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.

In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated at the discretion of
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed.

Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to compensate for the
reduced renal excretion of patients with renal impairment. Nonetheless, some modification of dosage is recommended,
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However,
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin
(<10%) is removed from the body after haemodialysis or peritoneal dialysis.

Creatinine Clearance
mL/s ImL/min)

SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection).
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be
carefully observed and given supportive treatment.

DOSAEE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the
susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function.

Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before or after meals. Absorption is faster on an empty stomach.
Patients should be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.

Adult The recommended dosages of oral CIPRO® are:
Location of Infection

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Mild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Lower Respiratory Tract
Bone & Joint
Skin & Soft Tissue

Mild/Moderate
Severe/Complicated5

500 mg
750 mg

q 12h
q 12h

1000 mg
1500 mg

Infectious Diarrhea

Mild/Moderate/Severe 500 mg

q 12h

1000 mg

Dose

> 0 .5 (30)

No Dose adjustment

< 0 .5 (30)
and patients on haemodialysis or
peritoneal dialysis

Use recommended dose once daily or
half usual dose twice daily

When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient)
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal
function:

In traditional units ml/min

Creatinine Clearance ml/sec
Males:

Weight (kg) x (140 - age)
49 x serum creatinine (pmol/L)

Females:

0 .8 5 x the above value

Males:

W eight (kg) x (140 - age)
72 x serum creatinine mg/100 mL

Females:

0 .8 5 x the above value

Children
The safety and efficacy of CIPRO® and CIPRO® I.V. in children have not been established.

* e.g. hospital-acquired pneumonia, osteomyelitis
Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period
should be approximately 7 to 14 days. Generally, treatment should last 3 days beyond the disappearance of clinical symptoms or
until cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 to 8 weeks and up to 3 months.
W ith acute cystitis, a five-day treatment may be sufficient.

Intravenous Administration
Adult The recommended adult dosages of CIPRO® I.V. (ciprofloxacin injection) are:

AVAILABILITY OF DOSAGE FORMS
Tablets:
CIPRO® 250

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Moderate/Severe/
Complicated

200 mg to
400 mg

q 12h

400 mg to
800 mg

Lower Respiratory Tract
Skin or Skin Structure
Blood
Bone

Moderate

400 mg

q 12h

800 mg

Definitive clinical studies have not been completed in severe respiratory tract and other infections.
The duration of treatment depends upon the seventy of infection. Generally ciprofloxacin should be continued for at least 3 days
after the signs and symptoms of infection have disappeared. The usual duration is 7 to 14 days. However, for severe and
complicated infections more prolonged therapy may be required. Bone and joint infections may require treatment for 4 to 6
weeks or longer.

References: 1. Cipro/Cipro I.V. Canadian Product Monograph, MILES CANADA INC., September 1991.

Each tablet is engraved MILES on one side and 5 12 on the other and contains ciprofloxacin hydrochloride
equivalent to 250 mg ciprofloxacin. Bottles of 50.

CIPRO® 500

Each tablet is engraved MILES on one side and 5 13 on the other and contains ciprofloxacin hydrochloride
equivalent to 500 mg ciprofloxacin. Bottles of 5 0 ,1 0 0 and unit dose packages of 100.

CIPRO®750

Location of Infection

2. Current manufacturers' prices as of March, 1992.

CIPRO® and CIPRO® I.V. should not be used in prepubertal patients (see WARNINGS).

Each tablet is engraved MILES on one side and 5 14 on the other and contains ciprofloxacin hydrochloride
equivalent to 750 mg ciprofloxacin. Bottles of 50 and unit dose packages of 100.

Injection:
CIPRO® I.V.

Each mL contains 10 mg of ciprofloxacin, in vials of 20 mL and 40 mL.

Product Monograph available upon request.
© MILES CANADA INC., 1992
® Registered Trademark. MILES CANADA INC., is the Registered User of the Trademark CIPRO®, the original brand of
ciprofloxacin hydrochloride.
IM The trademark of the CIPRO® tablet, consisting of it's colour, shape and size, is a trademark of MILES CANADA INC.

CI024-0492 E

ORIGINAL ARTICLES

Management of Papillary Carcinoma
Arising in Thyroglossal-Duct Anlage
Donna Maziak, MD, CM; Zenon J. Borowy, BSc(Med), MD, FRCSC; Mervyn Deitel, MD, FRCSC, FACS;
Thomas Jaksic, PhD, MD, FRCSC; Anthony Ralph-Edwards, BSc, MD
Cysts of the thyroglossal duct are common congenital abnormalities. They present
as asymptomatic midline cervical swellings. The risk of malignant change is low;
only 103 cases have been reported in the world literature, 85% of which were
papillary adenocarcinomas. The appropriate treatment for this condition remains
controversial. The authors describe three patients who had papillary carcinoma
contained within a thyroglossal-duct rest. All were treated by cyst resection and
thyroid suppression, but without thyroidectomy and radioactive thyroid ablation.
Postoperatively, all patients remained disease free, with no recurrence at follow-up
ranging from 10 to 29 years. Isolated papillary carcinomas arising from primitive
thyroid remnants, associated with a palpably normal thyroid gland at surgery and a
negative thyroid scan, can be treated adequately by excising the thyroglossal mass.

Les kystes du canal thyroglosse constituent une anomalie congenitale frequente. Ils
apparaissent sous la forme de tumefactions cervicales medianes. Le risque de
transformation maligne est faible; seulement 103 cas ont ete signales dans la
litterature mondiale, dont 85 % d’adenocarcinomes papillaires. Le traitement
approprie de cette affection est debattu. Les auteurs decrivent trois patients qui
presentaient un carcinome papillaire cloisonne dans un reliquat du canal
thyroglosse. Tous furent traites par resection kystique et suppression thyroi'dienne,
mais sans thyroi'dectomie ou ablation thyroi’dienne par isotope. Apres l’operation,
tous les patients sont demeures exempts de cette maladie, sans recidive apres une
surveillance allant de 10 a 29 ans. Les carcinomes papillaires isoles issus des
reliquats thyroidiens et associes a la palpation d’une thyroide normale a la chirurgie
et a une scintigraphie thyroi'dienne negative peuvent etre traites de fafon
appropriee par excision de la masse thyroglosse.

hyroglossal-duct cysts are the
most common congenital cystic
lesions of the cervical region. In
early fetal life, a solid cord of cells

T

grows from the foramen cecum at
the junction of the middle and
posterior third of the tongue into
the midline o f the neck in front of
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and behind the hyoid bone. After
passing the thyroid cartilage, the
thyroglossal duct expands to form
the thyroid gland. If a portion of
the duct does not obliterate but
remains patent, a thyroglossal cyst
may develop. The development of
carcinoma in a remnant of this type
is extremely rare, with an incidence
o f less than 1%A The first case of
papillary adenocarcinoma arising in
a thyroglossal-duct cyst was report
ed in 1927 by Owen and Ingleby.2
Since then, 103 cases have been
reported in the world literature.13’4
Of the reported cases, 85% have
been papillary adenocarcinomas,
and the overall survival rate has
been reported at 98% on long-term
follow-up. We report three cases of
papillary adenocarcinoma arising in
a thyroglossal-duct anlage and sug
gest a plan o f treatment.

Case Reports
Case 1
In 1961, a 61-year-old woman
presented with a 7-month history of
a painless mass in the midline ante
rior aspect o f her neck above the
thyroid gland. She had no history
of pressure sensation or symptoms
related to thyroid dysfunction.
Physical examination revealed a
seemingly mobile spherical mass
below the level o f the hyoid bone

PAPILLARY CARCINOMA

just to the right of the midline,
measuring 2 X 3 cm. The mass
appeared fixed to the thyroid carti
lage. At operation, the mass ap
peared solid and was excised; on
frozen section it was found to be a
papillary carcinoma in a cyst. The
operation was then completed as a
Sistrunk procedure, removing the
anterior hyoid with a core of genioglossus extending to the base of the
tongue. Postoperative recovery was
uncomplicated. A scan of the thy
roid gland showed no abnormalities,
and the patient was treated with
thyroid replacement to achieve thy
roid-stimulating-hormone suppres
sion. The patient died of unrelated
causes 29 years later, and there was
no evidence of recurrence.
The pathologist’s report de
scribed the specimen as a 2 X 3-cm
cystic lesion. Sections demonstrated
an island of papillary carcinoma
within the cyst (Fig. 1). There was
no evidence of microvascular or
capsular invasion.
Case 2

In 1975, a 45-year-old man pre
sented with a 4-year history of a
painless enlarging mass in the ante
rior neck to the right of the mid
line. Examination revealed a 5 X
6-cm, solid, mobile mass overlying
the right thyroid cartilage. Thyroid
function testing gave normal re
sults. At the time of operation, a
cystic mass was found adherent to
the thyroid cartilage. A wide local
excision was performed. Postoperatively, a thyroid scan was negative,
and thyroid suppressive agents were
administered. The patient shows no
evidence of recurrence 17 years
later.
Pathologic examination revealed
a cyst 4 cm in diameter. Two foci of
well-differentiated papillary carcino
ma were identified within the cyst,
lined with thyroid tissue. There was
malignant invasion into the cyst

wall, but the invasion did not ex
tend to the margins of resection.
Case 3

In 1982, a 56-year-old man pre
sented with a 3-week history of a
painless swelling in the central an
terior part of his neck. Examination
revealed a 3 X 4-cm, firm, lobulated
mass overlying the thyroid carti
lage. No other masses were palpa
ble in the neck, and thyroid func
tion testing gave normal results. A
thyroid scan demonstrated a normal
thyroid gland and that the mass
was cold. Findings on fine-needle
aspiration of the mass were consis
tent with papillary carcinoma. At
operation, the mass was found to be
a poorly circumscribed cystic lesion
with a single, involved, delphian,
precricoid lymph node. The cyst at
its inferior pole was adherent to the
upper portion of the thyroid isth
mus. A wide local excision, includ
ing the thyroid isthmus and the
lymph node, was performed. The
patient was treated with thyroid
suppressive agents postoperatively.
The patient has no evidence of
recurrence 10 years later.

The excised specimen measured
5 X 3 cm and contained the cystic
mass. Invasive papillary carcinoma
was seen on histologic examination
(Fig. 2). Psammoma bodies were
present. The excised lymph node
was positive for metastatic papillary
carcinoma. The thyroid isthmus
was histologically normal.

Discussion
Carcinoma arising in a thyroglossal-duct remnant is extremely rare.3
Controversy exists as to whether a
papillary carcinoma in a thyroglossal-duct cyst is a metastasis from a
primary tumour of the thyroid or de
novo neoplasia occurring in ectopic
thyroid tissue.5 In 1974 Livolski,
Perzin and Savetsky6 concluded
that papillary adenocarcinoma can
arise de novo in thyroglossal-duct
remnants. In 1975, Joseph and Komorowski7 suggested the following
criteria for the diagnosis of thyro
glossal-duct carcinoma: the lesion is
cystic and in the midline of the
neck; papillary carcinoma is found
within benign cuboidal, columnar
or squamous cells of thyroglossal-

FIG. 1. Section of thyroglossal-duct cyst shows papillary carcinoma lining fibrous
wall of cyst (hematoxylin-eosin, original magnification X 400).
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duct origin; normal thyroid tissue is
found within the cyst; and the pa
tient has a clinically normal thyroid
gland.
Papillary carcinoma has account
ed for 85% of the reported cases of
primary malignant lesions arising in
thyroglossal-duct remnants.1 The
death rate is low (2%). Other types
of malignant tumour reported in
thyroglossal-duct cysts include
squamous, mixed-papillary and fol
licular, adenocarcinomatous, follic
ular and anaplastic. A death rate of
29% at 5 years has been reported
for squamous-cell carcinoma.8
Preoperative assessment plays an
important role in treatment. A com
plete head and neck examination,
including palpation of the thyroid
gland is mandatory. If there is any
suggestion of malignancy (e.g., the
cervical mass is firm or there is a
concomitant mass palpable in the
thyroid gland), thyroid function
tests, scanning and fine-needle aspi
ration of the mass should be done
initially.
Benign thyroglossal-duct cysts
have been removed by simple exci
sion, the Schlange method (partialduct excision) and the Sistrunk

technique (recurrence 50%, 20%
and 4% respectively).1 All cysts
should be opened at the time of
operation. If a mass is present with
in the cyst or the results of fineneedle aspiration were positive preoperatively, frozen sections should
be obtained intraoperatively. If the
frozen sections are positive for pa
pillary carcinoma, the thyroid and
the anterior neck should be exam
ined intraoperatively for masses or
involved lymph nodes. If no other
abnormalities are found, the wound
should be closed and thyroid scan
ning requested, if not already done.
If the thyroid scan is negative,
thyroid suppressive agents should
be administered.
Total or subtotal thyroidectomy
is indicated at the time of operation
when a concurrent thyroid mass is
removed by lobectomy and found to
be a carcinoma or, subsequently,
when a postoperative thyroid scan
demonstrates the presence of a cold
nodule. If cervical lymph nodes are
involved, a modified neck dissection
is also performed. Postoperatively,
patients are placed on thyroid sup
pression. If cervical lymph nodes
are positive for malignancy and the

thyroid gland is normal, a modified
neck dissection alone is performed.
From a review of the literature, it
appears that high thyroglossal ma
lignant tumours, nearer to the fora
men cecum, tend to be squamous
cell carcinomas. As with descending
structures elsewhere, portions of
the duct may remain and may leave
thyroid anlage or rests, whereas
other parts are obliterated. These
rests have been implicated in thy
roid uptake after total thyroidecto
my.9 It is known that a pyramidal
lobe, which may be to the right or
left of the midline, is a remnant or
persistence of a portion of the prim
itive thyroid. Our three cases of
papillary carcinoma were lower in
the neck than the usual thyroglos
sal-duct cyst and were nearer to the
thyroid gland (although separate
from it) than to the hyoid bone. We
question whether a Sistrunk opera
tion is necessary in these cases of
low papillary carcinoma. However,
papillary carcinoma is known to be
associated with a high incidence of
multicentricity, hence an accompan
ying total thyroidectomy has been a
consideration. When thyroid palpa
tion and scanning are negative, our
experience suggests that routine
thyroidectomy is unnecessary.

Conclusions

FIG. 2. Wall of cyst (bottom) with papillary carcinoma (off stalks) and central
benign thyroid follicles in cyst (hematoxylin-eosin, original magnification X 40).
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Our three patients were treated
with wide local excision and thyroid
suppression but without thyroidec
tomy and radioiodine thyroid abla
tion. These patients were free of
disease after 29, 17 and 10 years
respectively. We suggest that isolat
ed papillary carcinoma arising from
thyroglossal-duct remnants anterior
to the thyroid cartilage, with a
normal thyroid gland and no cervi
cal lymphadenopathy at the time of
surgery and a negative thyroid
scan, can be treated adequately by
wide local excision of the mass.

®PRIMAXIN® I.V.

PAPILLARY CARCINOMA

(imipenem and cilastatin sodium
for injection)
I.V. Infusion
Antibiotic
We are indebted to the late Dr. Robert
M ustard for providing the first patient.
We also th an k Dr. Fred Harris for
review of the pathology specimens and
Dr. Elaine Stone for endocrinologic fol
low-up.
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CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN® especially when
recommended dosages based on renal function
and body weight were exceeded. These
experiences have occurred most commonly in
patients with CNS disorders (e.g., brain lesions
or history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules is
urged, especially in patients with known factors
that predispose to seizures.

ACTION
Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.
PRIMAXIN® consists of two components: (1)
imipenem, a derivative of thienamycin, a carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzyme which m etabolizes and inactivates
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concomitant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in
the urine.
Inhibition of cell-wall synthesis is achieved in
gram -negative bacteria by the binding of
imipenem to penicillin binding proteins (PBPs). In
the case of Escherichia coli and selected strains
of Pseudomonas aeruginosa, imipenem has
been shown to have highest affinity for PBP-2,
PBP-1a and PBP-1b, with lower activity against
PBP-3. The preferential binding of imipenem on
PBP-2 and PBP-1b leads to direct conversion of
the individual cell to a spheroplast resulting in
rapid lysis and cell death without filam ent
formation. When imipenem is removed prior to
complete killing of gram-negative species, the
remaining viable cells show a measurable lag,
termed a “post-antibiotic effect" (PAE), prior to
resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium)
may be indicated in the treatment of serious
infections when caused by sensitive strains of
bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient’s clinical condition.
Imipenem is active in vitro against a wide range
of gram-positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactamase producing. Patients have
responded while under treatment with PRIMAXIN®
for single or mixed infections of the following body
systems, when they were associated with a
number of pathogenic species and strains of the
genera listed:
1.
2.
3.
4.
5.
6.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
Endocarditis caused by Staphylococcus
aureus
7. Bone and Joint Infections
8. Skin Structure Infections

PRIMAXIN® is not indicated for the treatment of
meningitis.

® Trademark Merck & Co., Inc.
Merck Frosst Canada Inc., R. U.

Gram -positive Aerobes
•
•
•
•

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains which
are methicillin resistant)
Streptococcus (excluding S. faecium)

Gram-negative Aerobes
•
•
•
•
•
•
•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella
Morganella morganii
Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram -positive Anaerobes
•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes
•
•

Bacteroides fragilis
Bacteroides (non fragilis)

CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium) is
contraindicated in patients who have shown
h yp e rse n sitivity to either com ponent of this
product.

WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium)
SHOULD BE ADMINISTERED WITH CAUTION
TO ANY PATIENT WHO HAS DEMONSTRATED
SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF
AN A LLER G IC REACTION TO PRIMAXIN®
O CCURS, DISCONTINUE THE DRUG.
SERIOUS HYPERSENSITIVITY REACTIONS
MAY REQUIRE EPINEPHRINE AND OTHER
EMERGENCY MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported
with the use of PRIMAXIN®. Therefore it is
important to consider this diagnosis in patients
who develop diarrhea during or after therapy. This
colitis may range from mild to life threatening in
severity.
Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
severe ca se s, m anagem ent may in clu d e
sigmoidoscopy, appropriate bacteriological studies,
fluid, electrolyte and protein supplementation, and
the use of a drug such as oral vancomycin, as
indicated. Other causes of colitis should also be
considered.

PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and
cilastatin sodium) may result in overgrowth of
resistant organisms. Repeated evaluation of the
patient's condition is essential. If superinfection
occurs during therapy, appropriate measures
should be taken.
CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have been
rep o rte d w ith PRIMAXIN® e sp e cia lly when
recommended dosages based on renal function
and body w eight were exceeded. These
experiences have occurred most commonly in
patients with CNS disorders (e.g., brain lesions or
h isto ry of seizures) and/or who have
compromised renal function. However, there were
rare reports in which there was no recognized or
docum ented underlying CNS disorder. Close
adherence to recommended dosage schedules is
urged especially in patients with known factors
that predispose to seizures (see DOSAGE AND
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ADMINISTRATION). Anticonvulsant therapy
should be continued in patients with a known
seizure disorder. If focal tremors, myoclonus, or
seizures occur, patients should be evaluated
neurologically and placed on anticonvulsant
therapy if not already instituted. If CNS symptoms
continue, the dosage of PRIMAXIN® should be
decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is
based on the severity of infection but the
maximum daily dose varies with the degree of
renal functional impairment (see DOSAGE AND
ADMINISTRATION - Dosage in Patients with
Renal Insufficiency).

Incidence (%)
Gastrointestinal
nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

CNS

Use in Pregnancy
The use of PRIMAXIN® in pregnant women has
not been studied, therefore, PRIMAXIN® should
be used during pregnancy only if clearly needed.
Use of this drug in women of childbearing
potential requires that the anticipated benefits be
weighed against possible hazards.
Reproduction studies with bolus I.V. doses
suggest an apparent intolerance to PRIMAXIN®
(including emesis, inappetence, body weight loss,
diarrhea and death) at doses equivalent to the
average human dose in pregnant rabbits and
cynomolgus monkeys that is not seen in non
pregnant animals in these or other species. In
other studies, PRIMAXIN® was well tolerated in
equivalent or higher doses (up to 11 times the
average human dose) in pregnant rats and mice
(see REPRODUCTION STUDIES under
TOXICOLOGY in Product Monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in
m ilk. If the use of PRIMAXIN® is deemed
essential, the patient should stop nursing.
Pediatric Use

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

Respiratory

oliguria/anuria
polyuria

Drug Interactions

Skin

Concomitant administration of PRIMAXIN® and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It
is not recommended that probenecid be given
with PRIMAXIN®.

rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

There is no evidence to suggest that association
of PRIMAXIN® with any other beta-lactam
antibiotics has any therapeutic advantage.

ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium) is
generally well tolerated. The following adverse
reactions were reported on 1,723 patients treated
in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult
to determ ine causal relationship of adverse
experiences to therapy with PRIMAXIN®,

0.1
<0.1
<0.1

Cardiovascular

Efficacy and tolerability in infants under the age of
3 m onths have not yet been e stablished;
therefore, PRIMAXIN® is not recommended in the
pediatric age group below the age of 3 months.

PRIMAXIN® should not be mixed with or
physically added to other antibiotics. PRIMAXIN®
has been administered concomitantly with some
antibiotics, such as aminoglycosides.

0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

Special Senses

hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Renal
<0.1
<0.1

The median duration of treatment with PRIMAXIN®
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for
which the median duration of treatment was
4 weeks.
PRIMAXIN® I.V.: INTRAVENOUS INFUSION
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

ADULT DOSAGE OF PRIMAXIN® I.V.
I.V. Administration
Severity
of Infection

Dose
(mg of imipenem)

Dosage
Interval

Daily
Dose

Mild

250 mg

6h

10 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

x Primarily some strains of P. aeruginosa.

Adverse laboratory changes, without regard to
drug relationship, that were reported during
clinical trials were:

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.
Dosage in Elderly Patients

Hepatic: Increased SGPT, SGOT, alkaline
phosphatase, bilirubin and LDH.

The recommended dosage of PRIMAXIN® I.V. in
elderly patients with normal renal function is the
same as given for adults above. Renal status of
elderly patients may not be accurately portrayed
by measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency

Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.
Marketing Experience

Adverse clinical reactions that were reported as
possibly, probably, or definitely related to
PRIMAXIN® were:

The dosage of PRIMAXIN® should be determined
by the severity of the infection, renal function,
body weight, the antibiotic susceptibility of the
causative organism(s) and the condition of the
patient. Doses cited are based on body weight of
70 kilos.

Adverse Laboratory Changes

Electrolytes: Decreased serum sodium, in
creased potassium, increased chloride.

Systemic Adverse Reactions

The dosage recommendations for PRIMAXIN®
(imipenem and cilastatin sodium) represent the
quantity of imipenem to be administered. An
equivalent amount of cilastatin is also present.

<0.1
<0.1

Incidence (%)
1.7
0.6
0.2
0.1

DOSAGE AND ADMINISTRATION

Severex infections
due to less sus
ceptible organisms
or life threatening
conditions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN® were:

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium) is
cleared by hemodialysis.

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Hemic: Increased eosinophils, positive Coombs'
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.

Local Adverse Reactions

•
•
•

Toxic epidermal necrolysis
Hepatitis
Acute renal failure. The role of PRIMAXIN®
in changes in renal function is difficult to
assess, since factors predisposing to prerenal azotemia or to impaired renal function
usually have been present.
Psychic disturbances
Anaphylactic reactions
Taste perversion

TABLE 1

Body as a whole
polyarthralgia
asthenia/weakness

•
•
•

TREATMENT OF OVERDOSAGE
0.4
0.3
0.2

transient hearing loss in patients with
impaired hearing
<0.1
tinnitus
<0.1

dyspnea
hyperventilation
thoracic spine pain

circumstances where a causal relationship could
not be established. However, in these rarely
reported events, that possibility cannot be
excluded. Therefore, these observations are listed
to serve as alerting information to physicians and
pharmacists:

The following reactions have been reported since
the drug was marketed, but occurred under

Patients with creatinine clearances of
<5 mL/min/1.73 m2 (<0.08 mL/s/1.73 m2) should
not receive PRIMAXIN® I.V. unless hemodialysis
is instituted within 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
hem odialysis. The patient should receive
PRIMAXIN® I.V. after hem odialysis and at
12 hour intervals timed from the end of that hemo
dialysis session. Dialysis patients, especially
those with background CNS disease, should be
carefully monitored; for patients on hemodialysis,
PRIMAXIN® I.V. is recommended only when the

benefit outweighs the potential risk of seizures
(see P R E C A U T IO N S ). C u rre n tly , th e re are
in a d e q u a te data to re c o m m e n d th e use of
PRIMAXIN® I V. in patients undergoing peritoneal
dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN® I.V.
IN RELATION TO RENAL FUNCTION

RENAL
FUNCTION
M ild
im p a irm e n t
M o d e ra te
im p a irm e n t
S e v e re x
im p a irm e n t

x

CREATININE
CLEARANCE
mL/min/1.73 m2
(mL/s/1.73 m2)

MAXIMUM
TOTAL
DAILY
DOSAGE

(g)

DOSAGE
INTERVAL
(h)

31 - 70
( 0 . 5 2 - 1 .1 7 )

0.5

6 -8

1 .5 -2

21 - 3 0
(0.35 - 0.5 0 )

0.5

8 - 12

1 -1 .5

0 .2 5 - 0.5

12

0.5 - 1.0 XX

DOSE

(g)

Contents of the vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.
A suggested procedure is to transfer a p proxi
mately 10 mL from the 100 mL of the appropriate
infusion solution to the vial (see list of diluents
under COMPATIBILITY AND STABILITY). Shake
well. Return the resulting 10 mL of suspension to
the remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the
vial to the infusion solution.

xx The highest dose is only recommended for infections
due to less susceptible organisms primarily some
strains of P. aeruginosa.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this
value into creatinine clearance (m L/m in). The
serum creatinine should represent a steady state of
renal function.
Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)
0.85 x above value.

When using the International System of units (SI),
the estim ated cre a tin in e cle a ra n c e (m L/s) in
males can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736
(72) x (serum creatinine concentration, pmol/L)
and in fe m a le s , th e e s tim a te d c re a tin in e
clearance (mL/s) is:

2.

Eisenberg JM, et al. What is the cost of nephro
toxicity associated with aminoglycosides? Ann
Intern Med December 1987;107(6):900-909.

3.

Heseltine PNR, et al. Imipenem therapy for
perforated and gangrenous appendicitis. Surg
Gynecol Obstet January 1986;162:43-48.

4.

G u e rra JG , et al. Im ip e n e m /c ila s ta tin vs.
gentam icin/clindam ycin fo r the treatm ent of
moderate to severe infections in hospitalized
patients. Rev Infect Dis Ju ly-A u g u st 1985;
7(Suppl 3):S463-S470.

5.

G onzenbach HR, Simmen HP, A m gw erd R.
Imipenem (N-F-thienamycin) versus netilmicin
plus clindamycin: A controlled and randomized
comparison in intra-abdominal infections. Ann
Surg March 1987;205(3):271-275.

6.

Hackford AW, et al. Prospective study comparing
im ip e n e m -c ila s ta tin w ith c lin d a m y c in and
gentamicin for the treatment of serious surgical
infections. Arch Surg March 1989;123:322-326.

CAUTION: CONTEN TS OF VIALS N O T FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
0-20
(0 - 0.3 3 )

Patients with creatinine clearance of 6 to
20 mL/min/1.73 m2 (0.1 - 0.3 mL/s/1.73 m2) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lower) every 12 hours for most pathogens. When the
500 mg dose is used in these patients, there may be
an increased risk of seizures.

Females:

Vials - PRIMAXIN " I.V.

List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Injection with 0.02% sodium
bicarbonate solution
5% D extrose and 0.9% Sodium C h lo rid e
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOLX-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%

(5116)

Reconstituted solutions
S o lu tio n s o f P R IM A X IN ® I.V. ra n g e fro m
colourless to yellow. Variations of colour within
th is ra nge do not a ffe c t the p o te n c y o f th e
product.
P R IM A X IN ® I.V., as s u p p lie d in v ia ls o r in
ADD-Vantagex vials and reconstituted as above,
maintains satisfactory potency for four hours at
room tem perature and for 24 ho urs under
refrigeration (4°C). PRIMAXIN® has been found
to be stable in 0.9% Sodium Chloride Injection for
10 hours at room tem perature and 48 hours
under refrigeration.

AVAILABILITY OF DOSAGE FORMS

(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN® I.V. is cleared by hemodialysis. After
each dialysis session the dosage schedule should
be restarted.
Dosage in Infants and Children
T h e re com m e nde d to ta l d a ily d o sage of
PRIMAXIN® I.V. in children and infants 3 months
of age and older is 60 to 100 m g/kg of body
weight divided into 4 equal doses given at six
hour intervals. The higher dosages should be
used for infants and young children. The total
daily dosage should not exceed 2 grams. Clinical
data are insufficient to recommend an optimum
dose for infants and children with impaired renal
function.
PRIM AXIN® I.V. is not recom m ended for the
therapy of meningitis. If meningitis is suspected,
an appropriate antibiotic should be used.
PRIMAXIN® I.V. may be used in children with
sep sis as long as they are not suspected of
having meningitis.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose
should be given by intravenous infusion over
tw enty to thirty minutes. Each 1000 mg dose
should be infused over 40 to 60 m inutes. In
patients who develop nausea during the infusion,
the rate of infusion may be slowed.
RECONSTITUTION
PRIMAXIN® I.V. is supplied either in vials or in
ADD-Vantagex vials of either 250 mg or 500 mg
imipenem equivalent and cilastatin equivalent
when reconstituted.

Intravenous Infusion:
PRIMAXIN® I.V. (imipenem and cilastatin sodium
fo r injectio n) is sup plied as a s te rile po w d er
mixture in vials containing imipenem anhydrous
and cilastatin sodium with sodium bicarbonate as
a buffer as follows:
3514 C a - 250 mg im ip e n e m e q u iv a le n t and
250 mg cilastatin equivalent in vials.
3516 C a - 500 mg im ip e n e m e q u iv a le n t and
500 mg cilastatin equivalent in vials.
3551 Ca - 250 mg im ip e n e m e q u iv a le n t and
250 mg c ila s ta tin e q u iv a le n t in
ADD Vantagex vials.
3552 Ca - 500 mg im ipe nem e q u iv a le n t and
50 0 mg c ila s ta tin e q u iv a le n t in
ADD Vantage1* vials.
For full details on preparation and adm inis
tra tio n w ith A D D -V a n ta g e x v ia ls - p le a s e
consult Product Monograph.
STORAGE
The dry p o w d e r s h o u ld
temperature below 30°C.

be s to re d

at a

FULL MONOGRAPH AVAILABLE
ON REQUEST
(363-a,2,92)

MSD
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Hashimoto’s Thyroiditis With Medullary
Carcinoma
David Gaskin, MD; Sushil K. Parai, MB, BS, FRCPC; Mira R. Parai, MB, BS, FRCPC
The association of Hashimoto’s thyroiditis with lymphoma and papillary carcinoma
has been recognized, but there have been few reports of an association between
Hashimoto’s thyroiditis and medullary carcinoma of the thyroid gland, especially in
Canada. The authors report three cases, seen in an 18-month period, of Hashimoto’s
thyroiditis and medullary carcinoma in patients whose relatives had multiple
endocrine neoplasia type II. The findings support the view that the thyroiditis
occurred in response to the tumour process and not vice versa.

L’association de la thyroi'dite chronique de Hashimoto et d’un lymphome ou d’un
carcinome papillaire est un fait bien connu. On ne retrouve toutefois, surtout au
Canada, que peu de cas signales associant thyroi'dite de Hashimoto et carcinome
medullaire de la thyroi'de. Les auteurs decrivent trois cas decouverts au cours d’une
periode de 18 mois, de thyroi'dite de Hashimoto et de cancer medullaire chez des
patients dont les families presentaient plusieurs cas de neoplasies endocrines de
type II. Les observations obtenues soutiennent Thypothese voulant que la thyroi'dite
survienne en reponse au processus tumoral, et non le contraire.

province of Newfoundland
I nandtheLabrador
there is a high
occurrence of familial multiple en
docrine neoplasia Ila (MEN Ila) syn
dromes. One of the manifestations
of these syndromes is medullary
carcinoma.
We identified three such cases
over an 18-month period. Interest
ingly, a coincident finding in all
three cases was a marked chronic
lymphocytic thyroiditis of the clas
sic Hashimoto’s type. A literature
search revealed little information on
this association, and the first re
ports are only recent.1-2 Some attri
buted the association to purely ran
dom occurrence as opposed to pa
pillary carcinoma and lymphoma

which are recognized associated le
sions.3 The MEN Ila syndromes are
not known to be associated with
Hashimoto’s thyroiditis.
The coexistence of a chronic lym
phocytic thyroiditis and thyroid car
cinoma is controversial in itself.
Whether the Hashimoto’s thyroidi
tis develops first, causing hyper
plastic then neoplastic change in
C-cells, or the medullary carcinoma
develops first, causing an autoim
mune response in surrounding thy
roid tissue is debatable.4
The purpose of this paper is to
document our three cases to add to
the knowledge base on this associa
tion of medullary carcinoma and
Hashimoto’s thyroiditis.
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Case Reports
Case 1

A 49-year-old woman, a member
of a known MEN Ila family, whose
father had had medullary carcinoma
of the thyroid, was found to have
increasing calcitonin levels on pentagastrin-calcium stimulation test
ing on two separate occasions. Thy
roid tests results before thyroidecto
my showed a free serum thyroxine
(T4) level of 18.8 pmol/L, a serum
thyroid-stimulating hormone (TSH)
level of 5.1 mU/L and a serum
calcium level of 2.21 mmol/L. The
serum calcitonin levels were as fol
lows: 693 ng/L at 0 minutes; 602
ng /L at 1 minute after the pentagastrin-calcium stimulation test;
1374 n g /L at 2 minutes; 6468
ng /L at 5 minutes; and 3808 ng/L
at 10 minutes. Investigations for
pheochromocytoma and hyperpara
thyroidism gave negative results.
Case 2

A 48-year-old woman was a mem
ber of a known MEN Ila family. Her
brother, uncle and cousin had all
had medullary carcinoma. Close fol
low-up revealed increasing cal
citonin levels on pentagastrin-calcium stimulation testing on two sepa
rate occasions. Results of thyroid
testing before total thyroidectomy
showed a free serum T4 level of 13
pmol/L, a serum TSH level of 2.0
mU/L and a serum calcium level of
2.20 mmol/L. The serum calcitonin
levels were as follows: 119 ng /L at
0 minutes; 122 ng/L at 1 minute

HASHIMOTO’S THYROIDITIS

after the pentagastrin-calcium stim
ulation test; 581 ng /L at 2 min
utes; 770 n g /L at 5 minutes; 455
ng/L at 10 minutes; and 294 ng/L
at 30 minutes. Investigations for
pheochromocytoma and hyperpara
thyroidism gave negative results.
Case 3

A 49-year-old man was a member
of a known MEN Ha family. Again,
close follow-up revealed increasing
calcitonin levels on pentagastrincalcium stimulation testing on two
separate occasions. Thyroid testing
before total thyroidectomy showed
a serum T4 level of 88 nmol/L, a
serum TSH level of 10.9 mU/L and
a serum calcium level of 2.37
mmol/L. The serum calcitonin lev
els were as follows: 92 ng /L at 0
minutes; 94 n g /L at 1 minute after
the pentagastrin-calcium stimula
tion test; 567 ng /L at 2 minutes;
735 ng/L at 5 minutes; 525 ng/L
at 10 minutes; and 343 n g /L at 30
minutes. Investigations for pheo
chromocytoma and hyperpara
thyroidism gave negative results.

areas of C-cell hyperplasia through
out the thyroid gland (Table I).
A chronic lymphocytic infiltrate
was also identified. This infiltrate
was seen not only around the tu
mour but diffusely infiltrating the
thyroid gland.5 The grading of this
infiltrate was from moderate to se
vere (Table II). There were numer
ous lymphoid follicles with germi
nal-centre formation. Thyroid follic
ular atrophy was a prominent fea
ture (Fig. 2) with mild to moderate
changes in the Hurthle cells. These
features are all in keeping with an

autoimmune chronic lymphocytic
thyroiditis of the typical Hashimoto’s type.1

Discussion
The patients presented here were
all from families known to have
members suffering from MEN Ha
syndrome and were all distantly
related to each other but did not
fulfil all the criteria necessary to be
classified as suffering from MEN Ha
syndrome. The families are all being

Findings
Gross

All three thyroidectomy speci
mens weighed approximately 16 g.
On sectioning, the tissue was a
diffuse pale pink to grey with a firm
consistency. No tumour mass was
identified grossly.
Microscopic

Sections revealed medullary car
cinoma with a sinusoidal pattern
(Fig. 1). Staining for calcitonin was
positive. There was abundant amy
loid formation within the tumour,
confirmed by Congo Red staining
and polarization. The tumours were
also found to be multifocal with

FIG. 1. Medullary carcinoma of thyroid gland showing sinusoidal pattern of small
round cells with amyloid deposition on right and normal thyroid tissue on left
(hematoxylin-eosin, original magnification X 200).
T a b le 1.

Tum our M orphology

C a s e no.

P a tte rn

A m y lo id

1
2
3

Sinusoidal
Sinusoidal
Sinusoidal

+ + +
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+ +

=
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1
2
3

+ +
+
+ +

severe

G e r m in a l
c e n tr e s

+++

+++

+++

+ + +
+ + +
+ + +

+++
+ + + =

L y m p h o id
in filtr a te
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M u lt if o c a l

+ +

T a b le II.
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C a lc ito n in

Thyroid Morphology
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+++
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+
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followed up closely for the develop
ment of thyroid cancer. Therefore
these tumours are being detected at
an early stage of the disease. The
patients continue to be followed up
for the development of the other
disease processes.
The number of cases here is
small, so no conclusions can be
drawn from the data. All three
patients were young at the time of
diagnosis, ranging in age from 48
to 49 years. The male-to-female
ratio was 1:2. Generally, with a
genetic disease such as MEN syn
drome one would expect equal num
bers of men and women, but thy
roiditis has a female predominance.
The initial finding in all three
cases was an increase in the serum
calcitonin levels on pentagastrincalcium stimulation testing. In two
of the cases there was also an
increase in the serum TSH level. No
tumour was detected clinically or on
gross examination of the thyroidec
tomy specimen.
Histologically, all specimens dem
onstrated thyroiditis diffusely in
volving the entire gland, with mul
tifocal involvement of medullary

carcinoma. The tumour showed
only an amyloid-forming sinusoidal
pattern. The thyroiditis was typical
of Hashimoto’s type.
A relationship between Ha
shimoto’s thyroiditis and MEN Ha
syndrome has not been reported in
the literature. Therefore the rela
tionship is most likely between the
Hashimoto’s disease and the tu
mour. This is unlikely to be a
random association since three
cases were identified within 18
months of each other.
Still unanswered is the question,
Was the thyroiditis involving the
gland before the neoplastic change
or did the thyroiditis develop in
response to the neoplastic change?
What we have reinforced here is
that there is a relationship with
medullary carcinoma. If we extrapo
late to thyroid carcinomas in gener
al, then the MEN Ila population is
ideal for examining this relation
using a specific carcinoma type.
The relationship appears to be
stronger in the setting of familial
MEN Ila, leading us to support the
view that the thyroiditis occurs in
response to the tumour process and

is not a premalignant lesion. Again,
the small numbers involved make
definite conclusions difficult to
draw. A converse approach this
subject would be to look at a
population of Hashimoto’s thyroidi
tis and observe the prevalence of
carcinoma. There are a number of
such studies, and they give varying
incidences and opposing views. This
variability may be the result of the
wide range of differing individual
criteria for Hashimoto’s thyroiditis.6

Summary
The cases reported here support
an association between Hashimoto’s
thyroiditis and medullary carcino
ma. They also provide a different
approach to the problem of thyroid
itis and carcinoma by looking at it
from a known population predis
posed to thyroid carcinoma rather
than a population of Hashimoto’s
thyroiditis, in which many differing
results and conclusions have been
obtained.
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Nontertiary Surgery in Manitoba:
Comparison of Provincial
and Teaching-Hospital Data
Robert J.W. Blanchard, MD, FRCSC
Do the teaching hospitals in Manitoba provide a suitable spectrum and sufficient
numbers of operations to prepare surgeons for practice in Manitoban communities?
To answer these questions, the author reviewed the types and frequencies of all
operations performed in Manitoba during 1985 and 1986 and compared them with
all operations performed in the two Manitoba teaching hospitals for the same years.
The 189 380 operations studied were categorized according to the surgical
specialist who usually performed each operation in the teaching hospitals. For some
procedures commonly performed in the province as a whole, there were too few
operations performed in the teaching hospitals to provide sufficient experience for
the trainees. A breakdown of nontertiary operations performed in Manitoba revealed
that 39% were in the category of general surgery, 29% were in gynecology and
operative obstetrics, 17% were in orthopedics, 10% were in urology and 4% were in
plastic surgery. The author concludes that a surgeon going to a smaller community
as the only surgical specialist requires training of a broader scope than is provided
currently in the standard general-surgery training programs in Manitoba.
Les hopitaux universitaires manitobains offrent-ils un eventail et un nombre
suffisants d’operations pour bien preparer le chirurgien a la pratique
communautaire au Manitoba? Dans le but de repondre a cette question, l’auteur a
etudie le type et la frequence de toutes les operations pratiquees dans cette province
en 1985 et 1986 et les a compares a ceux de toutes les operations effectuees dans les
deux hopitaux universitaires du Manitoba durant les memes annees. Les 189 380
operations etudiees ont ete classees selon le chirurgien specialiste qui effectuait
d’habitude ces operations dans les hopitaux d’enseignement. Pour quelques-unes
des operations pratiquees dans l’ensemble de la province, le nombre effectue dans
les hopitaux universitaires a ete insuffisant pour assurer une experience suffisante
pour les chirurgiens en formation. Le detail des operations non tertiaires pratiquees
au Manitoba revele que 39 % etaient dans le domaine de la chirurgie generale, 29 %
dans celui de la gynecologie et de l’obstetrique, 17 % en orthopedie, 10 % en
urologie et 4 % dans le domaine de la chirurgie plastique. L’auteur conclut que si un
chirurgien doit aller pratiquer dans une plus petite communaute comme seul
specialiste de chirurgie, il necessite une formation plus large que celle qui est
presentement offerte a l’interieur du programme regulier de formation en chirurgie
generale au Manitoba.
he surgical services in teaching
hospitals throughout Canada
have become increasingly commit
ted to highly specialized tertiary
care. This has displaced, in varying
degrees, the more common and rou

T

tine types of surgery from the
teaching hospitals. The shift from
routine to more tertiary types of
surgery has fostered the establish
ment of training programs for
subspecialties in many centres. On
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the other hand, there is concern
that these same teaching hospitals
may not provide enough experience
for common nontertiary surgery to
train surgeons in the larger pro
grams, especially general surgery
and orthopedics and to some extent
urology and plastic surgery. Of par
ticular concern is whether modern
training programs can provide a
suitable experience for surgeons
who will be serving in smaller com 
munities where subspecialists are
not available. Before we either justi
fy the status quo or introduce
changes, we must determine w heth
er deficiencies exist and, if they do,
what the specific deficiencies are.
This study was undertaken in an
attempt to determine whether Mani
toba’s teaching hospitals provide
for their residents sufficient expo
sure to operations that are regularly
performed in that province. This
report focuses particularly on gen
eral surgery, because most opera
tions outside urban centres are per
formed by general surgeons.

Methods
All operations billed to the Mani
toba Health Services Commission
(MHSC) during 1985 and 1986 for
all of Manitoba were obtained as
codes from the International Classi
fication of Diseases 9th Revision
Clinical Modification (ICD-9-CM)1
and downloaded into a database
management program used on a
desk-top computer. Similarly, the
codes for all operations performed
in the two teaching hospitals, the
Health Sciences Centre and the St.
CJS, VOL. 35, NO. 5, OCTOBER 1992
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Boniface General Hospital, Winni
peg, were downloaded into a data
base management program for anal
ysis and comparison. The opera
tions in the teaching hospitals had
been separated by specialty before
downloading. Separation into spe
cialties was determined by which
teaching-staff members performed
the various operations. Because the
surgeons in both teaching hospitals
are attached to specific training
programs, the identification of spe
cialty groups was quite precise.
Each operation in the provincial
data was assigned to a specialty
according to which specialist ordi
narily would perform the operation
in the teaching hospitals. Thus, the
provincial data were categorized by
specialty in a manner similar to that
used for the teaching hospitals
rather than according to which sur
gical specialist or generalist might
actually have performed the sur
gery. For both databases, the proce
dures were grouped into fairly
broad categories, such as “thyroid
surgery.” Each category of opera
tion was labelled either “tertiary”
or “ nontertiary.”
The operations in the province
were sorted according to their over
all frequency and according to their
frequency within each specialty. In
addition, an analysis was made of
“nontertiary” obstetric and gyneco
logic operations performed in Mani
toba. A breakdown of these opera
tions was not available for the

teaching hospitals. Operations
funded by the Workers’ Compensa
tion Board or by patients for cos
metic surgery were excluded from
the study.

Results
During 1985 and 1986 a total of
189 380 procedures were billed to
the MHSC. This amounted to ap
proximately 9 000 operations per
100 000 population annually. Of
the total, there were 111 608 “non
tertiary” operations, approximately
5 000 per 100 000 population an
nually. Table 1 shows the distribu
tion of nontertiary surgery by spe
cialty.
The 20 commonest nontertiary
operations performed in Manitoba
during 1985 and 1986 are indicated
in Table II. It appears that general
surgery trainees who enter practice
in small centres after their training
are inexperienced in a large number
of common surgical procedures re
quired in those communities. Table
III lists the 20 commonest catego
ries of surgery performed in the
general-surgery programs in the
two teaching hospitals. The list
differs appreciably from that in
Table II and further illustrates the
disparities between provincial surgi
cal activities and the spectrum of
general surgery in the teaching hos
pitals. Fig. 1 gives the percentage
of nontertiary operations performed

for each specialty in Manitoba. Gen
eral surgery makes up less than
50%.
To determine the average number
of common operations that could be
performed by residents in the train
ing programs, a calculation was
made based on the number of resi
dents and the number of years in
clinical services for each training
program. This calculation was then
adjusted to reflect the number of
operations in a 2-year period that
would be necessary to provide a
minimum of 10 procedures per resi
dent over the student’s total train
ing program. For most of the terti
ary-care specialties, there were suf
ficient numbers of the commonest
operations. However, in general
surgery and, to a lesser degree, in
orthopedics and urology, there were
too few of different types of operaTable II. Twenty Commonest Nontertiary
Operations Performed in Manitoba, 1985
and 1986

Operation

18 023
11 121
8 713
3 962
NA

(13 167)
( 3 603)
( 1 066)
( 2 061)
NA

Fracture treatment*
Currettage of uterus*
Tubal ligation*
Gallbladder, biliary
procedures
Tonsilectomy and/or
adenoidectomy*
Ovarian and/or salpinx
procedures*
Cesarean section*
Hysterectomy*
Groin-hernia repair
Skin lesion
Appendectomy
Abdominal procedures,
other
Prostatectomy*
Plastic repair, other
Large-intestine resection
Bladder operations*
Joint procedures*
Breast procedures
Testes/epididymis
procedures
Forceps delivery*

Total__________________________________ 111 608_____________ 41 819

(19 897)

Total

Table I. Comparison of Nontertiary Operations in the Province of Manitoba and in Two Manitoba
Teaching Hospitals, 1985 and 1986
Specialty

Manitoba, no.

General surgery
Orthopedics
Urology
Plastic surgery
Operative obstetrics and gynecology

43
19
11
4
32

757
210
144
975
522

Teaching hospitals, no.*

'Bracketed figures are numbers of operations that may be performed by general surgeons in
nontertiary hospitals.
NA = not available
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No. of
operations
(»/»+)
6 794
6 308
5 893

(6.1)
(5.7)
(5.3)

5 880

(5.3)

5 219

(4.7)

5 055
4 644
4 324
4 141
3 285
3 254

(4.5)
(4.2)
(3.9)
(3.7)
(2.9)
(2.9)

3 220
3 062
2 830
2 475
2 313
2 125
2 095

(2.9)
(2.7)
(2.5)
(2.2)
(2.1)
(1.9)
(1.9)

1 729
1 707

(1.5)
(1.5)

76 353 (68.4)

’ Not routinely included in general-surgery
training program
tPercentage of province total (111 608)

NONTERTIARY SURGERY IN MANITOBA

tions performed in the two teaching
hospitals to provide a minimum of
10 operations throughout each
trainee’s residency (Tables IV to
VI).
Fig. 2 compares the frequencies
of common general surgical proce
dures in the province and in the two
teaching hospitals. It is noteworthy
that in the teaching hospitals the
frequencies of the various opera
tions are not nearly as variable as
Table III. General Surgery Performed in
Manitoba Teaching Hospitals, 1985 and
1986

Operation
Colorectal procedures
Skin and subcutaneous
procedures
Gallbladder/biliary
procedures
Breast procedures
Other abdominal procedures
Inguinal-hernia repair
Appendectomy
Lymphatic procedures
Gastric procedures
Intestinal procedures
Anal/hemorrhoid
procedures
Thyroid procedures
Chest tubes/insertion and
removal
Other hernia repairs
Mouth and face procedures
Foreign-body removal
Pancreatic procedures
Lung procedures
Salivary-gland procedures
Hepatic procedures
Total

No. of
operations
(% ' ')
1117

(6.2)

1058

(5.9)

1056
954
756
671
632
486
408
383

(5.9)
(5.3)
(4.2)
(3.7)
(3.5)
(2.7)
(2.3)
(2.1)

347
282

(1.9)
(1.6)

188
171
145
128
120
109
88
79

(1.0)
(0.9)
(0.8)
(0.7)
(0.7)
(0.6)
(0.5)
(0.4)

cardiac surgery and neurosurgery
in the province. But, although the
teaching hospitals perform a large
number of operations in general
surgery, orthopedics and urology,
these operations make up a smaller
percentage of the provincial total.
However, especially in general sur
gery, there are so many different
types of procedures to be learned,
that even the large num ber per
formed in the teaching hospitals
does not provide “ sufficient” num
bers of some common operations
for resident learning. It was noted
that the teaching hospitals per-

they are in the province as a whole.
This is appropriate for teaching
purposes. Unfortunately for some
fairly common operations such as
varicose vein procedures and repair
of anal fistulas, insufficient num 
bers are available in the teaching
hospitals to provide an average of
10 operations per general-surgery
trainee.
The overall frequencies of opera
tions, tertiary and nontertiary, in
the province and in the two teach
ing hospitals by specialty group are
shown in Fig. 3. The teaching hos
pitals perform virtually all of the

Table IV. Commonest General-Surgery Operations Performed in Manitoba, 1985 and 1986

Operation
Gallbladder/biliary procedures
Unilateral inguinal-hernia repair
Appendectomy
Colorectal procedures
Hemorrhoidectomy
Mastectomy
Varicose-vein procedure
Umbilical-hernia repair*
Thyroidectomy
Other perianal procedures*
Vagotomy
Tracheostomy
Pyloroplasty*
Splenectomy*
Sialoadenectomy
Billroth II gastrectomy*
Ileostomy*
Sphincter of Oddi procedures
Internal drainage of pseudocyst*

Manitoba
(A)

Teaching
hospitals
(B)

Ratio
(B:A)

6032
3700
3254
1760
1089
872
639
470
446
332
315
220
213
199
196
130
82
43
20

1056
541
632
529
80
203
37
53
203
60
91
96
62
67
88
33
39
10
11

0.18
0.15
0.19
0.30
0.07
0.23
0.06
0.11
0.46
0.18
0.29
0.44
0.29
0.34
0.45
0.25
0.48
0.23
0.55

'Fewer than 10 operations per trainee on average

9178 (50.9)

'Percentage of general surgery performed
in teaching hospitals (18 023)

Table V. Commonest Orthopedic Operations Performed in Manitoba, 1985 and 1986

Operation

FIG. 1. Percentage of 111 608 opera
tions done in Manitoba, by specialty
during 1985 and 1986.

Open reduction and internal fixation
Closed reduction without internal fixation
Meniscectomy
Bunionectomy
Amputation of lower limb
Amputation of upper limb*
Closed reduction dislocation
Open reduction dislocation
Suture muscle or tendon, hand
Arthroplasty, upper limb
Synovectomy
Bursectomy*
Sequestrectomy*

Manitoba
(A)

Teaching
hospitals
(B)

Ratio
(B:A)

2964
1976
1333
1116
777
162
483
214
332
289
110
66
24

1229
897
298
138
164
12
171
95
283
100
40
15
13

0.41
0.45
0.22
0.12
0.21
0.07
0.35
0.44
0.85
0.35
0,36
0.23
0.54

'Fewer than 10 operations per trainee on average
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formed a relatively large proportion
of common emergency operations,
especially in orthopedics and gener
al surgery. In orthopedic surgery, a
large number of closed fracture
reductions were performed in the
teaching hospitals and much smal
ler numbers of meniscectomies and
bunionectomies. The large number
of common emergency surgical pro
cedures naturally make an impact
upon available time and resources

for performing the common elective
procedures necessary for training
programs.

Discussion
This numerical evaluation of sur
gery in the province of Manitoba
and its two teaching hospitals has
provided useful information about
the clinical resources available for

Table VI. Commonest Urologic Operations Performed in Manitoba, 1985 and 1986

Operation
Transurethral resection of prostate
Circumcision
Dilatation of urethra
Varicocele excision
Nephrectomy
Unilateral orchiectomy
Suprapubic prostatectomy*
Retropubic prostatectomy
Hydrocele excision*
Radical prostatectomy

Manitoba

Teaching
hospitals

(A)

(B)

Ratio
(B:A)

2762
1411
477
367
248
214
174
126
121
56

584
180
127
54
98
32
11
77
9
41

0.21
0.13
0.27
0.15
0.40
0.15
0.06
0.61
0.07
0.73

'Few er than 10 operations per trainee on average

FIG. 2. Frequencies of common general surgery operations in Manitoba (white
bars) and in two Manitoba teaching hospitals (black bars), 1985 and 1986. UIH
repair = unilateral inguinal-hernia repair.
534

JCC, VOL. 35, NO 5, OCTOBRE 1992

training surgeons for Manitoba. Be
cause the first specialist, and some
times the only specialist, appearing
in smaller centres is usually a gen
eral surgeon, it is appropriate to
evaluate the relevance of training
for general surgeons who intend to
practise outside major centres. In
smaller communities, unless there
are sufficient numbers of patients
requiring gynecologic, orthopedic
or urologic surgery to support spe
cialists in these fields, the general
surgeon will have to deal with many
of the common elective and emer
gency procedures ordinarily dealt
with by subspecialists in larger cen
tres. In this study, therefore, I have
focused on that particular aspect of
the provincial need and compared it
with the teaching-hospital re
sources, finding some deficiencies.
There were relatively fewer deficien
cies in the numbers of cases for
training within the subspecialties.
General surgery comprised only
39% of nontertiary operations out
side the teaching hospitals. This is
the same proportion that general
surgery comprised in a similar
study of surgical care in district
hospitals of Pakistan.2 The signifi
cance of this fact is the need to
prepare surgical trainees wishing to
practise in smaller centres with a
broader surgical experience, be
cause it is likely that no other
surgical specialist will be available
in the community.
This study has shown that the
two teaching hospitals continue to
provide a broad range of surgery in
each of the specialties and, in par
ticular, in general surgery. Howev
er, some disparities exist between
the teaching hospitals and the com
munity in terms of the numbers of
certain types of operation. Unfortu
nately, most of the wide disparities
are for some of the more common
elective procedures being performed
in the community. It is interesting
that the two teaching hospitals per-
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form a large number of common
nontertiary emergency operations
that could reasonably be managed
in some of the nonteaching hospi
tals. If more of the common emer
gency operations were handled in
nonteaching hospitals, pressure on
the teaching hospitals would be
relieved, and there would be more
time for operations that are re
quired to provide adequate training
experience. Such a trade-off would
not necessarily guarantee a shift of
common nontertiary elective cases
to the teaching hospitals because of
pre-existing referral patterns. How
ever, if such a shift were to occur,
there appears to be sufficient capac
ity within the teaching hospitals for
them to fulfil their tertiary-care
roles as well as to provide appropri
ate surgical experience for trainees
without sending residents to non
teaching centres for long periods.
Before adjustments are made to
improve surgical training experi
ence, provincial surgical resources

should be examined to determine
patient surgical needs and resident
training objectives. General-surgery
residents who wish to follow an
academic career probably see an
appropriate spectrum of surgical
patients.
In the ongoing planning of surgi
cal training programs, several addi
tional matters need to be consid
ered. It would be helpful to identify,
early in their training programs,
residents who intend to practise in
smaller centres. This will mainly
affect general-surgery trainees.
They will require exposure to a
much broader scope of procedures
than is normally available in the
general-surgery divisions of the two
teaching hospitals in Manitoba.
However, a flexible program can be
made available through cooperative
arrangements with the department
of obstetrics and gynecology, and
the divisions of orthopedics, urolo
gy and plastic surgery. For trainees
of all types and in all programs, it

may be possible to meet some of the
deficiencies by reorganizing clinical
rotations or by arranging rotations
in selected nonteaching hospitals.
If major changes in resident as
signments or patterns of referral are
attempted, caution should be exer
cised to avoid a dispersal of resi
dents that could result in reduced
communication among residents or
reduced numbers of residents for
educational programs.
It is apparent that some opera
tions are performed so infrequently
in Manitoba that adequate training
for these procedures is either re
dundant or should be acquired dur
ing a clinical fellowship in centres
where a concentration of these pro
cedures occurs.
Finally, it is not obvious how one
should determine the minimum
number of cases required for ade
quate surgical training, and appar
ently no study has addressed this
question. Some residents learn
more quickly than others. There
may be a crossover effect in learn
ing a new procedure using skills
already developed in other proce
dures. The postoperative death
rates in Manitoba for 11 surgical
procedures have compared favoura
bly with those in New England.3 It
is not unreasonable to infer from
this that the quality of surgery, and
likely of surgical training, in Mani
toba is the equivalent to that in
New England.
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A Technical-Skills Course for 1st-Year
Residents in General Surgery:
a Descriptive Study
Alan G. Lossing, MD, FRCSC; Elizabeth M. Hatswell, RN, MSc; Thomas Gilas, MD, FRCSC;
Richard K. Reznick, MD, FRCSC; Lloyd C. Smith, MD, FRCSC
The proper teaching of operative skills to surgical residents is increasingly
constrained by operative time, complex procedures and medicolegal concerns. A
technical-skills program was developed and introduced over a 3-year period to 28
lst-year residents in general surgery. To introduce the residents to the principles of
surgical techniques in a simulated environment outside the operating room, the
program consisted of a combination of two didactic sessions and six “wet labs”
taking 3 to 4 hours per week for 8 weeks between January and March each year.
The didactic sessions included instruction on suture material and the use of stapling
devices; the “wet lab” used a “hands-on” approach. Educational objectives in the
“wet lab” included instruction on preparation of the patient and draping, aseptic
technique, principles of bowel anastomosis, incisions, instrument use and handling,
principles of hemostasis, intraoperative surgical emergencies, surgical assisting and
overall conduct in the operating room.
The residents’ surgical technique and skills improved over the course period. The
overall value, teaching and understanding of surgical principles were rated highly.
Problems cited during resident feedback were the use of live animals and insufficient
time to practise. The efficacy of a surgical-skills program has been demonstrated,
but its effectiveness requires further evaluation.
Le bon enseignement des techniques operatoires est de plus en plus gene par le
temps operatoire, la complexite des interventions et les considerations
medicolegales. Sur une periode de 3 ans, un programme d’apprentissage des
techniques a ete mis au point et offert a 28 residents de l 4rc annee en chirurgie
generale. Afin d’initier les residents aux principes des techniques chirurgicales dans
un environnement simule, hors du bloc operatoire, le programme les a menes a
travers deux seances didactiques et six «labos pratiques® prenant de 3 a 4 heures par
semaine et s’etendant de janvier a mars, chaque annee. Les seances didactiques
comprenaient des renseignements sur les materiaux de suture et les instruments
servant a brocher; le «labo pratique® a pris la forme de mises en situation. Les
objectifs pedagogiques des «labos pratiques® comprenaient les renseignements
relatifs a la preparation des malades, la couvertures des champs steriles, la
technique aseptique, les principes d’anastomose intestinale, les incisions, Temploi
des instruments, les principes d’hemostase, les urgences chirurgicales
peroperatoires, l’assistance chirurgicale et la conduite a tenir dans le bloc
operatoire.
La technique chirugicale des residents de meme que leur habilete se sont
ameliorees durant cette periode. La valeur globale du programme, Tenseignement et
la comprehension des principes chirurgicaux furent hautement notes. Les problemes
mentionnes par les etudiants concernaient Tutilisation d’animaux vivants et le
manque de temps de pratique. Les resultats d’un programme d’apprentissage des
techniques chirurgicales ont ete demontres mais son efficacite necessite davantage
devaluation.
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espite the advent of innovative
and technically demanding sur
gical procedures over the last 20
years, progress has been slow in the
development of new methods by
which surgeons and residents ob
tain a solid grounding in basic
surgical skills. A skilfully performed
operation comprises 75% decision
making and 25% manual dexterity.1
Traditionally, dexterity has had a
low priority with respect to other
skills required by surgical residents.
Technical skills are usually acquired
from experience as an assistant in
the operating room or in the animal
laboratory. Gradually, responsibility
is increased and expertise acquired,
and it is hoped that the surgical
resident will finish training with
proficency in clinical and technical
skills. As surgeons, we have been
raised on the “see one, do one,
teach one” philosophy. However,
seeing one does not imply ability to
do one, and doing one certainly
does not imply that the surgeon is
ready to teach. Since the develop
ment of craft workshops in England
during the mid-1970s to foster the
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TECHNICAL-SKILLS COURSE FOR RESIDENTS

art of surgery,2 technical-skills
workshops and courses have been
gaining prominence in response to a
perceived need for formal instruc
tion in surgical skills. For example,
the addition of structured teaching
in basic technical skills for clinical
clerks has been shown to improve
their performance on a simulated
appendectomy.3 As a result, techni
cal-skills workshops are becoming
highly regarded by both partici
pants and teachers.3-5

Historical Review
Before 1846, speed was vital as
surgeons performed their proce
dures without the benefit of anes
thesia. With the introduction of
ether, surgeons were able to slow
down and concentrate on technique
and tissue handling. Halsted, the
acknowledged father of American
surgery, inaugurated the residency
training system in the United States
with its strong emphasis on graded
responsibility.6 This system remains
the cornerstone of surgical training
programs today.
In Canada, a course in surgical
technique for medical students was
organized and held as early as
1962.7 In the United States, the
need for psychomotor-skills train
ing in orthopedic surgery was rec
ognized in the mid-1960s, and this
specialty has been a leader in devel
oping psychomotor-skills laborato
ries to ensure that orthopedic resi
dents and surgeons become and
remain competent in the technical
skills of orthopedics.8 Increasingly,
surgeons and those interested in
the training of surgeons recognized
the importance of technical training
outside the operating room.
In England, craft workshops have
been specifically designed to teach
basic surgical skills such as tying
knots and suturing visceral and
vascular anastomoses. Workshops

and courses in fundamental surgical
techniques have been organized in
the United States and in Europe,
using simulated materials and ani
mal viscera.2’910 Suture boards,11
abdominal aortic aneurysm jigs,9
lung models,12 abdominal wall jigs
for abdominal wound closure,13
fracture fixation,14 joint replace
ment and arthroscopic models15 and
pelvis simulators for colorectal sur
gery (Ian Flack, Annex Art, Gwy
nedd, Wales: Personal communica
tion, December 1990) are now wide
ly used simulation methods.
A wide variety of microvascular
surgical models exist to permit mas
tery of fine-suture techniques; they
include paraffin, foliage and turkey
skins.16 Latex tubing, Penrose
drains, polytetrafluorethylene and
pig’s feet have also been used as
models to demonstrate surgical
skills. In addition, computer graph
ics,17 videotapes,18 use of live pigs19
and canine models for in-situ bypass
surgery20 are some of the most
recent methods for teaching techni
cal skills.

Objectives
A consensus of general surgeons
at the University of Toronto deter
mined that the following skills were
necessary at the introductory level:
incising, cutting, dissecting, light
tissue handling, suturing, ligating
and securing hemostasis. A course
was designed to offer lst-year sur
gical residents concentrated handson exposure to these basic surgical
techniques.
Our objectives were to teach the
following:
• Basic surgical manoeuvres
such as use of the scalpel, scissors,
clamps and sutures
• Methods of hemostasis
• Halstedian techniques
• The properties and uses of
sutures

• The principles of stapling
techniques
• The principles of safe and ef
fective wound closure
• The principles of surgical as
sisting
• Maintaining a goal-directed
approach to surgical procedures
• Understanding the concept of
operating as a team
• Assisting in the development
of critical thinking and problem
solving skills.

Methods
From 1989 to 1991, 28 lst-year
residents in general surgery attend
ed the technical-skills course, which
included both “dry-lab” and “wetlab” experiences. Instructional ma
terial included a course outline,
three reference books on surgical
skills21-23 and an atlas on stapling
techniques.24 Residents were asked
to complete a background question
naire on their medical training. The
course ran for 8 weeks, 3 to 4
hours per week, between January
and March each year. All residents
were excused from clinical duties to
attend the course. Live dogs and
pigs were used, with two to three
residents per animal. Four animals
were used for each session. Four
University of Toronto surgeons at
tended each session and acted as
instructors. Two surgeons had a
special interest in surgical educa
tion. A veterinarian was present
during all wet-lab experiences.
Laboratory Experiences
Week 1: the pretest — wet lab.
To obtain a baseline assessment of
technical skill, residents were asked
to perform a small-bowel resection
from skin to skin. A faculty member
acted as the first assistant but did
not provide any direct instruction.
Residents were allowed 90 minutes
CJS, VOL. 35, NO. 5, OCTOBER 1992
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to complete the operation. An oper
ative checklist was completed (Ta
ble I).
Grading consisted of performing
the skill correctly (two marks), in
correctly (one mark) or not at all
(no mark). A videotape was taken of
the pretest, allowing 10 minutes on
average for each resident.
Week 2: feedback and suture
materials — dry lab. In the class
room, the videotapes and operative
checklists of the residents’ perfor
mances were reviewed. Weaknesses
in the general principles of techni
cal skills were identified and re
viewed individually. A lecture on
suture materials covered the cate
gories of materials used in the oper
ating room and the advantages and
disadvantages of each. The resi
dents were given packages of each
type of suture so that they could
become familiar with their proper
ties and handling characteristics.
Week 3: small-bowel anastomo
sis — wet lab. Here the residents
received instruction in the tech
nique of small-bowel anastomosis.
Specific attention was given to the
overall plan of an operation: the
role of surgical assisting; tissue
handling and instrument handling;
wrist, hand and arm movements;
Table I. The Operative Check List
Mesentery
Resection line chosen with blood supply
Peritoneum scored with scissors or knife
Wedge-shaped mesenteric defect
Vessels isolated before taken
Instrument held for assistant to place
snap
Ligated with appropriate tie
No unnecessary bleeding
Mesentery taken down to bowel wall
Adequate length of bowel cleared
Anastomosis (inner layer)
Suture (chromic or Dexon, 2-0 or 3-0)
Running suture
Bites through all layers
Distance between sutures (3 -8 mm)
Needle driver
Held correctly
Needle positioned 1/2 to 2/3 back
Needle rotated through curve
Needle inserted into tissue at right angle

538

JCC, VOL. 35, N° 5, OCTOBRE 1992

suture placement and suture cut
ting; and closing. Each resident was
allowed to practise two to three
anastomoses. Errors in technique
were identified, and the residents
had an opportunity to practise sug
gested modifications. Principles of
safe and effective wound closure
were emphasized.
Week 4: stapling devices and
techniques — dry lab. This session
provided a combination of video
tape, lecture and practice on sta
pling techniques. The residents
were given the opportunity to prac
tise assembling and disassembling
stapling devices. Foam models of
stomachs and small bowel were pro
vided for practising stapled anasto
mosis before the next wet lab. A
take-home examination was given
to the residents and reviewed the
following week.
Week 5: techniques of anasto
mosis with stapling devices — wet
lab. This session was devoted to
performing stapled anastomoses in
live animals (i.e., partial gastrecto
my, gastroenterostomy and anterior
resections). A staff surgeon provid
ed instruction and immediate feed
back.
Week 6: a day with the profes
sor — wet lab. Four University of
Toronto surgeons each spent a ses
sion with two to three residents.
The surgeons were chosen for their
known ability to teach in the oper
ating room. This session gave the
residents early exposure, on a oneto-one basis, to the professor’s sur
gical expertise. The professors were
allowed a free hand in taking each
resident through an operative pro
cedure of their choice. These usual
ly included liver resection, nephrec
tomy, oophorectomy and various
gastrointestinal procedures. The
professor not only provided con
structive critical feedback on the
resident’s surgical technique but
also tips on the methods of proper
surgical assisting.

Week 7: surgical trauma and
hemostasis — wet lab. At each
station an injury was created with
the resident absent from the room.
Injuries included those of the inferi
or vena cava, aorta, kidney, liver
and ureter. Residents were called to
the operating room and confronted
with a potentially life-threatening
situation that they had not seen
before and were required to repair.
A core surgeon was present as an
assistant and reviewed the princi
ples of repair in each injury. No
animals were lost during this ses
sion.
Week 8: small-bowel anastomo
sis — wet lab. Residents were re
quired to perform a small-bowel
resection, with surgeons from the
University of Toronto acting as ex
aminers. The post-test scores were
compared with the pretest scores to
determine if there was any improve
ment in the residents’ skills.
Results
Results of the pre- and post-test
were compared (Fig. 1). The data
are preliminary and subjective in
nature, and the operative checklist
has not yet been validated. Overall,
we observed a noticeable improve
ment in the ability of all residents to
perform basic surgical skills and
complete an operation.
Resident Feedback

At the end of the course, the
residents were asked to rate the
following: overall value; improve
ment of surgical technique; under
standing of surgical principles; and
quality of teaching. All residents
thought their skills had improved
considerably, and they felt more
confident about performing basic
surgical procedures. All found the
course informative, helpful and well
worth the time spent. They appreci-
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ated the close supervision and cons
tant feedback even though they
were apprehensive at the beginning
of the course. Suggestions included
starting the course in July, no di
dactic sessions, no use of live ani
mals and more time to practise.

Discussion
This course was designed in re
sponse to a perceived need for for
mal instruction in basic surgical
techniques. A review of the video
taped sessions of the residents per
forming surgery highlighted the
fact that they were ill prepared for
the operating-room environment.
Many lacked the basic skills to
carry out even the simplest proce
dure. We acknowledge that lst-year
surgical residents are not expected
to perform at a senior level.
Barnes25 stated that surgical pro
gram directors should balance ef
forts to teach the craft as well as
the science of surgery for several
reasons:

• The increasing complexity of
operations with ancillary technolo
gy
• The increasing constraints on
the use of laboratory animals for
the development of surgical skills
• The limitations of available pa
tients
• The increasing medicolegal
pressures requiring that graduates
have optimal surgical skills
• Fiscal constraints.
Surgeons have long recognized
that many of the complications
after surgery are secondary to oper
ator error in technique. In fact,
errors in operative technique may
be more important than preopera
tive prognostic formulas in predict
ing morbidity and mortality.26 Oth
ers27 believe that technical causes
should be considered when examin
ing studies that analyse factors in
surgical outcome. The relationship
between errors in operative tech
nique and postoperative outcome
has been well documented.28 An
increased incidence of benign bileduct strictures has been reported

FIG. 1. Results of pretest (black bars) and post-test (shaded bars) scores for 1991
for 8 of 12 lst-year residents in general surgery who took technical-skills course.

when inexperienced surgeons per
formed cholecystectomies without
senior back-up present.29 Technical
ability has been suggested as a
major consideration in regular re
view of trainees and should be con
sidered more seriously when mak
ing consultant appointments.27
Simulation techniques for surgi
cal-skills teaching are becoming in
creasingly important.2'12’13 The costs
for an animal laboratory are high,
and the use of live animals is con
troversial. The use of lyophyllized
bovine or porcine intestine for
teaching anastomosis techniques is
becoming more widespread, particu
larly in Europe where the use of live
animals is illegal.510 Further de
velopment of simulation techniques
will allow surgical trainees the op
portunity to practise even the most
complicated procedures.
Schueneman, Pickleman and
Freeark30 have demonstrated that
age, gender and lateral dominance
are predictors of operative skill
among surgery residents. Surgicalskills programs have been intro
duced with the principal purpose of
developing psychomotor skills to
enhance the manual dexterity of
surgical residents.25 Barnes, Lang
and Whiteside18 described the use
of a head-held videocamera to re
cord resident’s fine motor skills,
which could then be evaluated ac
cording to predetermined criteria.31
However, no objective measurement
instrument has been developed to
assess the progress of skills im
provement that is both reproducible
and accurate. We are attempting to
refine such measurement instru
ments.
Preliminary feedback from the
residents suggests that the course
is of value. They all felt that skills
training outside the operating room
was essential. Steeles, Logie and
Munro32 examined how residents
viewed their training and found that
the majority felt they had insuffiCJS, VOL. 35, NO. 5, OCTOBER 1992
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cient supervised operating time, and
a substantial proportion reported
that they seemed out of their depth
when performing delegated emer
gency operations.32 Those who at
tended surgical workshops found
these activities to be very useful.
Photographic atlases and video
tapes were not found to be of any
value in improving technical skill.
Although we recognize that sur
geons must be adept at dealing with
tissues manually, staplers have be
come part of the general surgeon’s
armamentarium and, therefore, are
included at this introductory level.
Our objectives are to allow surgi
cal residents to become exposed at
an early stage to the principles of
conducting and performing an oper
ation. It should be made clear that
simulation techniques will never re
place the “real thing.”
Developments in simulation
should not be viewed as a threat to
trainees and trained surgeons but
rather as an opportunity to improve
technical skills.33 It has yet to be
proven that simulation techniques
are effective, but resident feedback
is encouraging. The current system
is weighted very heavily on graded
exposure in the hope that proper
technique will be achieved at the
end of a training program. We do
not claim to furnish the resident
with the “right” way of doing
things and are aware of the differ
ent approaches to various surgical
procedures. In fact, each of the core
surgeons in our course varied in
experience and technique and often
asked another surgeon “How do
you do this?” or “What’s been your
experience with this method?” The
residents can only benefit from this
type of exposure.
We have demonstrated that a
technical-skills program is effica
cious for lst-year residents in gen
eral surgery. Data are required on
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the effectiveness of the course, and
the development of simulation mod
els needs to be refined and pursued.
We propose through a SurgicalSkills Inventory Profile (SSIP) to
maximize the objectivity and reli
ability of the evaluation process.
The validation of the SSIP is essen
tial to all ongoing efforts to deter
mine the effectiveness of this
course.
We acknowledge the contributions of
Davis & Geek and Auto Suture Canada
to this study.
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T h e Advanced Trauma Life Support
Course for Senior Medical Students
Jameel Ali, MD, FRCSC, FACS; Mary Howard, RN
The authors conducted the Advanced Trauma Life Support (ATLS) Course for 90
students who were in their 4th year of medicine at the University of Manitoba. The
impact of the course was evaluated through questionnaires completed by students,
instructors and emergency-room physicians. The students’ performances were also
compared with those of 96 practising physicians who took the ATLS course in
Manitoba. The failure rate for students (3.3%) was not statistically different from
that for practising physicians (4.2%). Overall, the students’ performances in the
written test were better (55% of students scored over 90% on the test compared with
15% of practising physicians). The student-to-faculty ratio was 1.5:1 and included 21
physician-instructors. Ninety-five percent of the faculty and students suggested that
this course should be mandatory in the 4th year curriculum of medicine and that the
course improves trauma care provided by the students and interns by increasing
their confidence and improving communication with specialist surgeons. However,
10% of the faculty suggested that more time should be allocated to the
surgical-skills practicum. The authors’ experience with this program suggests that
the ATLS course should be uniformly incorporated in the Canadian undergraduate
4th year medical curriculum and that techniques used in this course should be
considered in other areas of the undergraduate medical curriculum.

Les auteurs ont offert a 90 etudiants en medecine de 4e annee de l’Universite du
Manitoba, le cours sur les techniques specialisees de maintien des fonctions vitales
des traumatises. L’impact de ce cours a ete mesure a l’aide de questionnaires remplis
par les etudiants, les instructeurs et les urgentologues. Les resultats obtenus par les
etudiants ont ete compares a ceux de 96 medecins traitants qui ont suivi le meme
cours au Manitoba. Le taux d’echec des etudiants (3,3 %) n’a pas ete statistiquement
different de celui des medecins traitants (4,2 %). Au fait, la performance des
etudiants au test ecrit a ete superieure a celle des medecins (55 % des etudiants ont
obtenu un score superieur a 90 %, comparativement a 15 % des medecins). Le
rapport etudiants/enseignants etaient de 1,5 pour 1 et on comptait 21 medecins
instructeurs. Quatre-vingt-quinze pourcent des enseignants et des etudiants ont
propose que ce cours devienne obligatoire pour les etudiants de 4e annee. Tous
croient que ce cours aura ameliore les soins aux traumatises donnes par les
etudiants, en augmentant leur confiance et en ameliorant les communications avec le
chirurgien specialiste. Neanmoins, 10 % des enseignants proposent que plus de
temps soit alloue a la pratique des habiletes chirurgicales. L’experience menee par
les auteurs suggere que le cours sur les techniques specialisees de maintien des
fonctions vitales devrait etre incorpore aux programmes d’etudes des etudiants de 4e
annee en medecine au Canada, et que les methodes utilisees pour ce cours
pourraient etre etendues a d’autres domaines du programme d’etudes medicales.
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he Advanced Trauma Life Sup
port (ATLS) course was initiat
ed in 1977 in Lincoln, Neb., and
was aimed at improving trauma care
by concentrating on the education
of primary-care physicians in the
concepts of resuscitation of the
multiply injured patient.1-2 Since its
inception, over 5000 ATLS courses
have been conducted, at which over
100 000 physicians have been
trained in the concepts of ATLS.
The course has become widely ac
cepted throughout North America
where most emergency departments
require that their physicians com
plete this program before they are
hired. Recently, the program has
been introduced in Europe, Austra
lia, South America and in some
developing countries.3 Although the
program was initially aimed at prac
tising physicians, three universities
in Canada (the University of Manito
ba, McGill University and McMaster
University) have introduced this
program at the senior-medical-stu
dent level. The course has also been
given to senior undergraduate medi
cal students in the United States,
particularly in the armed forces
medical schools.4
Most medical students in Canada
receive their undergraduate trauma
training primarily through didactic
lectures in their 3rd year. During
their internship, students with mini
mal previous clinical exposure to
trauma patients are frequently re
quired to manage such patients. At
the suggestion of many medical
students, the University of Manito
ba, McGill University and McMaster
University considered the possibility
of introducing the ATLS course at
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an undergraduate level in the 4th
year curriculum. The first medical
student ATLS course in Canada
was conducted at McGill University
and the second at the University of
Manitoba. In this report we describe
the experience at the University of
Manitoba in introducing this course
to 4th year medical students. The
course was evaluated to determine
whether it was appropriate for this
level of trainee and to compare the
performance of medical students
with that of a group of practising
physicians who had taken the ATLS
course.

Students and Methods
At the beginning of the second
term, 90 4th year medical students
took the ATLS course. There were
58 faculty members, of whom 37
were paramedical staff. All physi
cians participating in the student
course as faculty had previously
taught the course to postgraduate
practising physicians from the com
munity. The course was evaluated
by students and faculty, and the
same criteria for satisfactory com
pletion of the course were used as
in the standard ATLS course for
practising physicians.
The presentation of the course
was modified for the medical stu

dents in a number of ways.
• All the lectures were delivered
to the entire class (two groups of
45 students) as opposed to separat
ing the students into smaller
groups.
• A videotape was shown to
introduce the students to the surgi
cal-skills laboratory. This tape origi
nated from McGill University. The
tape outlined the indications, con
traindications and anatomical as
pects of the surgical skills to be
taught and gave a very clear de
monstration of these skills. The
students then discussed the tape.
• The course was also extended
over 4 days for each group of 45
students, and the triage scenario as
well as the multiple-choice ques
tions were completed by the entire
group of 45 students at the same
time, rather than being conducted
for smaller groups. This necessitat
ed some minor changes in the
schedule for the entire program.
However, the order of the lectures
was not disturbed, and the skill
stations were never conducted be
fore the presentation of the relevant
lecture material.
The impact of the course was
evaluated with two major tech
niques. First, all the students and
instructors were asked to respond
to a questionnaire. Second, by ex
amination of the pass percentage

and performance on the written
test, the performance of the stu
dents was compared with that of
practising physicians who had
taken the course at the University
of Manitoba.
On a scale of “strongly agree,”
“agree,” “indifferent,” “disagree,”
“strongly disagree,” the instructors
evaluated the course by responding
to 10 questions on a questionnaire.
(Table I).
Using a similar scale, the stu
dents were asked to grade the
ATLS course (Table II).
At 1 year after taking the ATLS
course, 30 of the students who had
functioned as interns in emergency
departments were randomly selected
and asked to complete a question
naire (Table III).
In addition, 16 attending physi
cians were asked to complete a
questionnaire (Table IV), covering
the performance of these 30 in
terns. All 16 of these physicians
functioned as co-ordinating emer
gency-department physicians.

Results
Faculty Questionnaires

Of the 21 medical faculty, 20
completed the questionnaire. All
considered that the course was well

.

Table 1 Results of Faculty Questionnaire on Advanced Trauma Life Support (ATLS) Course for 4th Year Medical Students (n = 20)
Answers to questions

Course was well run
Students appeared well prepared
Course should be continued for future classes
Course should only be conducted fo r postgraduate
physicians
Course should be mandatory for 4th year students
Students surpassed prior expectations
Students’ enthusiasm surpassed that of postgraduate
physicians
Students’ overall performance surpassed that of
postgraduate physicians
Students’ overall performance equalled that of
postgraduate physicians
Students’ overall performance was below that of
postgraduate physicians
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Strongly
agree

Agree

Indifferent

10
8
10

10
10
8

2
2

8
4

10
12

8

12

D isagree

Strongly
disagree

2
2
2

12

6

6

6

8

10

6

4

4

6

8

2

2
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run (Table I), and approximately
90% felt that the students were well
prepared for the program. Ninety
percent of the faculty also indicated
that the course should be continued
for future classes, and a similar
number disagreed with the concept
that the course should only be
conducted for postgraduate physi
cians. Over 90% of physicianinstructors also thought that the
course should be mandatory for 4th
year medical students.
Approximately 80% of the faculty
considered that the students ex
ceeded expectations, and all respon
dents agreed that the students’ en
thusiasm surpassed that of post
graduate physicians. Only 60% of
the faculty were of the opinion that
the students’ overall performance
surpassed that of postgraduate phy
sicians, but 80% felt that the stu
dents at least equalled the perfor
mance of postgraduate physicians.
Only 20% of the physician faculty
thought that the students’ perfor
mance was below that of postgradu
ate physicians.

1 year after the course, all stated
that they believed the course had
improved their management of trau
ma patients in the emergency de
partment (Table III). Furthermore,
they indicated that the course had
improved their confidence, allowed
better trauma care and improved
their ability to communicate with
specialist surgeons regarding their
trauma patients in the emergency
department. Eighty percent indicat
ed that the course allowed improved
outcome in their trauma patients.
However, six interns felt they could
not assess this question, because
they had not closely analysed their
outcome data. All 30 interns stated
that they would recommend the
course to other students and that
the course was relevant to trauma
care in the emergency setting. They
also indicated that the course met

met (Table II). They all thought
that the course was well organized,
that this was the correct time in the
curriculum to offer the course, that
the didactic lectures were well con
ducted and that the small-group
skills sessions and surgical-skills
sessions were well done. However,
only 77% students indicated that
there was enough “hands on’’ expe
rience, and 95% stated that there
was enough supervision during the
small-group sessions. All respon
dents indicated that the patientassessment stations were a valuable
teaching experience. Ninety-eight
percent thought that this course
should be mandatory in the under
graduate curriculum.
Interns ’ Questionnaires

Students’ Questionnaires

Eighty-eight of the 90 students
completed the student evaluation of
the ATLS course, and all of them
agreed that the objectives of the
course were well defined and were

When 30 interns were questioned

T a b le III. R e s u lts o f In te rn s' Q u e s tio n n a ire C o n d u c te d 1 Y e a r A fte r A T L S C o u rs e
Q uestions
A t 1 y e a r a fte r th e A d v a n c e d T ra u m a L ife S u p p o rt c o u rs e , do
yo u c o n s id e r th e c o u rs e im p ro v e d y o u r m a n a g e m e n t o f
tra u m a p a tie n ts in th e e m e rg e n c y ro o m ?
In w h a t w a y d id th e c o u rs e b e n e fit y o u ?
Im p ro v e d m y c o n fid e n c e
A llo w e d b e tte r care
Im p ro v e d o u tc o m e in m y p a tie n ts
Im p ro v e d m y a b ility to c o m m u n ic a te w ith s p e c ia lis t s u rg e o n
W o u ld yo u re c o m m e n d th e course to o th e r s tu d e n ts ?
W a s th e co u rs e re le v a n t to tra u m a ca re in th e e m e rg e n c y
s e ttin g ?
Do yo u th in k th e co u rs e m e t its o b je c tiv e s o f im p ro v in g tra u m a
ca re ?

T a b le II. R e s u lts o f S tu d e n ts ' Q u e s tio n n a ire o n A T L S C o u rs e

A n sw ers to q uestions
O b je ctiv e s w e re c le a rly d e fin e d
O b je ctiv e s w e re m e t
C o u rse w as w e ll o rg a n ized
T h is is th e c o rre c t tim e in th e c u rric u lu m to g iv e th e
co u rs e
D id a c tic le c tu re s w e re w e ll d o n e
S m a ll-g ro u p “ s k ills ” s e s s io n s w e re w e ll d o n e
S u rg ic a l-s k ills s e s s io n s w e re w e ll done
T h e re w as e n o u g h “ h a n d s o n ” e xp e rie n c e
T h e re w as e n o u g h s u p e rv is io n d u rin g s m a ll-g ro u p
s e s s io n s
P a tie n t a s s e s s m e n t s ta tio n s w e re a va lu a b le te a c h in g
e xp e rie n c e
C o u rse sh o u ld be m a n d a to ry in th e u n d e rg ra d u a te
c u rric u lu m

S tro n g ly
a g ree

A gree

62
34
64

26
54
24

74
44
58
60
20

(n = 3 0 )

Y es

No

30

0

30
30
24
(6 u n s u re )
30
30

0
0
0
0
0

30

0

30

0

(n = 8 8 )

in d iffe re n t

D is a g re e

14
44
30
28
48

18

2

24

60

4

74

14

64

22

S tro n g ly
d is a g re e

2
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its objectives of improving trauma
care.
Emergency-Room Physicians'
Questionnaires

Twelve of the 16 supervising
physicians in the emergency depart
ment who were questioned stated
that they could differentiate interns
who had taken the ATLS course
from those who had not (Table IV).
The reasons the physicians gave
were that the interns who had
taken the ATLS course demonstrat
ed greater confidence, more appro
priate treatment and were able to
institute more timely and appropri
ate consultations. All the consul
tants, including those who were not
certain they could differentiate the
interns with ATLS training from
those without, recommended that
the course should be taken by all
medical students before their intern
ship in the emergency department.

was a failure rate of 4.0%. This was
not a statistically significant differ
ence (Fisher’s exact test).
Using a comparison criterion
score of 90%, we found that the
students performed at a higher level
than practising physicians in the
written test. The score of 90% or
greater was achieved by 55% of the
students and by only 15% of the
practising physicians (p < 0.05,
Fisher’s exact test).
Although most of the comments
were very positive, 20% of the stu
dents thought that the pace for the
course was too rapid. Ten percent
of the faculty suggested that there
should be more time for the surgi
cal-skills laboratory because of the
relative inexperience of these stu
dents in such skills. The faculty
also indicated that this course
should be conducted just before the
clinical exposure period of the in
ternship.

Pass and Fail

Discussion and Conclusions

There were three failures (3.3%)
among the 90 medical students. All
occurred primarily as a result of
failure to pass the initial assessment
station. Seven students, however,
required remedial instruction and
were successful in passing the
course, according to the criteria
used by the American College of
Surgeons Committee on Trauma.
Among the most recent 96 practis
ing physicians who participated in
the ATLS course in Manitoba there

From our assessment of the
ATLS course for 4th year medical
students conducted at the Universi
ty of Manitoba we found that the
course was well received both by
faculty and students and that the
students considered this an appro
priate training program for them.
The undergraduate students per
formed as well as practising physi
cians when judged by pass and fail
criteria and performed at a superior
level in the written test.

T a b le IV . Results of Supervising Emergency-Room Physicians' Questionnaire
Q u e s tio n s

Can you differentiate the interns who have taken the ATLS
course fro m those who have not?
If the answer is YES to the above question please indicate in
w hat area(s) these differences are observed in relation to
traum a management:
Greater confidence
More appropriate treatm ent
More tim ely and appropriate consultation
W ould you recommend this course for medical students prior
to their internship in the emergency department?
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(n = 16)

Y es

No

12

4

12
12
12

0
0
0

16

0

We also found that this course
can be given without difficulty to a
large group of 4th year medical
students, provided the necessary
precautions are taken in introduc
ing the surgical-skills laboratory. It
was suggested that the time spent
in the surgical-skills laboratory may
need to be increased so that the
students may assimilate the techni
cal knowledge more readily during
these sessions. As suggested by
many of the students, the duration
of the course may need to be
lengthened to allow more time at
the individual stations.
The results of this study indicate
that the ATLS course should be
adopted more uniformly into the
senior-medical-student curriculum
in Canada. Furthermore, the degree
to which the students appear to
enjoy this particular type of teach
ing should encourage the incorpo
ration of similar concepts in other
areas of teaching in the undergrad
uate curriculum. However, to con
duct such programs the ratio of
faculty to students required is quite
high, and this will necessitate a
marked increase in the number of
faculty willing to participate in this
form of teaching. It is interesting
that the students performed at a
higher level than practising physi
cians in the written test, but this
should not be taken to mean that
they will perform in clinical situa
tions at a higher level than practis
ing physicians. The students’ resuscitative skills, especially, would not
be expected to equal those of prac
tising physicians. Although this
particular concept needs to be pur
sued in a more formal manner be
fore a definitive answer can be
provided, based on our survey of
interns 1 year after the course, both
the supervising physicians in the
emergency department and the in
terns functioning in the emergency
department felt that the ATLS
course had better prepared interns

ATLS COURSE FOR MEDICAL STUDENTS

for managing trauma patients in the
emergency setting by improving
their confidence, allowing them to
provide more appropriate treatment
and more timely and appropriate
consultation. Both the interns and
the supervising physicians agreed
that this course should be contin
ued for medical students before in

ternship in the emergency depart
ment.
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BOOK REVIEWS
continued from page 501

tion for examination. Although the au
thors highlight the similarity of surgical
procedures performed throughout the
world, they do not seem to appreciate
the considerable difference in surgical
training that exists between Britain and
North America. Unlike the British resi
dent, the American and Canadian surgi
cal resident is rarely, if ever, unsuperv
ised at the operating table.
Much of the text offers sound surgi
cal advice but rarely addresses alterna
tive options or issues. The text seems
needlessly dogmatic in its suggestion of
types of suture material, use of drains
and anastomotic techniques. The chap
ter on breast disease fails to discuss
surgical techniques of needle localiza
tion or level of axillary dissection at
mastectomy. Similarly, no mention is
made of splenic preservation tech
niques. In the chapter on Whipple’s
procedure, no alternatives for anasto
motic hook-ups are provided. A Nissen

360° wrap is advocated without men
tion of other wrap methods or hiatal
hernia repairs. A more detailed account
of how to handle the appendiceal stump
in difficult cases, as for example when
Crohn’s disease is present, would have
been useful.
Scattered throughout the book are
descriptions of surgical procedures and
instruments of which, I suspect, many
Canadian residents will not have heard.
For example, “a triple bypass” is more
usually associated with coronary artery
bypass grafting than obstruction due to
a pancreatic carcinoma. In our centre,
sadly, the Lane’s twin gastrectomy
clamp has been relegated to the antiqui
ties display cabinet. I was concerned to
read in the book that the use of Bake’s
dilators is advocated during commonduct exploration, and that the use of
the trochar is advocated during chesttube insertion. The chapter on trauma
surgery does not fit with the Advanced

Trauma Life Support guidelines and
does not cover issues such as when and
when not to explore a retroperitoneal
hematoma, which colonic injuries may
be repaired and what pelvic fractures
are associated with rectal injuries. The
chapter on inguinal hernia covers the
Bassini or modified Bassini repair tech
niques but fails to cover extensively the
McVay procedure commonly performed
in North America.
It is with some regret, therefore, that
I was unable to recommend to our
surgical residents or library the pur
chase of this clearly laid out and wellillustrated, but somewhat dogmatic, op
erative surgical text.
C.J. de Gara, MB, BS, MS, FRCS
Assistant professor, general surgery
Department of Surgery
Henderson General Hospital
711 Concession St.
Hamilton, ON
L8V 1C3
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A Family Exhibiting Carotid Body
T umours
Zenon J. Borowy, MD, BSc(Med), FRCSC;* Louis Probst, MD;* Mervyn Deitel, MD, FRCSC, FACS;*
Lalitha Shankar, MD, FRCPCf
The authors describe the surgery carried out for 11 carotid body tumours (CBTs)
that were found in three generations of a Greek family. Eight patients with CBTs
were operated upon at St. Joseph’s Health Centre, Toronto, within 1 year. Three
patients had bilateral CBTs, which were removed in two stages. Only one of the
CBTs occurred in a female. Seven CBTs were excised by meticulous subadventitial
dissection. In the eighth, a previous attempt at removal in another hospital had
proved unsuccessful, and excision of the tumour required ligation of the external
carotid artery and partial excision of the carotid bulb. The authors conclude that
most CBTs can be excised directly without ligation, shunts or bypasses. In eight
operations carried out on five patients, the only complication was a transient
neuropraxia of the hypoglossal nerve that resolved within 2 weeks.
Les auteurs decrivent l’excision chirurgicale de 11 tumeurs du glomus carotidien
(TGC) decouvertes chez des representants de trois generations d’une famille
grecque. En un an, huit TGC ont ete excisees au St-Joseph Health Centre de
Toronto. Trois patients souffraient de TGC bilaterales qui furent operees en deux
temps. Une seule TGC est survenue chez une femme. Sept TGC ont ete excisees par
dissection sous-adventitielle minutieuse. Dans un huitieme cas, une tentative
d’excision dans un autre hopital ayant echoue, l’ablation de la tumeur necessita la
ligature de la carotide externe et l’excision partielle du bulbe carotidien. Les auteurs
concluent que la plupart des TGC peuvent etre excisees directement, sans ligature
ou derivation. Dans huit operations pratiquees chez cinq patients, la seule
complication fut une neuropraxie transitoire du nerf hypoglosse qui disparut en 2
semaines.

arotid body tumours (CBTs) are
rare, slow-growing, vascular tu
mours of the neck. There is contro
versy regarding their malignant po
tential, diagnosis and surgical man
agement. The familial variety of this
tumour is much less common and
behaves differently from the sponta
neous form.1'3 Eight members of
one family with a total of 11 CBTs
are presented. Eight of the CBTs
were excised at our hospital by one
of the authors (Z.J.B.)

C

Patients and Methods
Patients

The family tree with respect to
CBTs is summarized in Fig. 1.
Patient 1-1 was the first known
member of the family to have had a
CBT. He died when the large CBT
invaded the base of his skull and
brain. Patient II-5 was the only son
in the second generation to have
had a CBT; this was removed at

From the *Department o f Surgery and fDepartment o f Diagnostic Imaging, St. Joseph's Health
Centre, University of Toronto, Toronto, Ont.
Accepted for publication July 18, 1991
Reprint requests to: Dr. Zenon J. Borowy, Department o f Surgery, St. Joseph’s Health Centre,
30 The Queensway, Toronto, O N M 6R 1B5
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another hospital without complica
tions. Patient III-8 had a unilateral
CBT resected at another hospital.
Resection was followed by a tempo
rary hemiplegia which eventually
resolved; however, the patient was
left permanently blind in one eye.
Patients III-l, III-3, III-4, III-5 and
III-6 had their CBTs investigated
and excised at our centre. Patient
III-l was the first member of the
family treated for CBT at our hospi
tal. The CBT of patient III-5 had
been initially explored at another
hospital 12 years previously, but
because of uncontrollable hemorrh
age it had been firmly packed but
not excised. All patients had a rou
tine surgical work-up followed by
computed tomography of the neck
(Fig. 2) and bilateral carotid angiog
raphy (Figs. 3 and 4).
Operative Technique

To provide adequate exposure we
used a generous oblique incision
(Fig. 5). The lower pole of the
parotid gland was mobilized for
better access to the internal and
external carotid arteries superiorly.
These two vessels and the common
carotid artery were isolated and
controlled with tapes. Meticulous
subadventitial dissection of the tu
mour was performed, particular
care being taken in the region of
the posterior aspect of the bulb
where adherence was most intimate.
The external carotid artery had to
be sacrificed in only one of our
eight operations (patient III-5 who
had initially been operated on un
successfully elsewhere). Angio-

FAMILIAL CAROTID BODY TUMOURS

graphic studies suggested that
shunts and bypasses were not
necessary. Hemovac suction was
used, and post operatively the pa
tients were observed in the acute
care unit.

of the carotid bulb, and experienced
a transient neuropraxia of the hypo
glossal nerve, which resolved in 2
weeks.

Discussion
Results (Table I)

The carotid body is a pinkishgrey ovoid mass, 3 to 4 mm in
diameter, located in the adventitia
of the posteromedial surface of the
carotid bifurcation. Its proposed
function is to regulate pulmonary
ventilation by way of the glossopha
ryngeal nerve, by monitoring pri
marily hypoxia as well as hyper
capnia and acidosis.
Tumours of paraganglionic tissue
are of neural-crest origin. They ap
pear grossly as well-circumscribed
red-brown nodules. Microscopically,
they have nests of epithelioid cells,
“ Zellballen,” with eosinophilic
granules, separated by a trabeculated vascular network. They have
been collectively termed non
chromaffin paragangliomas or chemodectomas. Van Baars and col
leagues1 found that this histologic
group of tumours is composed of

The mean age at the time of
surgery for the five patients (four
men, 1 woman) treated at St. Jo
seph’s Hospital was 36.5 ± 5.7 (±
SD) years. Three patients had bilat
eral CBTs, which were removed in
two stages, and two had a unilateral
CBT (for a total of eight CBTs)
excised at our centre. In the entire
family, 7 men to 1 woman had
CBTs. The mean size of the eight
CBTs at surgery was 4.5 ± 0.7 cm.
The tumours were histologically be
nign in all cases (Fig. 6). The only
perioperative complication that oc
curred was in patient III-5 who had
had a previous unsuccessful at
tempt at resection at another hospi
tal 12 years earlier. This patient
required ligation of the external
carotid artery and partial excision

!H t-0
1

•
1

tumours of the carotid body (78%),
the glomus jugulare (16%), the glo
mus vagale (4.5%) and the glomus
tympanicum (1.5%). A high inci
dence of CBTs has been reported in
Peru, which suggests that chronic
hypoxia is a stimulus for carotid
body hyperplasia.3
CBTs are slow-growing vascular
tumours that gradually enlarge over
several years. As the tumour en
larges, it presses on nearby struc
tures, including the vagus, hypo
glossal and glossopharyngeal
nerves and the sympathetic trunk.
CBTs are very vascular; they adhere
to and encircle the carotid bulb and
bifurcation and can eventually oc
clude the carotid system. On physi
cal examination, a neck mass is
palpable at the angle of the jaw in
the area of the carotid bifurcation.
The mass is usually laterally mobile
but vertically restricted. The tu
mour usually has a transmittable
pulse but rarely produces a bruit.
CBTs are compressible due to their
extreme vascularity.
The familial form of CBT was
first described by Chase in 19332
and is estimated to occur in about
10% of all cases of CBT.3 Bilateral
ity has been reported to occur in
approximately 30% of the familial

2

l O
i ::p •
:p «
-jO
10
■■IBC 6
\ <
it
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\

0
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F irst CBT Identified
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►CBT by History
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Unilateral CBT
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|

Bilateral CBT

Sex Unknown

| * l ( • ) Oenetic Carrier

Q

Deceased

FIG. 1. Family tree. Top row: generation I; middle row: generation II; bottom row:
generation III. Patient III-5 was explored, “packed off” and closed without excision
of CBT, 12 years before our surgical removal of same tumour.

FIG. 2. Computed tomography scan of
neck with intravenous contrast demon
strates bilateral large enhancing CBTs.
Internal jugular vein (i) and internal
carotid artery (arrow) are displaced
posterolaterally.
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cases and in approximately 5% of
the sporadic variety.3 Malignant
forms of these tumours, demon
strating local invasion and lymphat
ic or hematogenous dissemination,
have a controversial incidence; how
ever, in a comprehensive review,
Grufferman and associates3 found

an incidence of malignancy of 12%
in sporadic cases and only 2.5% in
the familial form. Multicentric para
gangliomas, which develop in the
other areas of paraganglionic tis
sue, occur in about 6% of both
types of CBT.3 For both the familial
and the sporadic forms, there is a

similar age of onset at approximate
ly 40 years, unlike other familial
tumours in which the familial forms
usually have a younger age of on
set. CBTs of both varieties have
been reported to have an equal sex
distribution,3 although in our series
there were 7 males to 1 female.

«

4
A

FIG. 3. Carotid angiography demonstrates vascular CBT (T)
arising at bifurcation of common carotid artery. Internal
carotid artery (I) and external carotid artery (E) are displaced
by CBT.

4
FIG. 4. Carotid angiography demonstrates adequate collateral
circulation through circle of Willis (W). CBT (T) splays
internal carotid artery (I) and external carotid artery (E).

i
f

t

"1
'

'Y

FIG. 5. (Left) Intraoperative view from head of table showing excision of left-sided CBT (T). Tumour is located posterior to
common carotid artery (C), carotid bulb (B), external carotid artery (E) and internal carotid artery (I). CBT has been dissected
medially and laterally, but still remains attached posteriorly. (Right) Further photograph of excision of left-sided CBT. Tumour
is being delivered medial to common carotid artery, carotid bulb, external carotid artery and internal carotid artery.
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Since pedigree analyses of the
familial cases of CBT show an equal
sex distribution, this suggests an
autosomal mode of inheritance. The
average rate of phenotypic expres
sion in the literature is approxi
mately 40%, which suggests that a
dominant form of inheritance as a
recessive mode of transmission
would be expressed in only 25%.3
The Auerbach hypothesis of a mul
ti-step delayed mutation and Knudson’s two-step mutation model both
try to explain how the CBT is
inherited in an autosomal dominant
manner and yet initially skips gen
erations.4'5 In Auerbach’s model, a
labile genetic premutation, which
has a normal phenotype, is trans
mitted through carriers. This may
revert back to normal or undergo a
second change or telomutation,
which would result in affected chil
dren of carrier parents. Since the
inherited mutation was prezygotic,
it would affect the entire pool of
pluripotent cells, increasing the
probability of bilateral or mul
ticentric tumours. It is proposed
that this mutation would be ex
pressed in a highly penetrant auto
somal dominant form.3'6'8
Attempts at predicting the malig
nant potential of these tumours
have focused on clinicopathological
analyses and DNA studies. No rela
tionship has been found between
mitotic activity, perineural or vascu
lar invasion or nuclear pleomorphism and the clinical behaviour.9
However, in one study, perineural
and vascular invasion occurred only
in tumours with abnormal DNA
histograms, which suggests that

demonstrates the CBT as a vascular
mass at the carotid bifurcation with
splaying of the internal and external
carotid arteries. The tumour blush,
which persists into the venous
phase of the angiogram, indicates
the cephalic extent of the CBT and
helps to plan surgical exposure.
Bilateral angiography will identify
concurrent atherosclerosis and will
uncover multicentric tumours.10-12
Biopsy of these vascular lesions
should not be done because it could
result in a major hemorrhage.
Because CBTs have demonstrat
ed persistent growth with a tenden
cy to encircle the carotid vessels
causing progressive complications
and have a definite, unpredictable
malignant potential, surgical exci
sion is recommended in all appro
priate patients. Radiotherapy is not

this may have some predictive value
in the future.9 Computed tomogra
phy of the neck with contrast dem
onstrates the CBT as a profusely
enhancing mass located near the
carotid bifurcation, which displaces
the internal carotid artery posterolaterally.10-12 Magnetic reso
nance imaging (MRI) provides supe
rior tissue characterization by dem
onstrating the high vascular flow of
the CBT as the characteristic “salt
and pepper” appearance on 71- and
T2-weighted images. MRI also bet
ter identifies invasion and constric
tion of the carotid vessels.13
Carotid angiography is still
necessary to assess the relationship
of the CBT to the major vessels and
to identify arterial feeders that are
predominantly from the external ca
rotid artery. Carotid angiography

FIG. 6. Photomicrograph from CBT showing nests of epithelioid cells, “Zellballen,” (arrows) and vascular spaces (V) (hematoxylin-eosin, original magnification X
100 ).

Table I. Data on Five Patients With Carotid Body Tumours Treated at St. Joseph's Hospital, Toronto
Age, yr

Sex

No. of yr
present

Side

Size at
surgery, cm

Type

Complications

in-1
III-3
III-4
III-5

27
34
36
39

M
M
M
M

2
5
3
12

Left
Bilateral
Bilateral
Bilateral

4
5.5, 5.5
4.5, 4
4.5, 4

Benign
Benign
Benign
Benign

III-6

42

F

3

Left

4

Benign

None
None
None
Cranial nerve 12
neuropraxia
None

Patient
no.
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DIFLUCAN
(fluconazole/pfizer)

AN OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
n a m e of drug

DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14alpha-demethylation. Mammalian cell demethylation is much less sensitive to fluconazole
inhibition. The subsequent loss of normal sterols correlates with the accumulation of 14-alphamethyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment of:
1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of
serious system ic candidal infections, including urinary tract infection, peritonitis, and
pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal
meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology)
should be obtained prior to therapy to isolate and identify causative organisms. Therapy may
be instituted before the results of the cultures and other laboratory studies are known; however,
once these results become available, anti-infective therapy should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have shown
hypersensitivity to fluconazole, to any of its excipients, or other azole related compounds.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored for
the development of more severe hepatic injury. Although serious hepatic reactions have been
rare and the causal association with DIFLUCAN uncertain, if clinical signs and symptoms
consistent with liver disease develop that may be attributable to fluconazole, DIFLUCAN
should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
In rare cases, as with other azoles, anaphylaxis has been reported.
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential benefit
outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: Fluconazole is secreted in human breast milk at concentrations
similar to plasma, hence its use in nursing mothers is not recommended.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not been
established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimefidine and Antacids Absorption of orally administered DIFLUCAN does not appear to be
affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clin ica lly meaningful extent; reduction of about 13% in AUC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Adm inistration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
administration had no clinically relevant effects on the absorption or elimination of fluconazole
in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN with
an increase in cyclosporine plasma concentrations in renal transplant patients with or without
impaired renal function. Therefore, when DIFLUCAN and cyclosporine are coadministered,
cyclosporine levels should be monitored and cyclosporine dose accordingly adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was small (12%), careful monitoring of prothrombin
time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential for hypoglycemia due to decreased elimination
and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide, glipizide and
tolbutamide) has been demonstrated with concomitant administration of DIFLUCAN. Blood
glucose levels should be monitored closely and the dose of the hypoglycemic agent should be
adjusted as necessary.
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC of phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant administration of DIFLUCAN and rifampin resulted in a 25% decrease
in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole should be
increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,
these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Theophylline Concomitant administration of DIFLUCAN and theophylline resulted in an 18%
decrease in the mean plasma clearance of theophylline. Patients who are receiving high doses
of theophylline or who are otherwise at increased risk for theophylline toxicity should be
observed for signs of theophylline toxicity while receiving fluconazole, and therapy modified
appropriately if signs of toxicity develop.
Oral Contraceptives In pharmacodynamic studies, single and multiple 50 mg oral doses of
DIFLUCAN had no clinically significant effects on ethinyl estradiol or levonorgestrel
pharmacokinetics in healthy women taking oral contraceptives. However, at 200 mg daily, the
AUCs of ethinyl estradiol and levonorgestrel were increased, 40% and 24%, respectively.

Drug/Drug Interaction Interaction studies with other medications have not been conducted, but
such interactions may occur.
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of
patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected and
non-HIV infected patients were similar. The proportions of patients discontinuing therapy due
to clinical adverse events were sim ilar in the two groups (1.5%). The two most serious
adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative skin
disorders 2. Hepatic necrosis Because most of these patients had serious underlying disease
(predominantly AIDS or malignancy) and were receiving multiple concomitant medications,
including many known to be hepatotoxic or associated with exfoliative skin disorders, the causal
association of these reactions with fluconazole is uncertain. Two cases of hepatic necrosis
and one exfoliative skin disorder (Stevens-Johnson syndrome) were associated with a fatal
outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea 3.7%
Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea 1.5% Other
treatment-related clinical adverse events which occurred less commonly (0.2 to <1%) are
presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia.
General: fatigue, malaise, asthenia, fever.
In rare cases, anaphylaxis has been reported.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions of
patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route (p.o.
or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly with one
or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral
hypoglycemic agents. Clinically significant increases also were more frequent in patients
who: 1) had SGOT or SGPT elevations greater than three times the upper limit of normal
(>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis at any
time during the study and, 3) were identified as alcohol abusers. The overall rate of serum
transaminase elevations of more than 8 times the upper limit of normal was approximately
1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Number*
Percent
Number
Percent
Lab
of
Percent
Drugof
Percent
DrugParameter
Patients
Abnormal
Related
Patients
Related
Abnormal
Baseline >3xULN
Baseline < 3xULN
SGOT
9.4
53
3.8
3007
4.2
0.8
SGPT
65
3.1
0.0
2874
4.8
1.0
Hepatitis Patients
Non-Hepatitis Patients
SGOT
160
10.6
1.9
0.8
2900
3.9
SGPT
140
11.4
2.1
2799
4.4
1.0
Alcohol Abuse
Non-Alcohol Abuse
SGOT
42
9.5
2.4
3018
0.9
4.2
SGPT
40
10.0
1.0
2.5
2899
4.7
Received
Never Received
I.V. Fluconazole
I.V. Fluconazole
SGOT
144
5.6
1.4
0.9
2916
4.2
SGPT
139
5.0
0.7
1.0
2800
4.7
> 65 Years Old
< 65 Years Old
SGOT
277
4.3
1.1
2783
4.3
0.9
SGPT
258
3.9
1.2
2681
4.8
1.0
'Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions of
patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6% ) .
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: There has been one reported case of overdosage with DIFLUCAN. A 42-year-old
patient infected with human immunodeficiency virus developed hallucinations and exhibited
paranoid behavior after reportedly ingesting 8200 mg of DIFLUCAN. The patient was admitted
to the hospital, and his condition resolved within 48 hours.
Treatment: in the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine following oral administration in man. The oral bioavailability is essentially
complete (greater than 90%), and is independent of dose. Peak plasma concentrations after
oral administration are attained rapidly, usually within 2 hours of dosing. Since oral absorption
is rapid and almost complete, the daily dose of DIFLUCAN (fluconazole) is the same for
oral and intravenous administration. The term inal plasma elimination half-life is
approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the infecting
organism, the patient's condition and the response to therapy. Treatment should be
continued until clinical parameters and laboratory tests indicate that an active fungal infection
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FAMILIAL CAROTID BODY TUMOURS

useful, and perioperative emboliza
tion is no longer recommended by
most authors.14-17 Over the last 55
years, there has been a dramatic
improvement in the perioperative
stroke rate, dropping from 23% to
2.7%; however, the incidence of
cranial-nerve dysfunction postoperatively reported in the literature has
remained constant at 40%.17
We thank Fred Harris, MD, FRCPC,
Department of Pathology, and Roger J.
Harris, Medical Photography, for valu
able assistance.
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has been cured or has subsided. An inadequate period of treatment may lead to recurrence of
active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal
candidiasis usually require maintenance therapy to prevent relapse.
Recommended Adult Dosages
Loading Dose: Administration of a loading dose on the first day of treatment, consisting of
twice the usual daily dose, results in plasma concentrations close to steady state by the
second day. Patients with acute infections should be given a loading dose equal to twice
the daily dose, not to exceed a maximum single dose of 400 mg, on the first day of
treatment.
Oropharyngeal Candidiasis: 100 mg once daily. Treatment should be continued for at least 2
weeks to decrease the likelihood of relapse.
Esophageal Candidiasis: 100 mg to 200 mg once daily. Patients should be treated for a
minimum of 3 weeks and for at least 2 weeks following resolution of symptoms.
Systemic Candidiasis: 200 mg to 400 mg once daily. These patients should be treated for a
minimum of 4 weeks and for at least 2 weeks following resolution of symptoms.
Cryptococcal Meningitis: 200 mg to 400 mg once daily. Although the duration of therapy for
cryptococcal meningitis is unknown, it is recommended that the initial therapy should last a
minimum of 10 weeks.
Prevention of Recurrence of Cryptococcal Meningitis in AIDS: 200 mg once daily.
DIFLUCAN (fluconazole) may be administered either orally or by intravenous infusion. The
intravenous infusion of DIFLUCAN should be administered at a maximum rate of approximately
200 mg/hour given as a continuous infusion. See Directions for Use .
Dosage in Patients With Impaired Renal Function
Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with impaired
renal function, an initial loading dose of 50 to 400 mg should be given. After the loading
dose, the daily dose (according to indication) should be based on the following table:
Creatinine Clearance (mL/min)
Percent of Recommended Dose
>50
100%
21-50
50%
11-20
25%
Patients receiving
one recommended
regular hemodialysis
dose after each dialysis
When serum creatinine is the only measure of renal function available, the following formula
(based on sex, weight, and age of the patient) should be used to estimate the creatinine
clearance.
Males:
Weight (kg) x (140-age)
72 x serum creatinine (mg/100 mL)
Females:
0.85 x above value
Composition: DIFLUCAN Tablets (pink) contain 50, 100 or 200 mg fluconazole. Also
contains the following non-medicinal ingredients: microcrystalline cellulose, dibasic calcium
phosphate anhydrous, povidone, croscarmellose sodium, FD & C Red No. 40 aluminum lake
dye, and magnesium stearate.
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DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.
Directions for Use: Inspect visually for particulate matter or discoloration prior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR MULTIDOSE
USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a maximum rate of 200 mg/hour. Flush DIFLUCAN intravenous solution remaining
in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets (“giving" sets).
DIFLUCAN I.V. infusion is compatible with (i.e. not susceptible to absorption) sets constructed
of a delivery tube (PVC) luer lock (modified phenylene oxide), flash ball (latex) drip chamber
(polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg,
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution for direct infusion. Each mL contains
2 mg fluconazole and 9 mg sodium chloride. Supplied in clear glass bottles of
100 mLand 200 mL, affording doses of 200 mg and 400 mg fluconazole respectively, sealed
with a rubber bung.
STORAGE
DIFLUCAN TABLETS (fluconazole) 50,100, and 200 mg: Store below 30°C.
DIFLUCAN I.V. (fluconazole) 2 mg/mL: Store below 30°C. Do not freeze.
References: 1. DIFLUCAN new drug submission, Data on file, Pfizer Canada Inc.
2. Product monograph-DIFLUCAN*.
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Bronchogenic Cyst Masquerading
As a Chronic Post-traumatic
Pseudoaneurysm of the Aortic Isthmus
Ciaran J. McNamee, BSc, MD, CM, MSc, FRCSC; John L. Knight, MB, BS, FRACS, FRCSC
The serious nature of false aneurysms that develop in the aortic isthmus after blunt
chest trauma is well known. The authors describe the case of a 33-year-old woman
who presented with symptoms of chronic post-traumatic pseudoaneurysm of the
aorta 3 months after blunt chest trauma. Radiologic investigations could not
substantiate an aortic disruption. A bronchogenic cyst masquerading as a false
aneurysm of the aorta was identified at thoracotomy. Bronchogenic cysts are one of
the most common causes of primary mid-mediastinal masses and should be
considered as potential causes of mid-mediastinal enlargement. However, this
consideration should not delay urgent surgery if vascular damage cannot be ruled
out.

La gravite des faux anevrismes qui se developpent dans l’isthme aortique apres un
traumatisme thoracique ferme est bien connue. Les auteurs decrivent le cas d’une
femme de 33 ans qui a presente les symptomes d’un pseudo-anevrisme
post-traumatique chronique, 3 mois apres avoir subi un traumatisme thoracique
ferme. Les examens radiologiques n’ont pu demontre la presence d’une lesion
aortique. A la thoracotomie, un kyste bronchogenique ayant les apparences d’un
faux anevrisme fut identifie. Les kystes bronchogeniques represented l’une des
causes les plus frequentes des masses mediomediastinales et ils devraient etre
consideres comme cause possible des tumefactions mediomediastinales. Toutefois,
cette possibilite ne devrait pas retarder une intervention chirurgicale urgente quand
on ne peut ecarter la possibilite d’une lesion vasculaire.

ediastinal cysts make up 20%
to 25% of primary mediastinal
masses reported in current large
series.1'2 The middle mediastinum is
the commonest location of these
cysts,2 with bronchogenic cysts
making up the majority (40% to
85%) of cystic lesions in this area.1' 4
We describe a case in which a
symptomatic bronchogenic cyst in
the subaortic area resembled acute

M

accident 3 months previously and
had suffered blunt chest trauma,
when her sternum hit the steering
wheel. She had complained of non
specific chest pain when seen in the
emergency room at another hospi
tal. However, chest radiography had
not been done, and there was no
previous chest x-ray film available
for comparison. Functional inquiry
elicited a recent hoarseness in her
voice, which she attributed to a
flu-like illness circulating at her
workplace. Physical examination
was noncontributory. A chest x-ray
film obtained on admission revealed
a large left middle mediastinal mass
(Fig. 1). Computed tomography
(CT) with contrast confirmed a
mass in the subaortic area at the
level of the ligamentum arteriosum

enlargement of a chronic posttraumatic pseudoaneurysm of the
thoracic aorta.

Case Report

A 33-year-old woman was re
ferred because of a 2-day history of
acute left-sided chest pain. She had
been involved in a motor vehicle
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FIG. 1. Chest x-ray film demonstrates
large left medistinal mass.

BRONCHOGENIC CYST

(Fig. 2). Angiography did not dem
onstrate any traumatic tear of the
thoracic aorta. Because of the acute
onset of symptoms and a possible
left recurrent nerve palsy from an
expanding pseudoaneurysm, urgent
surgery was recommended.
On first inspection the subaortic
lesion appeared to be intimately
associated with the aorta and re

sembled a traumatic false aneu
rysm. The aortic arch proximal to
the ligamentum arteriosum, the left
subclavian artery and the distal de
scending aorta were clamped, and
the mass was opened. The mass
contained a large quantity of white
fluid, which had an amylase content
of 5000 U/L and a triglyceride-tocholesterol ratio of 1.5:1. The vas

cular clamps were quickly removed
(total clamp time less than 2 min
utes). Further dissection revealed a
large cyst adherent to the aorta and
based at the carina. Despite diligent
searching no fistula was found.
However, as a precaution, the base
of the cyst was oversewn after its
excision. Histologic examination of
the cyst wall revealed a fibrous
capsule covering a layer of ciliated
columnar epithelium, consistent
with a foregut cyst (Fig. 3). No
cartilage was seen in the walls of
the cyst. Postoperatively, a left vo
cal-cord paresis was demonstrated
by indirect laryngoscopy; however,
on follow-up at 6 weeks the paresis
had resolved. Esophagography with
barium in the early postoperative
period revealed a normal esopha
gus.

Comment

FIG. 2. Contrast-enhanced computed tomography scan showing low-attenuation
mass (arrow) in subaortic area.

FIG. 3. Histologic appearance of cyst wall shows fibrous capsule over layer of
ciliated columnar epithelium (hematoxylin-eosin, original magnification X 40).

Bronchogenic cysts in adults are
less innocuous than earlier litera
ture would suggest. Over a 30-year
period, Sirievella and colleagues5
reviewed 12 bronchogenic cysts and
found that 83% were symptomatic,
with chest pain occurring in 75%.
Gourin and associates6 reported
progressive respiratory symptoms
caused by bronchogenic cysts in
five of six patients, and, in a
10-year radiologic survey, Rigertz
and Lidholm7 found that 11 of 19
patients suffered ongoing respirato
ry complaints before removal of a
bronchogenic cyst. Estrera, Landay
and Pass8 reported on three cases of
mediastinal carinal bronchogenic
cysts and emphasized the threat
these lesions can pose.
In our case the history of recent
chest trauma prompted urgent in
vestigation and treatment. It is im
possible to say whether there was a
causal relationship between the ac
cident and the later expansion of
the cyst. However, it is difficult to
CJS, VOL. 35, NO. 5, OCTOBER 1992
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believe that the cyst would expand
3 months later and not at the time
o f the accident if the cyst was due
to the trauma of the accident.
Chronic traumatic false aneu
rysms are usually located at the
aortic isthmus, and, over time, ap
proximately 50% give rise to symp
toms of pain, dyspnea, cough or
hoarseness.9 In the few patients
who undergo serial radiography,
21% o f the false aneurysms have
been shown to enlarge, and the
death rate approaches 100% in pa
tients whose false aneurysms rup
ture.9 Despite the normal angio
gram in our patient and failure of
the mass to opacify on contrastenhanced CT, the acute onset of
symptoms coupled with the poten
tial for CT and angiography to miss
acute vascular injuries1011 prompted
urgent thoracotomy. At surgery,
initial inspection could not rule out
a false aneurysm o f the aorta, and
the diagnosis of bronchogenic cyst
could only be made after vascular
control was obtained and the cyst
was opened.
The fluid in most bronchogenic
cysts is o f water density3 and usual
ly has low attenuation on the CT
scan.12-13 If the fluid content is very
viscous, a high-density mass may be
seen on the CT scan.12 We attribute
the high amylase content of this
cyst to a small fistulous connection
to the esophagus as has previously
been reported.14 At surgery we did
not find a fistula between the carina
or the esophagus. However, we
considered it appropriate to oversew
the base to prevent a fistula from
developing.
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The triglyceride-to-cholesterol
ratio could have been caused by a
tributary o f the thoracic duct drain
ing into the cyst or by swallowed
cream trapped in the cyst if there
was a patent fistula. Postoperatively, no chylothorax developed, and
esophagography with barium failed
to demonstrate an abnormality.
Serious reported complications of
bronchogenic cysts include pulmo
nary-artery stenosis,15'16 bronchial
and superior-vena-caval compres
sion,16 left atrial compression17 and
rupture o f cyst material into the
pericardium causing pericardial
tamponade.4 We wish to add to this
list the complication of a symptom
atic bronchogenic cyst masquerad
ing as a false aneurysm of the
thoracic aorta. We suggest emer
gency investigation of middle medi
astinal masses adjacent to the aortic
isthmus to distinguish vascular
from nonvascular structures. Ur
gent surgery should be carried out
if an expanding aneurysm cannot be
ruled out, and if exploration reveals
a bronchogenic cyst we suggest
cyst excision with oversewing of its
base.
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Surgical Management of Fulminant
Pseudomembranous Colitis
Thomas K. Waddell, MD; Robin S. McLeod, MD, FRCSC, FACS; Ori D. Rotstein, MD, FRCSC, FACS;
Zane Cohen, MD, FRCSC, FACS
The presentation of pseudomembranous colitis ranges from mild self-limiting
diarrhea to fulminant colitis with overwhelming sepsis. The management of the
severe forms of this disease, including the role of surgical intervention, is poorly
defined. To evaluate the management and outcome in severe cases, the authors
reviewed the records of six patients (four women, two men) seen at The Toronto
Hospital between 1985 and 1989 with pseudomembranous colitis manifesting as
fulminant colitis. The patients ranged in age from 19 to 69 years (mean 52 years).
All presented with nonbloody diarrhea, had peritoneal signs and were severely
dehydrated, and all had received antibiotics between 4 days and 6 weeks before the
onset of symptoms. The mean preoperative leukocyte count was 40.9 X 109/L .
Radiologically, the colon appeared to be dilated in three patients. Two patients were
operated on immediately. The other four were treated medically, but three of them
required surgery within 24 hours of presentation. Four (67%) of the six patients
died. All four had been treated surgically. The mean age of the survivors was 28
years compared with 64 years for those who died.
Pseudomembranous colitis can present as severe acute colitis and can carry a high
mortality, especially in the aged. Surgical treatment may be required in those who
fail to respond to medical management or have peritoneal signs.

Le tableau clinique de la colite pseudo-membraneuse peut aller de la diarrhee legere
a resolution spontanee, jusqu’a la colite fulminante avec sepsie irrepressible. Le
traitement de cette forme grave de la maladie, y compris le role de la chirurgie, est
mal defini. Dans le but d'evaluer le traitement et les resutats dans les cas graves, les
auteurs ont etudie les dossiers de six patients (quatre femmes, deux hommes) r?us a
l’Hopital Toronto entre 1985 et 1989 alors qu’ils souffraient de colite
pseudo-membraneuse dans sa forme fulminante. L’age des patients variait de 19 a 69
ans (moyenne de 52 ans). Tous avaient une diarrhee non sanglante, presentaient des
signes peritoneaux et etaient severement deshydrates; ils avaient tous recu des
antibiotiques de 4 jours a 6 semaines avant l’apparition des symptomes. La
numeration leucocytaire preoperatoire moyenne etait de 40,9 X 109/L . Chez trois
patients, le colon paraissait dilate a la radiographie. Deux patients furent operes
immediatement. Les quatre autres furent traites par des moyens medicaux, mais
trois d’entre eux durent etre operes dans les 24 heures qui suivirent leur
hospitalisation. Quatre (67 %) des six patients moururent; tous avaient ete operes.
L’age moyen de ceux qui survecurent etait de 28 ans, comparativement a 64 ans
pour ceux qui sont decedes.
La colite pseudo-membraneuse peut prendre la forme d’une colite aigue grave et
entrainer une mortalite elevee, surtout chez le vieillard. La chirurgie peut etre
necessaire chez ceux qui ne repondent pas au traitement medical ou qui ont des
signes peritoneaux.
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n acquired inflammatory disor
der of the colon, pseudomem
branous colitis (PMC) is character
ized by fever, abdominal pain, wa
tery diarrhea and leukocytosis. It is
now known to be associated with
antibiotic use and has been shown
to be caused by toxins produced by
Clostridium difficileA2 The frequent
use of antibiotics by surgeons, par
ticularly for prophylaxis, makes
PMC an important clinical entity in
surgical practice. The incidence of,
and death rates in, antibioticassociated colitis are difficult to
determine. Teasley and colleagues3
noted that 29.6% of hospital in
patients with diarrhea had either
positive stool cultures or a positive
toxin assay. A more recent study4
documented that stool cultures in
21% of patients with negative stool
cultures on admission became posi
tive during their hospitalization. Of
these, only 37% subsequently suf
fered from diarrhea, and none had
colitis endoscopically. Clearly, there
exists a spectrum of disease from
mild to fulminant forms, and the
latter may result in a very high
death rate. Fewer than 30 patients
with severe PMC requiring surgery
have been reported in the literature,
and the indications and choice of
operation are yet be defined. We
reviewed our own experience over 5
years of patients with severe PMC
to evaluate the presentation, man
agement and outcome and to deter
mine what factors, if any, determine
prognosis.

A

Patients and Methods
All patients with PMC requiring a
CJS, VOL. 35, NO. 5, OCTOBER 1992
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general surgical consultation at The
Toronto Hospital between 1985 and
1989 were identified by discharge
diagnosis code and review of office
records. Charts were reviewed to
determine preoperative risk factors
and pertinent patient characterist
ics. Preoperative information, which
included laboratory data, type of
operation, medical therapy and out
come, was recorded. The ages of
survivors and nonsurvivors were
compared by the Wilcoxon rank
sum test.

Findings
Patients

Six patients (four women and two
men), with an average age of 52
years (range from 19 to 69 years),
were seen by the general surgery
service for the management of se
vere PMC. No patient had a history
of underlying or antecedent bowel
disease, and none had any chronic
medical illness, although one had a
history of psychiatric illness. Four
patients were referred to general
surgery from the emergency room,
including one who was transferred
after emergency laparotomy for di
arrhea and abdominal pain at anoth
er hospital. Two patients had been
hospitalized for severe trauma but
had recovered from the acute phase
of their injury when the diarrhea
developed.
T a b le 1.

Presentation

Antibiotic Use

Two patients had diarrhea for
approximately 1 month before presentatin. The remainder were seen
within 3 days of the diarrhea devel
oping. Four patients had received
antidiarrheal agents. Table I sum
marizes the details of the clinical
presentation of the six patients.
During the course of their illness,
all patients had abdominal pain and
watery, nonbloody diarrhea. Three
patients were febrile and two were
hypothermic. All had peritonitis
(diffuse in three and localized in
three). The unique aspect of the
clinical presentation was that four
patients were profoundly hypoten
sive (systolic blood pressure less
than 100 mm Hg), and all were
clinically dehydrated. Two patients
were intubated and ventilated in the
intensive care unit before being re
ferred.
Four patients had a striking leu
kocytosis initially, which worsened
before the operation. The leukocyte
count at the time of presentation
was 16.1 ± 6.8 X 109/L (mean ±
standard deviation) and at the time
of operation was 40.9 ± 23.9 X
109/L. One extremely ill patient
had a low leukocyte count (4.8 X
109/L). If this patient is excluded,
the mean preoperative leukocyte
count was 50.0 =t 17.6 X 109/L.
The count was much lower in the
patient managed medically (19.5 X
109/L at the time of presentation).

All patients had recently received
or were receiving antibiotics at the
time the diarrhea developed. Two
patients received oral antibiotics for
ill-defined upper respiratory symp
toms (ampicillin in one case and
amoxicillin in the other). One pa
tient was receiving cephalothin in
travenously for a wound infection
after combined coronary artery by
pass and crossover femoral bypass
grafting. One patient had been
treated 1 month previously at an
other institution with a combination
of antibiotics (one was met
ronidazole; the other was unknown)
for a suspected but unproven tuboovarian abscess. Of the two trauma
patients who became ill in hospital,
one had been given cefazolin parenterally as perioperative wound pro
phylaxis and the other had received
a variety of antibiotics during a
long hospital stay. These included
clindamycin, netilmicin and pipera
cillin, but the temporal relationship
appeared to incriminate trimetho
prim-sulfamethoxazole given for an
aspiration pneumonia.
Diagnosis

In two patients the diagnosis of
PMC was suspected from the histo
ry of antibiotic use associated with
watery diarrhea and abdominal
pain. In these cases, as well as that
of the patient treated medically, the

Clinical Presentation of Six Patients With Fulminant Pseudomembranous Colitis
Signs an d sy m p to m s

P a tie n t
no.

Age, yr

P ain

1

69

2
3
4
5
6

69
55
64
19
37

None
initially
Constant
Constant
Constant
Crampy
Constant

D ia rrh e a

T e m p e ra tu re ,
°C

Blood p ressure,
m m Hg

O rgan fa ilu re *

W B C , X 1 0 9/L

Diffuse

Watery

35.5

160/70

Resp/renal

43.7

LLQ
Diffuse
LLQ rebound
Diffuse
LLQ rebound

Watery
Watery
Watery
Mucous
Watery

34
38.5
39.5
37.3
39

70/50
90/65
140/60
90/60
80/p

Resp/comatose

36.0
4.8
40.0
19.5
80.0

T e n d e rn e s s

—
—
—

—

•Respiratory (resp) failure is defined as the need for mechanical ventilation, renal failure as the need for dialysis. LLQ = left lower quadrant. WBC =
leukocyte count
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finding of pseudomembranes at sig
moidoscopy confirmed the diagno
sis (Table II). In the remaining three
patients, the diagnosis was made at
laparotomy, when the colon was
found to be markedly thickened and
erythematous. Plain radiographs
demonstrated colonic dilatation in
three patients. In one patient ul
trasonography strongly suggested
PMC, documenting a dilated colon
with a thickened hypoechoic wall.
In all six patients, the toxin assay
confirmed the diagnosis of colitis
due to C. difficile. This information
was not available preoperatively in
any patient.
Management
The initial treatment in three pa
tients was metronidazole intrave
nously for one, vancomycin orally
for another and both of these for
the third. One patient recovered
with medical treatment only. The
other two patients were operated on
within 24 hours because they failed
to respond to medical management.
One other patient, who was treated
with ampicillin and netilmicin, be
cause the diagnosis of PMC was not
suspected preoperatively owing to
the absence of pseudomembranes at
sigmoidoscopy, was operated upon
because she deteriorated clinically.
Two patients were operated on im
mediately because of the severity of
the abdominal tenderness.
Of the five patients operated
upon, two had laparotomy, which
excluded perforation or ischemic

grey pseudomembranes is the hall
mark. There is diffuse mural edema
with thickening of the bowel wall in
contrast to fulminant ulcerative co
litis.5
Sigmoidoscopy confirmed the di
agnosis in three of the four patients
upon whom it was performed. Rec
tum and sigmoid sparing with nega
tive sigmoidoscopy has been report
ed.67 One patient had abdominal
ultrasonography, which suggested
the diagnosis of PMC. The typical
findings of colonic dilatation and
thick-walled, hypoechoic colon with
some free intra-abdominal fluid
were noted. With additional experi
ence there may be a role for ul
trasonography or abdominal com
puted tomography in confirming
the diagnosis rapidly and reliably.
The management of PMC centres
around the cessation of the offend
ing antibiotic regimen and initiation
of specific therapy. Vancomycin and
metronidazole appear to be equally
effective,3’8 although metronidazole
has the advantage of substantially
lower costs. Indications for surgical
intervention have been classified
into three categories: perforation,
failure of medical management and
“ toxic megacolon.” In contrast to
megacolon associated with ulcer
ative colitis, most such cases devel
op slowly and are treated surgically
only after a trial of supportive ther
apy has failed. They, therefore, rep
resent failed medical management.
Here, we present six cases that may
define a new category — fulminant
pseudomembranous colitis.

bowel. No procedure was performed
once these two conditions were
ruled out. Both patients subse
quently died of multisystem organ
failure after long stays in the inten
sive care unit. One patient had a
transverse loop colostomy, and one
had a loop ileostomy and colosto
my. Both recovered from the PMC
although the latter subsequently
died of an unrecognized incarcerat
ed paraileostomy hernia. The fifth
patient had a subtotal colectomy
and died of complications related to
postoperative intra-abdominal bleed
ing. Death occurred after a long
stay in the intensive care unit dur
ing which time the patient suffered
acute renal failure, pneumonia and
sepsis. Thus, the death rate in pa
tients who underwent surgery was
80%. The death rate overall, includ
ing the medically treated survivor,
was 67%.
Older patients seemed to fare
worse than the younger patients.
The age of the survivors was 28 ±
13 years (mean ± standard devia
tion) versus 64 ± 6.6 years for
those who died (p = 0.10).

Discussion
PMC is an inflammatory bowel
disease caused by cytotoxins result
ing from an overgrowth of C. diffi
cile due to antibiotic therapy. Noso
comial spread may also play a role.4
The pathological findings can be
striking. Patchy mucosal inflamma
tion in the colon covered by yellow-

Table II. C lin ic a l D ia g n o s is in P a tie n ts W ith F u lm in a n t P s e u d o m e m b r a n o u s C o litis
Patient
no.
t
2
3

4
5
6

Radiologic findings
Gas in large and s m a ll b o w e l w ith o u t
d is te n s io n
U n re m a rk a b le
M e g a c o lo n
M e g a c o lo n w ith a ir flu id le v e ls
M e g a c o lo n , m u ra l e d e m a and
p s e u d o p o ly p s
U n re m a rk a b le

Sigmoidoscopic findings

Presence of
toxin

P s e u d o m e m b ra n e s

Yes

—

N e g a tive
P s e u d o m e m b ra n e s
N o t p e rfo rm e d
P s e u d o m e m b ra n e s

Yes
Yes
Yes
Yes

In tra o p e ra tiv e d ia g n o s is
Irre g u la rity o f b o w e l w a ll n o te d o n x -ra y
In tra o p e ra tiv e d ia g n o s is
U ltra s o n o g ra p h y s tr o n g ly s u g g e s tiv e

N o t p e rfo rm e d

Y es

In tra o p e ra tiv e d ia g n o s is

Comments
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There were no such cases
in our series. All patients reported
in the literature were managed by
resection without primary anasto
mosis. Three survived and four
died; the outcome was not reported
in the eighth patient.
We propose fulminant colitis as a
third major group of patients. Two
of our patients presented with
shock, high fever and leukocytosis
or peritonitis severe enough to war
rant immediate operation. Two pa
tients required surgery within 24
hours of presentation and another
within 3 days. These patients would
appear to be more appropriately
described as having fulminant coli
tis than refractory colitis. Four si
milar cases have appeared in the
literature.6'20' 22 If these are added to
our series, three patients had subto
tal colectomy and one died; four
had some form of decompressive
surgery and two died; two had
laparotomy only, and both died.
It is difficult to draw conclusions
regarding the optimal surgical man
agement of PMC because of the
small number of cases reported.
Most recommendations for the sur
gical management of complicated
PMC are based on the experience
with acute ulcerative colitis. Subto
tal colectomy appears to be the
preferred option. However, there
are theoretical reasons why the
management of complicated PMC
should differ. First, the bowel wall
in severe PMC is markedly thickened and edematous. This is in
contrast to ulcerative colitis in

The unique aspect of the patients
collected for this series was the
severity of illness at the time of
presentation to the surgical service,
as demonstrated by the magnitude
of fever, hypotension and leukocy
tosis and the prevalence of mul
tisystem organ failure (Table I). It is
difficult to estimate the percentage
of patients with PMC who fall into
this category of severe illness. In
1986, at The Toronto Hospital, 97
patients tested positive for C. diffi
cile, but it is impossible to know
how many were symptomatic or
how many were merely carriers (Dr.
R. Devlin: Personal communication,
1992). Our patients were operated
upon for a variety of reasons, nota
bly because of a lack of diagnosis in
the face of grave clinical findings
and to rule out intra-abdominal ca
tastrophes such as perforation or
intestinal ischemia.
The most common indication for
surgery in PMC in the literature is
failure of medical management,
usually after 7 to 14 days of thera
py (Table III). All our patients were
operated upon within 24 hours of
presentation and, thus, would not
fall into this category. In 1988,
Bradley and associates9 reported
two such cases and collected anoth
er five from the literature. Three
others have been identified in case
reports.10' 12 An overall survival rate
of 78% may indicate the more be
nign course of this type of illness.
Colonic perforation is a rare compli
cation, with only eight cases reported in the recent surgical literatu-

e s , 13-19

which the bowel wall tends to be
thin. Thus, the risk of perforation
may be much lower. In support of
this contention only eight cases of
PMC with perforation have been
reported. The alternative therapy
for PMC is both specific and effec
tive in that, although relapse rates
are high, the initial response rate is
quite good. Finally, the long-term
prognosis is quite different. Follow
ing treatment, the successfully
treated patient with PMC is cured
whereas most patients with ulcer
ative colitis will eventually require
colectomy. For these reasons de
compressive surgery has appeal, but
collected case reports appear to
favour subtotal colectomy.
It is distressing that, in retro
spect, antibiotic therapy was not
clearly indicated or properly used in
four of the six patients. The diffi
culties of managing these patients
emphasize the importance of pre
vention by the judicious use of
antibiotics.

Conclusions
Severe PMC remains a challeng
ing clinical entity and, as the inci
dence of PMC continues to rise,
surgeons may see more cases in the
future. The death rate, especially in
the elderly, can be extremely high
in the most severe forms. Preven
tion of this disease may not always
be possible, but restricting the unnecessary use of antibiotics and
aggressively pursuing the diagnosis

T a b le III. Indications in the Literature fo r Surgery on Patients With Pseudomembranous Colitis
S e rie s
re fe re n c e no.

Indication

5 ,1 3 -1 9

Perforation

5,9,12

Refractory
colitis
Fulminant
colitis

6 ,2 0 -2 2
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N o. of
p a tie n ts

A ge, yr

D uration of
illn ess, d

P rocedure
(no. of patien ts)

8

74 ± 11

6.8 ± 2.1

10

58 ± 13

6.6 ± 5.0

9

60 ± 1 2

0.5 ± 0.5

Resection (7)
None (1)
Resection (6)
Decompression (4)
Resection (3)
Decompression (4)
None (2)
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O utcom e
(no. of p a tie n ts )

Survived
Died (1)
Survived
Survived
Survived
Survived
Died (2)

(3)
(6)
(2)
(2)
(3)
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with a high degree of awareness
may be the key to minimizing mor
bidity and mortality.

8.
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SESAP VII Critique / Critique SESAP VII
Items 222 to 225
In large series of thyroid cancer, the joint features of the common well-differentiated carcinomas of the thyroid
gland, papillary and follicular carcinoma, become quite evident. Papillary carcinoma is more commonly seen in
young patients than is follicular carcinoma, but the incidence of both types peaks above the age of 30 years.
Both papillary and follicular carcinoma have been reported after irradiation to the head and neck. Neither can be
considered cured even if no disease is apparent two years after curative resection. The natural history of
well-differentiated thyroid carcinoma requires that follow-up be continued for decades to determine results of
therapy accurately. Both papillary and follicular carcinoma are appropriately managed with radioactive iodine
when systemic metastases that concentrate radioiodine are present. Unlike medullary thyroid carcinoma, neither
papillary nor follicular carcinoma is associated with pheochromocytoma.
222[ d ] 2 2 3 0 224[ d ] 225[c]
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Surgical Treatment in Non-Neoplastic
Parotid Disease: Indications and Results
Irving B. Rosen, MD. FRCSC;* Christopher R. McHenry, MD;* Yvan C. Bedard, MD, PhD, FRCPCf
Non-neoplastic disease of the parotid gland is an important entity, requiring
differential diagnosis and management. The incidence of non-neoplastic parotid
disease (NNPD) is increasing and makes up about 25% of cases for which
parotidectomy is indicated. NNPD can be categorized as type I (asymptomatic soft
diffuse enlargement or circumscribed firm nodular enlargement) or type II
(inflammatory lesions with recurrent pain and swelling, obstructive or
nonobstructive). Concern over possible malignancy is highest in type I nodular
lesions and least in type II lesions. Operative treatment may be indicated for
exclusion of tumour, relief of recurrent pain and swelling and patient anxiety. In 62
patients with NNPD who were operated on, the relevant clinical factors included
radiation, diabetes, tuberculosis, Sjogren’s syndrome and pulmonary sarcoidosis.
Superficial parotidectomy was effective, being associated with low morbidity, and
can be recommended as acceptable treatment, providing there is a complete patient
history and operation is carried out by a surgeon experienced in parotid surgery.

though NNPD has stimulated some
thoughtful clinical studies,7-8 it is a
relatively underdiscussed topic, per
haps explaining the still ill-defined
policy regarding the role o f surgical
management. Our own experience
has shown an increasing frequency
of NNPD, and this paper was un
dertaken to evaluate the role of
surgery in the management of pa
tients with NNPD.

Patients and Methods
Les lesions non neoplasiques de la parotide represented une entite importante qui
necessite et diagnostic differentiel et traitement. L’incidence des lesions non
neoplasiques parotidiennes est croissante et compte pour environ 25 % des cas
soumis a une parotidectomie. Les cas peuvent etre classes de type 1 (tumefactions
diffuses et souples, asymptomatiques, ou tumefactions nodulaires fermes et
circonscrites) ou de type 2 (lesions inflammatoires avec douleur et gonflement,
obstructives ou non obstructives). Les craintes de cancer sont plus fortes pour les
lesions nodulaires de type 1, et moindres pour les lesions de type 2. L’operation
peut etre indiquee pour exclure une tumeur, pour soulager une douleur et une
inflammation recidivantes, et pour diminuer Tanxiete d’un patient. Chez 62 patients
operes pour une lesion parotidienne non neoplasique, les facteurs cliniques
pertinents comprenaient une irradiation, le diabete, la tuberculose, le syndrome de
Sjogren et une sarcoi'dose pulmonaire. Reliee a un faible taux de morbidity la
parotidectomie superficielle s’est averee efficace et peut etre recommandee, en
autant que les antecedents medicaux du patient sont bien connus et que Toperation
est pratiquee par un chirurgien experiments en chirurgie parotidienne.

eoplastic disease has customar
ily been the prime focus of
scientific communications regarding
parotidectomy, frequently originat
ing from cancer institutions.1’2
However, in general hospital set

N

tings, non-neoplastic parotid dis
ease (NNPD) in its various forms is
a common problem for referral in
surgical practice and actually makes
up 13% to 27% of case diagnoses in
reports on parotidectomy.3' 6 Al
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A 25-year retrospective review
was carried out of patients who
underwent operative treatment for
NNPD. (In the 7 years from 1983
to 1990, 135 parotidectomies were
carried out, o f which 40 [30%] were
for NNPD [Fig. 1]). Such patients
could be divided into two different
clinical categories. The first catego
ry, type I parotid disease, comprised
asymptomatic unremitting or pro
gressive enlargements which, again
by clinical examination, could be
further divided into a soft diffuse
type (type I-D) with a low tumour
risk and a circumscribed firm nodu
lar form (type I-N) that resembled
classical tumour. The second cate
gory, type II parotid disease, com
prised inflammatory lesions, charac
terized by recurrent pain and swell
ing aggravated by food, which sia
lography could further subclassify
into types 2-0 (obstructive) and 2-N
(nonobstructive).
Chart reviews were then carried
out to note clinical presentations,
pathological findings, investiga
tions, indication for surgery, extent

NON-NEOFLASTIC PAROTID DISEASE

of surgery, surgical complications
and outcomes.

sarcoidosis in 3, tuberculosis in 2,
parotitis in 2 and branchiogenic
cyst in 2. Causes for the 14 patients
with type I-D disease included par
otitis in 6, radiation parotitis in 3,
lipomatosis in 2, an enlarged styloid
process in 2 and a branchial cleft
cyst in 1. The cause in the nine
patients with type II-O disease was
a calculus, whereas in patients with
type II-N disease the cause was
usually non-obstructive sialectasia.
Type II inflammation showed vary
ing degrees of chronic and acute
parotitis while the inflammatory in
filtrate in type I disease took the
form of patchy mild chronic inflam
mation with duct hyperplasia.
Notable clinical factors included
the following: radiation in four pa
tients (benign lymphoepithelial le
sion in one and parotitis in three);
diabetes in five (lipomatosis in two,
benign lymphoepithelial lesion in
one and parotitis in two); xeros
tomia in two (both benign lympho
epithelial lesions); disseminated
lupus erythematosus in one (a be

nign lymphoepithelial lesion);
healed postsuppurative wounds in
two (both tuberculosis); mediastinal
lymphadenopathy in three (all sar
coidosis); abscess formation in one
(pyogenic parotitis); and humanimmunodeficiency-virus positivity in
one (lymphadenitis).
Various investigations were car
ried out and positively revealed radi
opaque calculus on plain radio
graphs in 4 patients, calculus on
echography in 1 (Fig. 2), sialographic obstruction in 8 (Fig. 3),
sialographic sialectasia in 12 (Fig.
4), echogenic “tumour mass” on
ultrasonography in 7, a masseteric
“lesion” on computed tomography
in 1, nondiagnostic “normal duct
and blood cells” on fine-needle aspi
ration biopsy in 12, and lip biopsy
in 3 patients (revealing non-caseating granulomas in 2 and chronic
sialadenitis in 1).
Operative treatment included su
perficial parotidectomy in 44 pa
tients, total parotidectomy in 1,
total parotidectomy plus excision of

FIG. 1. Frequency of non-neoplastic parotid disease (cross-hatched bars) in cases of
parotidectomy, 1983 to 1990. Dotted bars = neoplastic disease.

FIG. 2. Ultrasonography of right par
otid gland and parotid duct demon
strating intraduct stone that was not
apparent on plain films. Patient had
persistent recurrent bouts of parotitis
characterized by severe pain and swell
ing that was responsive to antibiotic
therapy.

Results
Sixty-two patients (35 women, 27
men) with NNPD were selected for
surgical treatment. The patients
ranged in age from 15 to 72 years;
31 presented with type I-N, 15 with
type I-D, 7 with type II-N and 9
with type II-O.
The frequency of symptoms of
pain in type II disease was highly
variable, ranging from daily discom
fort to “several” episodes. The se
verity of symptoms described by
patients again was highly variable,
and pain severity did not necessarily
correlate with symptom frequency.
The causes in the 31 patients
with type I-N disease were an in
traparotid stone in 4 cases, benign
lymphoepithelial lesion in 6, lymph
adenitis in 9, masseteric lesions in 2
(hematoma and varix), tem 
poromandibular joint ganglion in 1,

CJS, VOL. 35. NO. 5. OCTOBER 1992

561

ROSEN. MCHENRY, BEDARD

a masseteric lesion in 3, partial
parotidectomy in 5, local excision of
parotid lesion and biopsy in 5, ex
ploration only in 2 and lip biopsy of
minor salivary glands in 5.
Complications included transient,
partial facial-nerve weakness in six
patients, deep calf phlebitis in one,
retained intraoral ductal stone in
one, persistent pain in the parotid
area in one and an unsatisfactory
scar in one. No hematoma or death
occurred. All patients with type II
disease were cured of symptoms of
recurrent pain and swelling.

Discussion
Type II disease (either obstructive
or nonobstructive) is inherently be
nign in nature7 and can produce

periodic discomfort that bears a
superficial resemblance to biliary
colic. However, the pain of parotitis
does not approximate the severity
of biliary colic, nor is there the
same possibility of serious sepsis
resulting from parotid-duct obstruc
tion that there is from commonduct obstruction. Sialography,8’9
viewed as ineffective for diagnosing
tumour, can differentiate obstruc
tive from nonobstructive type II
disease in about 50% of appropriate
patients. Watkin and Hobsley8 de
scribed 68 patients with recurrent
parotitis showing sialographic
punctate sialectasia in whom sialog
raphy was also abnormal in asymp
tomatic contralateral glands 70% of
the time. Sixty percent of their
patients had Sicca syndrome, 25%
had seropositive autoantibodies and

FIG. 3. Sialogram in 32-year-old man with recurrent parotitis shows small intraduct
stone (arrow) at junction of extra- and intraparotid ducts. Superficial parotidectomy
permitting removal of stone was curative.
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66% had lip biopsies compatible
with Sjogren’s syndrome. Fifty per
cent of this patient group showed
spontaneous resolution after 5
years of noninterventional follow
up. Forty percent of adults and 4%
of children underwent parotidecto
my for relief of symptoms or exclu
sion of tumour, with bilateral proce
dures being necessary in 5 of 17
patients. Watkin and Hobsley7 fur
ther noted that recurrent unilateral
swelling is almost always due to
calculus when Sjogren’s syndrome
can be excluded. Although the dis
ease appeared to resolve spontane
ously in 50% of such patients, paro
tidectomy was carried out and was
effective in one-third of patients,
and stomatoplasty was utilized for
stones impacted near the parotidduct orifice.
The management of noninflam
matory non-neoplastic (type I) dis
ease depends very much on clinical
interpretation of physical signs, al
though the myriad of investigation
al procedures in use may be of some
help. Ultrasonography2 can be uti
lized to detect intraparotid calculus,
suggest a cystic nature of a parotid
lesion and confirm an intraparotid
position of a neck mass (Fig. 5), but
the persistence for at least 1 month
of a nodular lesion (type I-N) is
usually sufficiently worrisome to
lead to some form of intervention
for biopsy purposes. Even a de
crease in size is still consistent with
disease, and this phenomenon was
observed in three cases of granulo
matous lymphadenitis, two of which
proved to be tuberculous in origin.
Bilateral lesions occurring in black
patients with hypercalcemia and
mediastinal lymphadenopathy were
looked for as indicative of sarcoido
sis, which can be verified on lip
biopsy of minor salivary glands and
was seen in two of our patients
(Fig. 6). Lip biopsies may also be
helpful in the diagnosis of Sjogren’s
syndrome, which usually has a

NON-NEOPLASTIC PAROTID DISEASE

polyglandular distribution. Fineneedle aspiration biopsy1011 may be
useful in indicating the presence of
tumour, but is not helpful in NNPD
because of lack of specificity unless
the stereotypical pattern of tubercu
losis or sarcoidosis is demonstrated.
Other more sophisticated forms of
imaging such as computed tomog
raphy and magnetic resonance im
aging are useful in demonstrating
the extent and invasiveness of tu
mour2 but cannot truly impart a
tissue diagnosis.12
Type I-D lesions that are clinical
ly soft and diffuse do not suggest
cancer or a tumour. Here, ul
trasonography, needle aspiration bi
opsy, minor salivary gland lip biop
sy and even sialography can also be
carried out in an attempt to advance
diagnosis. In our experience this
has not been effective, and the
persistence of an asymmetric en
largement of the parotid gland even
though it is clinically benign has

remained a problem for clinical so
lution.
Indications for surgical treatment
of NNPD must be highly individual
ized. In the type II recurrent dis
ease, patients obviously dictate the
acceptance of operative treatment
based on their willingness to toler
ate recurrent pain, swelling and
discomfort. Indeed, the individual
patient’s acceptance of recurrent
parotitis is variable and may not
reflect the severity of the pain itself.
Type I-N disease resembles tumour,
and operative resection is usually
acceptable. Expectant management
of type I-D disease is preferred, and
if the parotid mass diminishes in
size in combination with a negative
needle biopsy and a history of dia
betes, obesity, liver disease, sar
coidosis, radiation treatment or HIV
positivity, conservative management
is particularly indicated. Lacking
such factors, an operative approach
may be selected if the patient is

anxious over a persistent asymmet
rical parotid enlargement despite
appropriate reassurance.
Usually subtotal parotidectomy
can be carried out effectively with
out hazard and provides the resolu
tion of all forms of NNPD. Where
intraparotid lymphadenopathy can
be recognized, in particular where it
affects the lower pole of the parotid
gland, a not uncommon site, partial
parotid resection or resection of
affected nodes is feasible and diag
nostic, and minimizes operative
morbidity. Such an operative ap
proach for NNPD has permitted an
effective solution for various prob
lems which, if neglected, would
usually not result in patient death
or ill health, but rather in repeated
bouts of pain, discomfort or prolon
gation of unexplained swelling with
attendant patient anxiety. Patients’
acceptance of this surgical ap
proach has been highly satisfactory.

Summary
Parotidectomy is usually carried
out for neoplastic disease, and its
role in the management of non-neo-

FIG. 4. Sialographic appearance of nonobstructive recurrent parotitis characterized
by beaded dilatation of duct and sialectasia. No obstruction is noted. Parotidectomy
was curative.

FIG. 5. Echogram of diffuse, soft par
otid swelling in 60-year-old obese
woman that persisted for several
months. Swelling showed echogenicity
and presumptive solid tumour (“lipo
matosis?”) but was due to branchial
cleft cyst.
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Quebec Association of Urologists

FIG. 6. Photomicrograph of minor salivary gland tissue obtained by lip biopsy
under local anesthesia from girl with bilateral parotid nodules, reveals noncaseating granuloma with multinucleated giant cell, consistent with sarcoidosis. Paroti
dectomy was deemed unnecessary and steroid therapy was instituted (hematoxylineosin, original magnification X 250).

The 17th annual meeting of the Quebec
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Seasons Hotel in Montreal. For further
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H5B 1G8; phone: (514) 350-5131; fax;
(514) 350-5181.
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plastic disease is still being defined.
Parotidectomy and other forms of
parotid-related surgery in properly
selected patients can be an effective
and safe form of management for
both symptomatic and asymptomat
ic non-neoplastic disease, providing
appropriate surgical expertise can
be assured.
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The Lake of the Woods District Hospital, Kenora,
Ontario, a 148-bed acute and chronic fully accre
dited hospital is seeking a second general sur
geon. The successful applicant must have ful
filled the fellowship qualifications of the Royal
College of Physicians and Surgeons of Canada
in surgery.

Highland View Regional Hospital is seeking a General
Surgeon to replace a surgeon who will be relocating to the U.S.

The hospital has a busy, modern, well-equipped
surgical service which includes a laparoscopic
cholecystectomy unit and full range of endo
scopic procedures. On-site services include
pathology, radiology, internal medicine, pedia
trics and psychiatry.
Kenora is located on Lake of the Woods, 192 km
east of Winnipeg. The community offers excellent
education and recreational services. The area is
one of the largest tourist destinations for
mid-Canada and the United States and offers a
superb lifestyle.
Contact: Dr. R. Loewen, Chief of Staff
Lake of the Woods District Hospital
21 Sylvan Street
Kenora, Ontario
P9N 3W7
Fax: (807) 468-3939
Tel: (807) 468-9861
—S92-126

Highland View is a 100-bed hospital serving Amherst, Nova
Scotia and several surrounding communities with a catch
ment area of approximately 45 000. The surgical service
consisting of general surgery, obstetrics and gynecology, otor
hinolaryngology and ophthalmology is also complemented
by internal medicine. Experience in emergency orthopedics,
caesarean sections and laparoscopic techniques would be
an asset. Candidates should have their FRCSC or be eligible
to write the Canadian fellowship examinations.
In addition to a rewarding professional career, the area offers
an enviable lifestyle alternative. Located near the border of
New Brunswick, Amherst and its surrounding areas contain
the most appealing aspects of the Maritimes with the major
centres of Halifax and Moncton within easy reach. Summers
offer beautiful scenery, pleasant temperatures, warm waters
for swimming, boating and fishing. Winters offer downhill and
cross-country skiing, curling and a host of other activities.
Ready access exists to two major international airports as well
as the university centres of Mount Allison and Dalhousie and
abundant and affordable housing is available. If this unique
blend of professional opportunity and enviable lifestyle appeals
to you, please feel free to contact the undersigned in writing
or via telephone: (902) 667-3361; or fax (902) 667-0155.
David L. Turner
Executive Director
Highland View Regional Hospital
110 East Pleasant Street
Amherst, NS
B4H 1N6

—S92-127
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GENERAL SURGEON: ON - An opportunity
exists for a fellowship general surgeon to join
three other general surgeons at the city of
Welland situated in the middle of the Niagara
Peninsula in Southern Ontario. Excellent facili
ties for both inpatient and outpatient services
including all endoscopic equipment. Enquiries
or applications can be made to: Dr. J. Hope,
C hief of S ta ff, W elland C ounty G eneral
Hospital, 3rd St., W elland, ON L3B 4W6.
Tel: (416) 732-6111. Fax: (416) 732-3268.
________________________________—S92-119

Canadian Medical Association

G E N E R A L /V A S C U L A R S U R G E O N S :
N O RTH D A K O T A , US — B usy, w e ll-e s t
ablished de partm ent of six surgeons is
seeking to add additional BC/BE general and
vascular surgeons. Physicians will join large
multispecialty group practice with main clinic
located in metropolitan community of 130 000.
Affiliated 400-bed hospital is a regional tertiary
and trauma centre. Regional network of over
25 primary care clinics offers a substantial
referral population base. Excellent public and
parochial school education plus the addition of
two universities and a private liberal arts col
lege offer many amenities. Affiliation with medi
cal school and surgery residency program
available. Please respond with full curriculum
vitae to: Kathleen McKittrick Toft, 737 Broad
way, Fargo, ND, US 58123; or call: (701)
______________ —S92-117
234-2151.
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Davis & Geek

CLINICAL FELLOW
IN NEUROSURGERY

Dexon II Outside Back Cover

Applications are invited for the position of clinical fellow in neurosur
gery, Memorial University of Newfoundland. The post becomes
vacant Dec. 1, 1992, and is for a period of 1 year (renewable). The
Provincial Neurosurgery Unit is based at the Health Sciences Centre.
Previous experience in neurosurgery and the Medical Council of
Canada Evaluating Examination is required. Salary - $47 418.

Johnson & Johnson Medical
Products

In accordance with Canadian immigration requirements, priority will
be given to Canadian citizens and permanent residents. Closing date
fo r this advertisem ent is Nov. 30, 1992.

Inside Front Cover

For further information contact:
Dr. F. B. Maroun, Acting Chairman
Discipline of Surgery
Memorial University of Newfoundland
Health Sciences Centre
St. John’s, NF
A1B 3V6

Mercedes-Benz Canada, Inc.
480

Memorial University is com mitted to employment equity.
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North York Branson Hospital in Metropolitan Toronto
is seeking the addition to its staff of an orthopedic
surgeon. The hospital serves a community population
of 170,000 and has a busy orthopedic clinic with over
10,000 patient visits per year. Subspecialty interest
is considered an asset but not required.
Please phone enquiries and send r^sumds to:

Dr. S. Kesmarky, Section Head, Orthopedics •
630-4505 or Dr. A Juriansz, Chief of Surgery 630-9984
North York Branson Hospital, 555 Finch Ave.
West, WiUowdale, Ontario M2R1N5.

h
U

—S92-125
NORTH YORK
BRANSON HOSPITAL

A useful, Informative reference
for anyone whose life is touched by

Cancer
Everyone’s Guide to Cancer Therapy is a comprehensive and up-to-date resource for cancer patients,
their friends and families. An extensive glossary explains technical medical terms in simple language,
and, one by one, the book discusses the diagnosis, treatment and course o f recovery for the 50 most
common forms of cancer. In addition, Everyone’s Guide to Cancer Therapy describes:

v

►

♦ the early detection o f cancer
♦ how a malignancy develops

►

♦ how the correct stage of cancer
is determined
♦ how various treatments fight
cancer

A

♦ ways in which patients can cope
with cancer and contribute to
their own well-being during
recovery

,
**■

♦ sources of help and consultation

*

Orderyour copy today!
HARDBOUND

PAPERBACK

CMA members
postage/handling
subtotal
GST

$29.44
3.50
32.94
2.30

CMA members
postage/handling
subtotal
GST

$19.94
3.00
22.94
1.60

Total

$35.24

Total

$24.54

Nonmembers
postage/handling
subtotal
GST

$34.94
3.50
38.44
2.70

Nonmembers
postage/handling
subtotal
GST

$24.94
3.00
27.94
1.95

Total

$41.14

Total

$29.89

r

Save on orders of 3 or more copies!
Pay only $2.00 for postage and handling for each hardbound
and $1.50 p+h for each paperback. All orders must be prepaid.
GST registration # 121 765 705.

------------------- XS
'

Please send m e _______ copies o f Everyone’s Guide to Cancer Therapy today!
y

Enclosed cheque or money order (payable to the Canadian Medical Association)
□ Credit card

O VISA

O MasterCard

O American Express

E

Mail to:

r

Card n u m b er_____________________________ Expiry date ___________________________
N a m e _____________________________________________________________________________
Address _________________________________________________________________ ________
City ______________________________________

Province ____________________________

h

Postal code _______________________________ Telephone (

) _________________

Signature ________________________________ Total amount $ ______________________
P Please check if you would like to receive a list o f CMA publications.

Membership Services
Canadian Medical Association
1867 Alta Vista Drive
Ottawa, ON K1G 3Y6

Credit card payments:
Phone (Ottawa and area)
1 (613) 731-9331 ext. 2307
Toll free (outside Ottawa)
1 (800) 267-9703 ext. 2307
Fax
1 (613) 523-0937

Taking suture technology
to new heights
NEW

□

■
(B R A ID E D S Y N T H E T I C A B S O R B A B L E S U T U R E )

75 cm {30")

3.5 Metric

BI-COLOR* Braided Potyglycoiie
AcW Suture wltti Pofyraprolsts™
T - 1 2
■
Coating System
37 mm

otto

O
S®
bato-sk * cyaxauud caxaaa inc. Montreal, que.hsx ant
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Cyanamid Canada Inc.
Markham
•/™Registered U s e r: Cyanam id C an a d a Inc.

DEXONII, the newest generation
in the evolution of synthetic
absorbable sutures, offers markedly
different performance in handling,
tying and knot snug-in.
The unique new Polycaprolate™
Coating System...
• Allows the sutures to pass through
tissue smoothly with little or no
chatter or drag
• Provides superior suppleness and
silk-like feel
• Ensures minimal out-of-package
memory
In addition, DEXON II offers un
equalled out-of-package tensile
strength* and excellent knot security.

There is a difference.
See it.. .feel it.. .try it!
• DEXON compared to Vicryl.t Data on file.
tTrade mark of Ethicon.

